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ABSTRACT
Heme oxygenase-1 (HO-1) is the ultraviolet-A (UVA) (320-380 nm) inducible 
isoform of the rate-limiting enzyme involved in heme degradation. Up-regulation of 
HO-1 by UVA provides a crucial cellular defence mechanism against oxidative stress 
in human skin, but the events underlying HO-1 regulation by UVA remain poorly 
characterised in human cells. In murine models, work with other inducers (heavy 
metals, heme) has demonstrated that the HO-1 gene is transcriptionally activated by 
NF-E2-Related Factor 2 (Nrf2). In this study the oxidising UVA component of solar 
radiation has been employed as a model system to elucidate the molecular 
mechanisms involved in transcriptional up-regulation of the HO-1 gene by Nrf2 in 
human skin. Here evidence is provided showing that UVA causes immediate whole 
cell accumulation of Nrf2 in primary human skin fibroblasts. Previous work from 
this laboratory has shown that UVA treatment results in the release of the HO-1 
substrate heme from heme-containing proteins. In relation to this, the results of this 
study indicate that treatment with heme results in Nrf2 accumulation in human skin 
cells, and furthermore, that depletion of intracellular heme prevents UVA-mediated 
Nrf2 accumulation. Moreover, it is shown that UVA generated reactive oxygen 
species influence the amount of cytoplasmic Nrf2, and that UVA enhances NRF2 
transcriptional activation. Based on these observations, a molecular regulatory 
system is proposed where UVA promotes nuclear translocation of Nrf2, enhances 
transcriptional activation of NRF2, and stabilises Nrf2 through the release of heme. 
Here, it is suggested, that the resultant accumulation of Nrf2 may initiate up- 
regulation of the HO-1 gene which in turn degrades heme. In this study, the 
hypothesis that HO-1 modulates apoptosis in human melanoma cells has also been 
investigated. It is known that HO-1 possesses potent anti-apoptotic activity in both 
human and murine models, and that human melanoma cells often lack apoptotic 
potential and prove highly resistant to cytotoxic cancer therapies. The results of this 
study show that HO-1 over-expression in human melanoma cells prevents UVA- 
apoptosis in a dose-dependant manner. These data indicate that HO-1 may prove a 
suitable therapeutic target for pharmacological modulation in order to increase the 
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1. Introduction




In 1874 the first law of photochemistry was proposed by Theodor Grotthuss 
and John W. Draper. It states that light must be absorbed by a chemical substance in 
order for a photochemical reaction to take place. However, at this time the properties 
and composition of light were not fully understood. It was during the early 20th 
century that Max Planck first theorised that light was composed of energetic particles 
which he termed Tight quanta’. This resulted in the development of the second law of 
photochemistry. The second law of photochemistry (the photo equivalence or Stark- 
Einstein law), was formulated between 1908 and 1913 by the German bom physicists 
Johannes Stark and Albert Einstein. It states that for each photon of light absorbed, 
one molecule is activated for a photochemical reaction. Crucially, these two laws 
were the first to state that the energy and momentum of light could be imparted to 
solid matter.
The early development of light quantum theory by Planck underlies our 
current understanding of electromagnetic radiation. It was the development of the 
idea of light particles by Planck that led to the concept of electromagnetic waves. 
Today, electromagnetic radiation is defined as a self-propagating wave in space that 
has both electric and magnetic components, and is now considered in terms of wave- 
speed, wave-length X (m), and wave-frequency v (c'1); a relationship that is linked by 
the equation:
Wave speed (c) = frequency x wavelength
In this equation the frequency and wavelength of a beam of light are linked by the 
constant (c) which is equivalent to 3xl03 m/s, ‘the speed of light’. The 
electromagnetic spectrum is divided into sub-categories dependent on the frequency 
of the light. In order of increasing frequency the categories are: radio waves, 
microwaves, terahertz radiation, infrared radiation, visible light, ultraviolet radiation, 





The discovery of UVR is attributed to the German physicist Johann Wilhelm 
Ritter. In 1801 Ritter documented that an energy source at the violet end of the 
visible spectrum could darken silver chloride-soaked paper. Ritter referred to this 
uncharacterised energy source as "deoxidising rays", referring to the chemical 
properties of the rays. Later the term "chemical rays" was coined, and it wasn’t until
fhthe early 20 century that the term ultraviolet radiation was adopted. The term 
ultraviolet radiation relates to a fraction of the electromagnetic spectrum between 200 
and 380 nm. This range of ultraviolet wavelengths is sub-divided into ultraviolet-A 
(UVA) (320 -  380 nm), ultraviolet-B (UVB) (280 -  320 nm), and ultraviolet-C 
(UVC) (200-280 nm).
1.2.2 Ultraviolet-A
The majority of stars, as well as our own, emit electromagnetic radiation over 
a broad range of energies, including the ultraviolet range. However, only solar UVR 
with a wavelength in excess of 290 nm reaches the earth’s surface (reviewed in 
Tyrrell, 1991); UVR with a wavelength less than 290 nm is filtered out by the 
stratospheric ozone layer. Consequently, only UVA and UVB radiation exert an 
influence on biological systems on this planet. It is UVA radiation that this study will 
focus on.
UVA radiation comprises the majority of all solar UV reaching the planet’s 
surface, approximately 96 % (Wilkinson, 1983). Interestingly, it is believed that 
UVA radiation had a significant input into the origin of life on this planet. However, 
aside from a limited number of modem clinical therapeutic applications, UVA 
radiation has few beneficial effects for humans. UVA has been linked to deleterious 
effects such as erythema, immune suppression, photoaging, and skin cancer (Murphy, 
1998; Soter, 1990; Tyrrell, 1994). Consequently UVA is widely regarded as 
detrimental to human health.
3
1.2.3 The oxidative nature of UVA
Oxygen is the second most common component of the Earth (28 % by mass), 
and is necessary for sustainable respiration in all animals. However, oxygen is toxic 
and can cause irreversible cell damage, the effects of which can lead to cell death. 
The damage caused to a biological system by oxygen is termed oxidative stress.
All living cells maintain an internal reducing environment. This reducing 
environment is preserved by enzymes through a constant input of metabolic energy. 
Exogenous agents can cause an excess production of oxygen derived free radicals and 
/ or energised molecules, commonly referred to as reactive oxygen species (ROS). 
ROS cause disturbances in the normal cellular redox state, and this can lead to cellular 
damage if antioxidant defense systems become overwhelmed.
In 1970 work was published indicating that the effects of UVA may be 
dependent on oxygen in prokaryotes (Webb and Lorenz, 1970), findings that were 
confirmed in mammalian cells some years later (Danpure and Tyrrell, 1976). 
Crucially, these studies indicated that no such oxygen dependent relationship existed 
below 320 nm, therefore signifying that UVA exerts its influence by a unique 
photochemical mechanism. It is now understood that UVA irradiation initiates 
oxygen dependant photochemistry via endogenous chromophores. Consequently, 
although UVA is weakly absorbed by most bio-molecules, UVA exerts its effects 
indirectly by means of radicals and ROS (Tyrrell, 1996). Today, UVA is considered 
to be the primary source of oxidative stress to human skin.
1.2.4 Reactive oxygen species
Upon absorption of UVA photons, an electron within an unsaturated group on 
an absorbing chromophore is transferred to an orbital of higher energy. This electron 
can either maintain the same direction of spin, producing an unstable singlet species, 
or can undergo spin conversion to yield a more stable triplet species. As shown in 
figure 1.1, type I photosensitised oxidation can result in energy or electron transfer, or 
a direct addition reaction. In contrast, the favoured type II photosensitised oxidation 
results in the generation of reactive oxygen species (ROS) (Coohill et al., 1987; 
Tyrrell and Keyse, 1990). Within mammalian cells, quinones, flavins (Krishna et al, 
1991) and in particular reduced nicotinamide co-factors (Cunningham et al., 1985;
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Czochralska et al., 1984), as well as porphyrins (Carraro and Pathak, 1988) can act as 
chromophores. All of these molecules can yield large amounts of ROS such as singlet 
oxygen ( ^ 2) and superoxide anion (0 2 ’’) when UVA irradiated.
It has been shown that at least half of UVA-induced cell damage results from 
]02 (Tyrrell and Pidoux, 1989). It is the highly energised state of this molecule which 
is responsible for its destructive nature. Singlet oxygen is not a radical; it is an 
energised but uncharged form of the diatomic molecule in which the valence electrons 
are spin paired. Singlet oxygen displays an atomic state in which the two spin angular 
moments of the electrons cancel each other out, creating zero net spin, and a state 94 
kJ mol'1 higher in energy than the ground state (Halliwell and Gutteridge, 1990). In 
1988, Tyrrell published one of the earliest studies to implicate ]02 in UVA 
cytotoxicity (Tyrrell and Pidoux, 1989). The study employed a human fibroblast line 
(1BR/3) cultured from a skin biopsy of a normal adult human. In this study cells were 
treated at various UV wavelengths in the presence of the *02 lifetime enhancer 
deuterium oxide (D2O) (Lindig et al., 1980). In the presence of D2O, the study 
observed greatly reduced cell viability within the UVA and near visible spectrum, 
particularly around 365 nm, although no such relationship was observed outside of the 
UVA range; findings that were indicative of the unique oxygen dependent 
photochemistry of UVA. Further to this, Tyrrell and Pidoux showed that when cells 
were irradiated at 365 nm in the presence of sodium azide, a strong and reasonably 
specific quencher of !02, the inverse relationship was observed. In the presence of 
sodium azide, a two-fold protection against radiation at 365 nm was observed; 
consistent with the interpretation that at least half of UVA induced cellular damage is 
! 0 2  dependent.
Superoxide anion (0*2*) is another ROS that is generated by UVA. Superoxide 
anion is a one-electron reduction of diatomic O2, and is generated by type I or II 
photosensitised oxidation, particularly with respect to the UVA-mediated photo­
oxidation of NADH and NADPH (Cunningham et al., 1985; Czochralska et al., 
1984). Superoxide anion is relatively un-reactive towards most bio-molecules such 
as lipids and DNA (Fridovich, 1978); however, 0 *2’ does inactivate proteins that 
contain prosthetic groups such as heme or iron sulphur clusters (Gamer et al., 1995).
Hydrogen peroxide (H2O2) is yet another ROS that is generated by UVA. 
H2O2 is generated as a result of UVA-induced photo-oxidation of tryptophan 
(Czochralska et al., 1984; McCormick et al., 1976), macromolecules (Tyrrell et al.,
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1991), and NADH / NADPH (Cunningham et al., 1985; Czochralska et al., 1984; 
McCormick et al., 1976). Hydrogen peroxide is itself a reactive oxygen species, 
however, it is far more cytotoxic following its decomposition via the Fenton reaction 
which results in the generation of hydroxyl radicals (refer to figure 1.2). Hydroxyl 
radicals (OH') are a three-electron reduction of diatomic oxygen, they are highly 
reactive, and have been implicated in UVA inactivation of cells (Tyrrell et al., 1991). 
It is believed that OH” are primarily generated by the Fenton reaction (Walling, 1975), 
a reaction that is driven by a transition metal ion, particularly iron, and 0*2’. As with 
any reaction, the Fenton reaction proceeds at a rate dictated by its limiting factor. As 
stated, UVA generates H2O2 and O2''. It would therefore seem likely that iron would 
present as the limiting factor. However, work has shown that there is a substantial 
increase in intracellular free iron following UVA treatment, the result of UVA- 
induced proteolytic degradation of ferritin (Pourzand et al., 1999). UVA therefore 





3X + Substrate — > !x  + 3Substrate (Energy Transfer)
3X + Substrate —► X’+ + Substrate'* (Electron Transfer)




3X + 3o 2 - -> !X + l02  (Singlet Oxygen Generation)
3X + 3o 2 - ■* X*+ + O2'* (Superoxide Anion Generation)
X = Chromophore
Figure 1.1: The photochemistry of a Type 1 and Type II photosensitised
oxidation
The Fenton Reaction
[1] H20 2 + Fe2+ - -> OH + OH' + Fe3+
[2] 0 2" +  Fe3+ - -» 0 2 + Fe2+
Figure 1.2: The chemistry of the Fenton Reaction
[1]: The reduction of hydrogen peroxide driven by the oxidation of iron. 
[2]: The reduction of iron driven by oxidation of superoxide anion.
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1.2.5 Cellular damage
DNA has extremely low absorption in the UVA range (Kielbassa et al., 1997). 
Accordingly, UVA exerts genotoxicity by means of photosensitisers, which upon 
absorption of UVA photons, transfer energy via oxygen to other biomolecules, 
including DNA. UVA can introduce genetic damage in one of three forms: strand 
breaks, base modification, and base deletion. Base deletion is observed at a far lower 
incidence with respect to UVA when compared to other wavelengths of ultraviolet 
radiation (Cadet et al., 1992), and therefore warrants no further discussion. Base 
modification and strand breaks are the most common forms of genetic damage 
introduced by UVA.
Oxidation of guanine, induced in human skin by electromagnetic radiation 
ranging from 312 to 434 nm, is reputed to be the predominant form of UVA-induced 
DNA damage (Douki et al., 1999; Kvam and Tyrell, 1997; Pflaum et al., 1994; Zhang 
et al., 1997). The oxidative product of the reaction, 8-oxo-7,8,-dihydro-2’- 
deoxyguanosine (8-oxodGuo), is highly mutagenic, and results in non Watson-Crick 
base-pairing during replication. Studies have shown that it is UVA-generated ]Oi that 
is the cause of 8-oxodGuo (Devasgayam et al., 1991). Another form of base 
modification that has been attributed to UVA is pyrimidine photoproducts. 
Pyrimidine photoproducts are observed in two different forms, (6-4) photoproducts 
and cyclobutane pyrimidine dimers (CPDs). With respect to UVA, only the 
cyclobutane ring structures are observed (Applegate et al., 1999; Kuluncsics et al., 
1999; Mori et a l, 1988; Tyrell, 1973; Umlas et al., 1985). UVA induced CPDs, 
although observed at a lower frequency than oxidative products of guanine, are at 
least equally cytotoxic, and result in the insertion of erroneous bases during 
replication. Accordingly, CPDs correlate with cell death and often tumorgenicity 
(Hart et al., 1977; Sutherland et a l, 1985), an effect that has been demonstrated in 
vivo (Ley et a l, 1991; Vandaberg et al., 1994).
Strand breaks, both single and double, also result from UVA irradiation (Peak 
et al., 1987; Peak and Peak, 1990). Strands breaks however play a less significant 
role in UVA cytotoxicity. Endogenous endonucleases generate strand breaks to 
induce apoptosis, a key function in cell regulation. It is the introduction of erroneous 
strand breaks which is detrimental to cell health. Such strand breaks often occur as a
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result of deoxyribose degradation, the incidence of which has been linked to 
intracellular ROS (Murata-Kamiya et al., 1995). Both ]02 and OH’ possess the 
ability to cause such damage, the former of which is widely considered to be the 
principal mediator. In addition to this, work has shown that ]02 has the capacity to 
break covalent bonds within DNA (Blazek et al., 1989), particularly at guanine 
residues (Devasgayam et al., 1991).
1.2.6 UVA activation of signalling pathways
In mammalian cells, UVR initiates a complex web of signalling pathways. 
The distinct photochemical mechanisms associated with the different wavelengths of 
UVR result in the activation of different signal transduction pathways. UVC 
wavelengths, which do not generate active oxygen intermediates, are strongly 
absorbed by bio-molecules such as DNA. These short UVR wavelengths initiate 
transduction events the majority of which involve stress- and mitogen- activated 
protein kinase cascades (for review see Bode and Dong, 2003). Although UVB 
wavelengths do contain some oxidative components, the signalling pathways 
stimulated by this intermediate wavelength solar UVR exhibit greater similarity to the 
signal transduction pathways associated with UVC radiation rather than those 
associated with UVA.
In various models, experimental evidence has shown that UVB radiation is 
able to: stimulate the release of a wealth of immunomodulating cytokines (Hunt et al., 
2006; Jiang et al., 2005), initiate expression of cell adhesion molecules (Cornelius et 
al., 1994; Kimbauer et al., 1992), activate transcriptional up-regulation of proto- 
oncogene transcription factors (Soriani et al., 2000), as well as lead to the stabilisation 
of p53 (Chouinard et al., 2002; She et al., 2000). In addition to this, UVB radiation is 
reputed to activate proteins that are involved in an abundance of signal transduction 
pathways such as mitogen-activated protein kinases (MAPK), extracellular signal- 
regulated kinases (ERK), and c-Jun N-terminal kinases (JNK) (Fisher et al., 1998).
The unique oxidant dependent photochemistry that is associated with UVA 
has been shown to initiate signalling pathways that are not stimulated in response to 
the shorter UVB and UVC wavelengths. The literature suggests that following a 
physiological, non-cytotoxic, dose of UVA radiation, UVA induced gene expression 
is modulated through active oxygen intermediates. UVA has been shown to regulate
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expression of several genes; these include, amongst others, matrix metalloproteinases 
(Herrmann et al., 1993), the nuclear proto-oncogenes c-fos and c-jun (Bose et al., 
1999; Soriani et a l, 2000), and heme oxygenase-1 HO-1 (Keyse and Tyrrell, 1989). 
Previous studies have shown that UVA gene-regulation can be influenced by 
removing the intracellular antioxidant glutathione or enhancing ]C>2 lifetime. The 
literature indicates that it is l02 that is the primary effector in UVA gene regulation.
1.3 Heme Oxygenase
1.3.1 General remarks
At present three mammalian isoforms of heme oxygenase (HO) have been 
identified, HO-1, HO-2, and HO-3 (Maines, 1988; McCoubrey et al., 1997; 
Shibahara, 1988). Of the two catalytically active forms of HO, HO-1 and HO-2, it is 
the former that has been shown to be inducible, whilst HO-2 is constitutively 
expressed.
HO-1 is classified as a heat shock protein (HSP32). A wealth of 
physiological, pathophysiological, and non-physiological agents have now been 
shown to induce HO-1. These include, acute exercise (Thompson et al., 2005), the 
HO-1 substrate heme (Balia et al., 1995; Yoshida et al., 1988), hypoxia (Motterlini et 
al., 2000), heavy metals (Mitani et al., 1993), heat shock (Shibahara et al., 1987; 
Ewing and Maines, 1991), ROS such as H2O2 (Keyse and Tyrrell, 1989), and UVA 
radiation (Keyse and Tyrrell, 1989). In recent years it has become apparent that HO-1 
possesses potent cytoprotective properties, and it is now recognised that the protein is 
a crucial mediator of cellular homeostasis under conditions of stress. Consequently, 
considerable scientific endeavour has been expended elucidating the biological 
mechanisms that regulate HMOX1. Elucidation of the mechanisms underlying UVA 
regulation of HMOX1 is a primary concern of this study.
1.3.2 HO-1 structure and localisation
The human HMOX1 locus is located on chromosome 22 (22ql2.3). The post­
spliced transcript is composed of 5 exons which code for a 288 residue 32 000 Mr 
protein (Yoshida et al., 1988). HO-1 is preferentially localised in endoplasmic
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reticulum and microsomes. Studies have shown that the structure of HO-1 is largely 
d-helical (Schuller et al., 1999) and that the hydrophobic C-terminus functions as a 
microsomal membrane anchor protein (Yoshida and Sato, 1989). The conserved core 
o f HO-1 is completely novel when compared to other known structures in the Protein 
Data Bank. The core consists of hydrophobic inner chamber composed of two a  -  
helices which form a pocket in which the HO-1 substrate heme resides and undergoes 
enzymatic degradation.
1.3.3 The crucial defence enzyme HO-1
HO-1 is the rate limiting step in heme catabolism (Tenhunen et al., 1969). 
Equimolar amounts of three products are produced as a result of heme degradation: 
biliverdin, which is rapidly converted to bilirubin through the action of biliverdin 
reductase (Singleton and Laster, 1965; O’Carra and Colleran, 1971), ferrous iron 
(Fe2+), and carbon monoxide (CO) (Tenhunen et al., 1969) (refer to figure 1.3). The 
cytoprotective action of HO-1 is, at least in part, derived from its ability to degrade 
free cellular heme; a polar molecule with the ability to destabilise proteins, lipids, and 
nucleic acids. Further to this, the cytoprotective action of HO-1 has been related to 
the catabolites of heme which have been shown to possess anti-inflammatory, anti- 
apoptotic, anti-oxidant, as well as cell signalling properties (for review see: Maines, 
1997; Morse and Choi, 2002; Otterbein et al., 2003).
The heme catabolite biliverdin and its derivative bilirubin are known to 
possess powerful anti-oxidant activity in vitro (Stocker et al., 1987). Studies have 
indicated that bilirubin can reduce peroxyl radicals and that biliverdin can act as a 
peroxyl radical ‘trap’. Further to this, studies have related the potent cytoprotective 
action of bilirubin to the prevention of lipid peroxidation in liposomes (Stocker and 
Ames, 1987), the prevention of depletion of endogenous antioxidants (Neuzil and 
Stocker, 1997), and inactivation of ROS such as 0*2’ and *02 (Stevens and Small, 
1979), as well as the inhibition of photo-oxidative damage to proteins (Pederson, 
1977).
Carbon monoxide is another product of heme catabolism. Studies have shown 
that CO can act as a soluble second messenger (Furchgott and Jothianandam, 1991; 
Maines, 1997; Vema et al., 1993). The actions of CO have been implicated in a 
number of intracellular and extracellular effects, these largely include anti-
11
inflammatory, anti-apoptotic, and anti-proliferative actions (for reviews see: Christova 
et al., 2000; Heiman and Delbro, 2005; Herman 1997). Interestingly, work has shown 
that CO confers an inhibitory action on most heme containing proteins, including the 
heme-HO complex that may have generated the molecule. Carbon monoxide may 
therefore serve to inhibit HO-1 heme degradation.
The final catabolite of heme degradation is Fe2+. HO-1 releases Fe2+ from the 
core of the heme molecule, resulting in the up-regulation of the iron-sequestering
i
protein ferritin, as well as the activation of ATPase pumps that serve to remove Fe 
from the cell (Ferris et al., 1999). As stated previously, Fe2+ is extremely reactive 
towards oxygen, and can catalyse the conversion of un-reactive species into highly 
reactive species by means of the Fenton reaction. This results in the generation of 
ROS. Ferrous iron is therefore considered detrimental towards biological systems. 
The role of Fe2+ in biological systems has been reviewed elsewhere (Taketani, 2005; 
Torti and Torti, 2002).
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Figure 1.3: Diagrammatic representation of the HO-1 catalysed degradation of
heme
(next page)
The diagram shows the reduction of the »-Meso carbon bridge of the heme molecule by 
HO-1. The reaction requires NAPDH and the presence of oxygen to proceed. 
Biliverdin, ferrous iron, and carbon monoxide are the products of the reaction. 
Biliverdin is itself rapidly reduced to bilirubin through the action of bilverdin reductase. 
















1.3.4 The physiological importance of HO-1
HO-1 is the most dramatic example of oxidant-inducible gene expression in 
mammalian cells (Applegate et al., 1991; Keyse and Tyrrell, 1989). Increased 
expression of the protein has been shown to be crucial for protection against cell 
damage (Otterbein and Choi, 2000; Poss and Tonegawa, 1997; Ryter and Tyrrell, 
2000), and has been linked to resistance to tissue injury in a wealth of pathologies. 
This protection against tissue injury has been attributed to the removal of the pro­
oxidant heme, as well as the products of heme degradation, bilirubin and CO. Most of 
our current understanding relating to the functional significance and therapeutic 
benefits of HO-1 has been generated in a rodent model (for review see: Immenschuh 
and Ramadori, 2000), either through specific over expression of HO-1 by gene 
transfer, pharmacological modulation, or through targeted gene knock-out. However, 
few studies have addressed the functional importance of HO-1 in humans.
In 2002 the first autopsy findings relating to a HO-1'7' human were published 
(Kawashima et al., 2002). The autopsy notes describe a 6 year-old boy who weighed 
only 13 kg and measured 86.5 cm in height. The findings of the autopsy describe a 
long list of pathologies. These included: anaemia; leukocytosis; thrombocytosis; 
coagulation abnormalities; elevated levels of serum haptoglobin, heme, and ferritin; 
low serum albumin concentration; as well as hyperlipidemia. In addition to this, the 
autopsy notes describe amyloid deposits in the liver as well as kidney glomerular 
dysfunction. The boy also exhibited an irregular distribution of macrophages as well 
as fatty streaks and fibrous plaques around the heart. Reverse transcription 
polymerase chain reaction (RT-PCR) found that the HO-1 gene was mutated in both 
alleles. A two-nucleotide deletion within exon 3 was detected in the paternal band, 
and a complete loss of exon 2 was found in the maternal band (Saikawa et al., 2000; 
Yachie et al., 1999). Interestingly, the boy presented with a number of pathologies 
that are not observed in HO-1'7' mice, and which often exhibit extremely long 
survival.
Accumulating evidence has indicated the possible therapeutic value of 
pharmacological modulation of HO-1 by virtue of its anti-inflammatory (for review 
see Alcaraz et al., 2003; Immenschuh and Schroder, 2006), anti-apoptotic (for review 
see Fang et al., 2004), and pro-proliferative actions (for review see Durante, 2003). 
Clinical application of the enzyme has been proposed in a wealth of pathological
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states. These include: atherosclerosis (Ishikawa et al., 1997; Morita, 2005; Siow et 
al., 1999; Wang et al., 1998), hypertension (Ishizaka et al., 1997; Vera et al., 2006), 
acute renal injury (Akagi et al., 2005; Goncalves et al., 2006), toxic nephropathy 
(Agarwal et al., 1995; Horikawa et al., 1998), endotoxic shock (Lee and Chau, 2002), 
chronic obstructive lung disease (Carter et al., 2004; Xia et al., 2006), gastrointestinal 
diseases (Guo et al., 2000), Alzheimer’s disease (Calabrese et al., 2004; Ishizuka et 
al, 2002; Smith et al., 1994), transplant rejection (Bach, 2006; Hancock et al., 1998; 
Soares et al., 1998; Woo et al., 2000) and others (Chen et al., 1999; Horvath et al., 
1998; Levere et al., 1993; Otterbein et al., 1999)
Depending on the pathology, activation or suppression of HMOX1 may hold 
therapeutic value. One example of a disease state where HMOX1 up-regulation may 
be beneficial is coronary heart disease (CHD). Each year, in excess of 250 000 
individuals die globally as a result of CHD. Coronary heart disease is the 
consequence of an inflammatory process which results in the accumulation of 
atherosclerotic plaques within the walls of the arteries that supply the myocardium. 
Clinical studies have observed strong accumulation of HO-1 mRNA and protein in 
both animal and human atherosclerotic plaques (Wang et ah, 1998). Therefore, owing 
to the anti-inflammatory properties of HO-1, pharmacological activation of the HO-1 
gene may prove a hugely effective therapeutic tool in preventing plaque formation 
(for review see: Morita, 2005). Studies have also shown that pathologies such as 
Alzheimer’s disease (for review see: Calabrese et al., 2004) and acute renal failure 
(for review see: Akagi et al., 2005) may also benefit from over-expression of this 
gene. Furthermore, studies have shown that up-regulation of HMOX1 may hold 
significant protection against allograft and xenograft transplant rejection (Hancock et 
al., 1998; Soares etal., 1998; Woo et al., 2000).
An increasing amount of evidence indicates a vital role for HO-1 in both cell 
growth and cell death. Hence, the potential of the protein as a target in anticancer 
treatment is being evaluated (for review see; Fang et al., 2004). In contrast to other 
pathologies, the pro-proliferative and anti-apoptotic properties of HO-1 suggest that it 
is suppression of HMOX1 that may prove beneficial in order to increase the efficacy 
of existing cytotoxic cancer therapeutics.
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1.3.5 UVA up-regulation of HO-1
In 1987 it was shown that the oxidising component of solar radiation (UVA) 
could induce a 32 KDa stress protein in human skin fibroblasts (Keyse and Tyrrell, 
1987). It was later shown by molecular cloning that the protein was the oxidant 
inducible microsomal protein HO-1 (Keyse and Tyrrell, 1989). Up-regulation of HO- 
1 by UVA radiation is now known to represent a crucial cellular defence mechanism 
against oxidative stress, but the events underlying HO-1 regulation by UVA remain 
poorly characterised in human cells.
At present, ROS are reputed to be the principal mediator of UVA up- 
regulation of HO-1. Work from this laboratory has shown that it is ^  that is the 
primary effector in UVA regulation of the HO-1 gene in primary human fibroblasts 
(Basu-Modak and Tyrrell, 1993). Basu-Modak and Tyrrell (1993) observed that 
UVA fluence-dependent up-regulation of HMOX1 is enhanced in the presence of 
deuterium oxide (D2O), a strong and reasonably specific ]02 lifetime enhancer (Lindig 
et al., 1980). Further to this, in the presence of sodium azide, a ]02 quencher (Singh, 
1982), this study observed a substantial decrease in UVA fluence-dependent HO-1 
mRNA accumulation. Moreover, this study observed that other UVA generated ROS 
such as 0 *2’ and OH' marginally influence UVA-regulation of HMOX1. Researchers 
from this laboratory have also shown that the carotenoid beta-carotene, one of the 
most potent *02 quenchers in nature, can suppress UVA-induced HMOX1 up- 
regulation in human cells (Trekli et al., 2003). Trekli and co-workers observed a 
concentration-dependent suppression of UVA-induced transcriptional activation of 
HMOX1 at carotenoid concentrations that have been documented in human plasma 
after dietary supplementation; further evidence of the involvement of ^ 2  in the UVA- 
regulation of HMOX1. The HO-1 substrate heme has also been implicated in UVA 
up-regulation of HMOX1 in human cells (Kvam et al., 1999). Kvam and co-workers 
observed a cyclooxygenase dependent release of micromolar amounts of heme from 
microsomal hemoproteins following UVA treatment. Furthermore, Kvam and co­
workers documented a high degree of correlation between the amount of heme 
released and the subsequent degree of HMOX1 activation.
Taken together these studies indicate both an oxidant and substrate dependent 
mechanism for HMOX1 gene activation in human skin cells. Based on the 
observation that heme release from heme-proteins also occurs in response to H2O2
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(Kvam et al., 1999), and therefore indicating that the release of heme from heme- 
containing proteins is itself oxidant dependent, these two mechanisms for HMOX1 
gene activation appear to be intrinsically linked.
Work from this laboratory has established that there is a refractoriness o f the 
HO-1 gene to re-induction by UVA irradiation (Noel and Tyrrell, 1997). Crucially, it 
has been shown that the development of a refractory period to re-induction of 
HMOX1 is limited to UVA and heme, and is not observed using other known inducers 
of the HO-1 gene (unpublished observations, this laboratory). This refractoriness to 
re-induction therefore suggests that the molecular mechanism that underlies UVA- 
regulation of HMOX1 is unique. Studies have shown that neither UVA (Keyse et al., 
1990) nor heme (Srivastava et al., 1993) influence the half-life of HO-1 mRNA. 
Hence, the refractoriness event is not attributable to messenger stability. The products 
of heme catabolism have been shown to be involved in this effect, and thus a feedback 
mechanism may be present (Noel and Tyrrell, 1997). However, it was shown that 
HO-1 enzymatic activity is not the sole cause of this refractory period. Results have 
been obtained consistent with the notion that it is in fact insufficient intracellular 
heme containing proteins that is responsible for the refractoriness to induction of 
HMOX1 by UVA. Complete refractoriness to reinduction of HMOX1 by UVA was 
observed for 48 hrs following the initial UVA treatment. In relation to this, work has 
shown that more than half of the total detectable cellular microsomal hemoprotein is 
degraded by UVA, and that the amount of heme-containing protein does not recover 
for 48 hrs (Kvam et al., 1999).
These results indicate that both heme and ROS are involved in UVA up- 
regulation of HMOX1. A  major focus of this study will be the role of heme in UVA 
regulation of HMOX1.
1.3.6 HMOX1 regulation
Deletion studies using a murine model have shown that hmox-1 transcriptional 
regulation is dependent on conserved 1 0 -bp sequences termed stress response 
elements (StRE) (Inamder et al., 1996). Two StRE with the consensus sequence 
TGA(C/G)TCA(T/C) have been identified in the upstream region of the murine 
hmoxl promoter. These StRE are known to have a sequence that closely resembles 
the consensus sequence of several previously characterised response elements. These
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include the antioxidant response element (ARE), and the M af associated recognition 
element (MARE) which is known to act as a binding site for the activating 
transcription factor Nrf2. To some extent the terms StRE, ARE, and MARE have 
been used inter-changeably within the literature, but for the purposes of this 
discussion these cis-acting elements will be referred to as MARE sites.
MARE containing enhancer regions termed El and E2 have been identified in 
the murine genome situated approximately 3.85 and 9.65 kb upstream of the hmoxl 
transcriptional start site (Alam et al., 1989, Alam et al., 1995, Alam et al., 1999). 
Searches of human chromosome 22 have identified two similar cis-acting elements 
upstream of the HMOX-1 transcriptional start site (Takeda et al., 1994; Raval and 
Tyrrell, unpublished observations this laboratory). MARE are known to be 
recognised and bound by small Maf proteins (either MafK, MafG, or MafF) (Kataoka 
et al., 1994), and evidence has been provided indicating that various basic leucine 
zipper factors, specifically NF-E2-related factors, heterodimerise with Maf proteins 
and influence MARE-driven gene expression. Heterodimers comprising of a small 
M af protein and Nrf2 have been shown to activate the HO-1 gene (Itoh et al. 1997, 
Alam et al., 1999, Alam et al., 2000, Ishii et al., 2000, Kataoka et al., 2001). Bachl, 
another basic leucine zipper protein, has been shown to form heterodimeric 
complexes with small Maf proteins which serve to negatively regulate the HO-1 gene 
(Oyake et al., 1996; Igarashi et al., 1998, Sun et al., 2002). Much of our current 
understanding of HO-1 gene regulation is derived from work in mice, and few studies 
have addressed the issue in a human model. The conserved positioning of MARE 
between the murine and human genome indicates that similar regulatory mechanisms 
may exist between humans and mice; however, this has not been fully investigated. A 
primary concern of this study is to explore the regulation of HMOX1 in a human 
model.
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Figure 1.4: Diagrammatic representation of the upstream enhancer 
elements in the human and mouse heme oxygenase-1 promoter
(next Page)
Figure 1.4(a): The human HMOX1 promoter.
Searches of chromosome 22 upstream of HMOXl have identified two 
MARE-containing enhancer elements situated approximately 4.0 and 9.1 kb 
upstream of the HMOXl transcriptional start site.
Figure 1.4(b): The murine hmox-1 promoter.
Two MARE-containing enhancer elements situated at approximately 3.85 
and 9.65 kb upstream of the hmox-1 transcriptional start site have been 
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The NF-E2-related family of proteins includes N rfl, Nrf2, and Nrf3. These 
transcription factors are Cap ‘n’ Collar (CNC)-containing leucine zipper (b-Zip) 
proteins (Itoh et al., 2004; Jaiswal, 2004; Nguyen et al., 2004). NF-E2-related 
transcription factors are known to form heterodimers with small Maf proteins 
(Motohashi et al., 2002). These heterodimeric complexes are reputed to bind to 
MARE sites in the 5’-flanking region of phase II detoxifying enzymes (Rushmore et 
al., 1991), including the subject of this study, HMOXL Of the three known Nrf 
proteins, Nrf2 has been shown to be the most potent inducer of MARE-regulated 
genes (Jaiswal, 2004), and many studies have shown that Nrf2 provides substantial 
protection against cellular oxidative stress. Crucially, using a murine model, 
investigators have shown that Nrf2 plays a principle role in up-regulation of the 
oxidant inducible gene hmox-1 (Alam et al., 1999).
1.4.2 The physiological importance of Nrf2
Chemical and endogenous insult brought upon by environmental toxicants 
result in the expression of enzymes involved in detoxification (Primano et al., 1997). 
The cellular detoxification process is divided into phase I and phase II reactions. 
Phase I reactions are catalysed by the P-450 mono-oxygenase system, whist phase II 
reactions incorporate a larger cohort of enzymes that include NAD(P)H: quinone 
oxidoreductase 1 (NQOl), glutathione S-transferase (GST), and HO-1. In some 
instances phase I catalysed reactions produce chemical species that are potentially 
more toxic than the parental species; thus, phase II catalysed reactions are a 
requirement for complete detoxification and generally result in less toxic products. 
Under physiological (reducing) conditions, phase II enzymes are expressed 
constitutively at a relatively low level. It is endogenous or xenobiotic chemical insult 
that results in enzyme accumulation. It is now known that accumulation of enzymes 
involved in phase II detoxification is dependent on activating transcription factors. 
These activating transcription factors are known to up-regulate phase II genes through 
association with cis-acting regulatory elements. A recent study has demonstrated the
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importance of Nrf2 in phase II gene activation. Hayes et al., (2000) observed reduced 
phase II gene activation in nrf2 knock-out mice. In relation to this, investigators have 
shown that insufficient induction of phase II enzymes results in increased 
susceptibility to xenobiotic chemicals (Aoki et al., 2001; Enomoto et al, 2001; Chan 
and Kan, 1999; Goldring et al., 2004; Iizuka et al., 2005; Khor et al., 2006); and that 
Nrf2 plays a key role in cancer prevention (auf dem Keller et al., 2006; Ramos- 
Gomez et al., 2001; Yates et al., 2006).
Genome-wide screening has now implicated Nrf2 in the activation of in excess 
of 2 0 0  genes, and much of our current understanding of the physiological importance 
of Nrf2 is derived from work in murine models. However, the physiological 
implications of defective Nrf2 in humans are not yet fully understood.
1.4.3 Nrf2 structure and regulation
Nrf2 has six functional Neh [Nrf2-ECH (erythroid cell-derived protein with 
CNC homology) homology] domains (refer to figure 1.5). All six domains exhibit 
inter-species conservation (Itoh et al., 1999; Katoh et al, 2001; McMahon et al., 
2004). The Nehl domain located at the proteins C-terminus contains the CNC-bZIP 
region, and confers both MARE binding and dimerisation with small Maf proteins. 
The 100 residue Neh2 domain situated in the N-terminal region confers binding to the 
actin associated protein Keapl which serves to negatively regulate Nrf2 (McMahon et 
al., 2004). The domains Neh4 and Neh5 interact with CBP [CREB (cyclic AMP- 
response element binding protein) binding protein] and synergistically contribute to 
transcriptional activation of the protein (Katoh et al, 2001). The redox-insensitive 
Neh6  domain has been shown to be essential in the degradation of the protein in 
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Figure 1.5: Diagrammatic representation of the functional domains of Nrf2
Nrf2 has six functional Neh [Nrf2-ECH (erythroid cell-derived protein with CNC 
homology) homology] domains. Each o f the six domains is conserved inter species. 
The C-terminus o f Nrf2 contains a basic leucine zipper structure which aids in both 
MARE binding and dimerisation with small M af proteins. Nrf2 is negatively regulated 
by binding to the actin associated protein Keapl at the Neh2 domain. The domains 
Neh4 and Neh5 interact with CBP [CREB (cyclic AMP-response element binding 
protein) binding protein] which synergistically contribute to transcriptional activation of 
the protein.
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1.4.3 Nrf2 structure and regulation (cont)
Transcriptional up-regulation of nrf2 has been reported previously (Kwak et 
al., 2002). However, studies have shown that Nrf2 is primarily regulated by two post- 
translational mechanisms: cytoplasmic retention (anchoring), and modulation of 
protein half-life (Dhakshinamoorthy and Jaiswal, 2001; Itoh et al., 1999; Jaiswal, 
2004). Studies have shown that the cytoplasmic actin-binding protein Kelch-like 
ECH-associated protein 1 (Keapl) plays the co-ordinating role in the Nrf2 stress 
response mechanism. Under basal ‘reducing’ conditions Keapl is tightly complexed 
with Nrf2, anchoring Nr£2 within the cytoplasm (Kang et al., 2004), and therefore 
preventing transcriptional activation of phase II genes. It is now understood that 
Keapl acts as a sensor of oxidative and electrophilic stress, releasing Nrf2 in response 
to such stimuli. In addition to this, it has been reported that oxidative stress can 
initiate the release of Nrf2 from Keapl by phosphorylation of Nrf2 at serine 40. This 
has been related to the activation of protein kinase C and other cytosolic factors (for 
review see Jaiswal, 2004). A recent in vivo study using a murine model has evaluated 
the functional importance of Keapl (Wakabayashi et al., 2003). Wakabayashi and 
co-workers observed that Keapl mutation leads to postnatal lethality due to 
constitutive Nrf2 activation, therefore underlining the importance of this negative 
regulator of phase II gene activation.
Studies have shown that while complexed with Keapl, Nrf2 is rapidly 
degraded by means of the ubiquitin (Ub)- proteasome proteolysis system (Itoh et al., 
2003; Kobayashi et al., 2006; Nguyen et al., 2003; Sekhar et al., 2002; Stewart et al., 
2003; Zhang and Hannink, 2003). Two distinct molecular mechanisms by which 
Keapl modulates total cellular levels of Nrf2 have been proposed: Firstly,
cytoplasmic localisation of Nrf2 through binding to the actin associated protein Keapl 
may increase the proximity of Nr£2 to the proteasome system (Itoh et al., 2003; 
McMahon et al., 2003), thus increasing the probability of ubiquitination. Secondly, 
Keapl may effectively promote Nrf2 proteasomal degradation through active 
recruitment of proteasome subunits (Cullinan et al., 2004; Kobayashi et al., 2004). 
Devling et al., (2005), elegantly demonstrated the role of Keapl in Nrf2 degradation 
by means of RNAi. Using human keratinocytes, Devling and co-workers lowered the
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level of endogenous Keapl mRNA to < 30 % of control levels. The Keapl targeted 
RNAi markedly enhanced levels of Nrf2 protein and increased transcription of an 
ARE-driven reporter gene 2.3-fold.
A degree of complexity surrounds the possible mechanisms involved in ROS / 
electrophile induced separation of Nrf2 from Keapl. It has been proposed that 
sulfhydryl groups on cysteine residues within Keapl may mediate a conformation 
change of Keapl in response to cellular stress, releasing Nrf2 and resulting in nuclear 
accumulation of the transcription factor (Dinkova-Kostova et al., 2002; Itoh et al., 
1999). Indeed both murine and human Keapl are known to contain 25 highly 
conserved cysteine residues. However, more recent data have shown that 
modification of these residues does not cause dissociation of the Nrf2-Keapl complex 
(Eggler et al., 2005), rather that modification of these residues inhibits ubiquitin 
conjugation to Nrf2 (Kobayashi et al., 2006). Studies have also shown that 
phosphorylation of Nrf2 results in release from Keapl. However, the complex web of 
signalling cascades that may culminate in phosphorylation of Nrf2 cannot be fully 
explored within the confines of this discussion, and have recently been reviewed 
elsewhere (Giudice and Montella, 2006).
It is known that phase II gene activation by Nrf2 can be negatively regulated 
by Keapl, and that dissociation of Nrf2 from Keapl results in Nrf2 nuclear 
accumulation. Nuclear localisation of Nrf2 may decrease the rate of proteasomal 
degradation, favouring accumulation of the protein, and therefore increasing phase II 
genes activation (refer to figure 1.6). However, further research is required to fully 
elucidate all aspects of this regulatory mechanism.
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Figure 1.6: Diagrammatic representation of the Nrf2-Keapl regulatory system
(next page)
The diagram shows activation of Nrf2 by ROS and electrophiles. In an ‘un-stimulated’ 
cell, Nr£2 is localised to the cytoplasm through association with the cytoskeleton 
binding protein Keapl. In response to electrophiles or ROS Keapl and Nrf2 dissociate, 
this results in nuclear translocation of Nr£2. Nrf2 subsequently forms heterodimers with 
small Maf proteins which subsequently bind to MARE sites in the 5’-flanking region of 
phase II genes (including HMOXl). The Nrf2-Maf heterodimers activate phase II genes 
through the recruitment of proteins required for assembly of the pre-transcription 
complex. The cytoplasmic anchor protein Keapl also enhances the probability of 
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1.4.4 Nr£2 activation of HMOXl
Using both rodent and human models, Nr£2 has been implicated in HO-1 gene 
activation by a wealth of inducers. These include: arsenite, cadmium, heme, tert- 
butylhydroquinone (7-BHQ) (Alam et ah, 1999; Alam et ah, 2000), acrolein (Wu et 
ah, 2006), cobalt (Gong et al., 2001; Shan et al., 2006), curcumin (Balogun et al., 
2003; Rushworth et al., 2006), 15-deoxy-deltal2,14-prostaglandin j2 (PGJ2) (Gong et 
al., 2002), epigallocatechin-3-gallate (EGCG) (Wu et al., 2005), gold (Kataoka et al.,
2001), l-chloro-2,4-nitrobenzene (CDNB), diethyl maleate (DEM), glucose oxidase 
(GO), H2O2 (Ishii et al., 2000), 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) (Pae 
et ah, 2006), and hypoxia (Cho et ah, 2002).
Studies have shown that dissociation of Nrf2 from the cytoplasmic anchor 
protein Keapl is the dominant mechanism responsible for Nrf2 phase II gene 
activation. In relation to this, an abundance of known inducers of HMOXl have been 
shown to augment nuclear accumulation of Nrf2. Moreover, in addition to nuclear 
localisation, studies have shown that Nrf2 protein accumulation may occur through 
Nrf2 protein stabilisation. The HO-1 inducing agents cadmium (Stewart et al., 2003) 
and heme (Alam et ah, 2003), have been shown to increase Nrf2 protein half-life from 
13 to 1 0 0  mins and 13 to 1 1 0  mins respectively.
Electromobility shift assays have shown that Nrf2-Maf heterodimers bind to 
the MARE consensus sequence in vitro (Itoh et ah, 1997). As stated previously, it is 
known that a MARE regulatory element exists at approximately 4 kb upstream of the 
human HMOXl transcriptional start site (Takeda et ah, 1994). Unpublished searches 
of the human HMOXl upstream region by this laboratory have revealed the presence 
of a second MARE containing enhancer region approximately 9.1 kb upstream of the 
HMOXl transcriptional start site. As shown in figure 1.4, conservation of the 
structure, location, and multiplicity of MARE sites between the rodent and human 
genome defines a clear argument for the analogous conservation of regulation 
between these two species. A concern of this study is to provide insights into the 
UVA regulation of HMOXl by Nrf2 in human skin cells.
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1.5 The Oxidising Carcinogen UVA
1.5.1 General remarks
In the year 2000, over one million cases of skin cancer were diagnosed in the 
U.S., 78 % of which were basal cell carcinoma, 20 % squamous cell carcinoma, and 2 
% malignant melanoma. UVA wavelengths have been strongly implicated in the 
aetiology of the most life threatening cutaneous malignancy, malignant melanoma 
(Moan et al., 1999; Setlow et al., 1993). The incidence of malignant melanoma has 
increased by a factor of approximately 15 in the past 60 years. This increase has been 
attributed to an increasing number of fair skinned European and North American 
citizens travelling to foreign climates, and to the increasing use of sun beds in these 
societies (Westadahl et al., 2000). The ever-increasing number of individuals 
presenting with neoplastic related disorders has placed a huge burden on global health 
resources. Consequently, enormous emphasise has been placed on the elucidation of 
the aetiology of such pathologies.
1.5.2 Apoptosis and carcinogenesis
Cell death can occur by means of two processes, apoptosis or necrosis. The 
term apoptosis, or programmed cell-death (PCD), refers to a biological cascade of 
events that result in cell death, and that are therefore fundamental to physiological 
homeostasis. All apoptotic cells exhibit conserved morphological features that 
include a reduction in cell volume, membrane blebbing, chromatin condensation, and 
DNA fragmentation (Kerr et al., 1972, Wyllie, 1980). Necrosis, sometimes referred 
to as accidental or caspase-independent cell death, is less orderly. Necrosis is 
morphologically distinct from apoptosis, and although as efficient as apoptosis, 
necrosis may release harmful chemicals that damage adjacent cells and result in 
inflammation.
Apoptosis ensures that a suitable equilibrium between cell growth and cell 
death is maintained, and therefore that cell population and organ size is maintained 
(Kerr et al. 1972). Hence, regulated cell death is as vital for the continued survival as 
regulated cell growth. Abnormalities in the regulation of cell death have been 
implicated in the pathogenesis of a wealth of disease states. These include: acquired
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immune deficiency syndrome, ischemic injury, neurodegenerative injuries, 
autoimmune diseases, and cancer (Thompson, 1995). In recent times substantial 
emphasise has been placed on elucidation of the role of anti-apoptotic genes in 
carcinogenesis. The anti-apoptotic gene HMOXl is one such example. The role of 
apoptosis in cancer prevention and treatment has recently been reviewed elsewhere 
(Dlamini et al., 2005; Zhivotovsky and Orrenius, 2006).
1.5.3 UVA and apoptosis
Different wavelengths of UVR are known to influence biological systems by 
different photochemical mechanisms. The method by which different UVR 
wavelengths induce cell death has been examined previously (Godar et al., 1994; 
Godar et al., 1999). UVA (320 -  400 nm) was shown to induce both immediate ( 0 - 4  
h) and delayed apoptosis (approximately 20 h); while UVB (280 -  320 nm) and UVC 
( 2 0 0  -  280 nm) were shown to only induce delayed apoptosis.
Photo-therapies such as photodynamic therapy (PDT) are one of the few 
clinical applications of UVA and are used to remedy skin diseases. PDT is a 
therapeutic modality involving the photo-oxidation of biological material mediated by 
a localised photosensitiser. When UVA irradiated, the photosensitiser initiates cell 
death in the diseased tissue. The success of such phototherapies has, at least in part, 
been attributed to direct killing of diseased cells by apoptosis (Godar et al., 1999b). 
With regards to the dermatological application of PDT, UVA has been shown to be 
successful in the treatment of actinic keratoses, basal cell carcinomas, Bowen's 
disease, morphea, sarcoidosis, warts, and psoriasis (for review see; Gilaberte et al., 
2006). It is these therapeutic applications of UVA that have prompted investigations 
into the mechanism by which UVA causes cell death.
With respect to PDT, it is known that J0 2  is the fundamental mediator of UVA 
induced cell death (Morita et al., 1997). The role of ] 0 2  in UVA-induced cell death 
has also been investigated using transformed human lymphocytes by employing 
agents with the ability to generate ^  and 0 *2’ (Godar, 1999). This study concluded 
that ] 0 2  was involved in UVA immediate (0 - 4 h) cell death, and that 0 *2 ' was 
involved UVA late apoptosis (20 h). An objective of this study is to determine the 
role of the anti-apoptotic protein HO-1 in UVA-apoptosis.
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1.5.4 The anti-apoptotic protein HO-1
In excess of 30 % of all mortalities in Western societies can be attributed to 
neoplastic pathologies. Accumulation of HO-1 has been documented in a variety of 
cancers. These include: adenocarcinoma, hepatoma, sarcoma, glioblastoma, 
melanoma, and squamous cell carcinoma (Deininger et al., 2000; Doi et al., 1999; 
Goodman et al., 1997; Torisu-Itakura et al., 2000; Tsuji et al., 1999). Experimental 
studies have shown that accumulation of HO-1 results in cellular proliferation, a loss 
of apoptotic potential, and tumour angiogenesis, factors that are all important for in 
vivo tumour growth (Hellmuth et al., 2002; Sunamura et al., 2003). The anti- 
apoptotic properties of HO-1 have therefore drawn considerable attention in recent 
times (for review see; Fang et al., 2004). The HO-1 substrate heme is known to be 
pro-oxidant and has the ability to generate ROS (Ryter and Tyrrell, 2000). Hence, the 
anti-apoptotic action of HO-1 has been attributed to the degradation of this pro­
oxidant molecule. As well as this, the products o f heme degradation, biliverdin and 
CO, have also been shown to be involved in the anti-apoptotic action of HO-1. 
Moreover, it has been shown that modulation of labile iron is another factor that may 
contribute to this anti-apoptotic influence (Ferris et al., 1999).
Iron contributes to the formation of free radicals which subsequently damage 
DNA, proteins, and lipids (for review see: Meneghini, 1997; Puntarulo et al., 2005). 
Therefore, accumulation of free Fe2+ may ultimately lead to apoptosis. Iron therefore 
presents a considerable toxicological threat. The concentration of the intracellular 
iron storage protein ferritin has been shown to reflect cellular labile iron, and is 
therefore central to intracellular iron homeostasis (Ponka et al., 1998). In relation to 
this, studies have shown that the level of ferritin increases following up-regulation of 
HO-1 (Eisenstein et al., 1991; Vile and Tyrrell, 1993). It is therefore likely that the 
anti-apoptotic action of HO-1 is, at least in part, attributable to sequestration of the 
pro-oxidant iron. However, a study using human skin cells has shown that UVA, a 
known inducer of HMOXl, results in an immediate release of iron by means of 
ferritin proteolysis (Pourzand et al., 1999). Therefore, a degree of complexity 
surrounds the role of iron in apoptosis with regards to UVA up-regulation of HMOXl.
Biliverdin is a product of heme degradation, and is rapidly converted to 
bilirubin by the action o f biliverdin reductase. Bilirubin is a lipophilic tetrapyrole and 
is one of the most abundant endogenous anti-oxidants in humans. This anti-oxidant
32
action has been attributed to ROS scavenging activity (Minetti et a l , 1998). A recent 
study has shown that physiologically relevant concentrations of bilirubin can protect 
cells from a 10 000-fold excess of H2O2 (Baranano et al., 2002). In this study, 
Baranano and co-workers examined the influence of bilirubin on apoptosis in human 
keratinocytes. The results of this investigation showed that depletion of bilirubin by 
RNAi markedly augments ROS concentration and causes apoptotic cell death.
Carbon monoxide is another product of heme degradation and has also been 
implicated in anti-apoptotic effect of HO-1. Inhibition of apoptosis through the 
exogenous administration of CO has been shown in a variety of cell lines including, 
fibroblasts, endothelial cells, and vascular smooth muscle cells (Brouard et al., 2000; 
Liu et al., 2002). The anti-apoptotic influence of CO has been related to activation of 
p38 mitogen-activated protein kinase (MAPK) (Brouard et al., 2000; Silva et al., 
2006), as well as inhibited expression of the pro-apoptotic protein p53 (Liu et al.,
2002). In addition to this, researchers have shown that CO can inhibit apoptotic 
signalling by suppression of caspase cleavage, as well as inhibited activation of Bcl-2- 
related proteins (Kim et al., 2006; Wang et al., 2007; Zhang et al., 2003).
A lose of apoptotic potential contributes to the progression of carcinogenesis; 
therefore, modulation of the anti-apoptotic protein HO-1 is likely to influence the 
survival of neoplastic lesions. Several recent studies illustrate this point. Zhang et 
al., (2004) observed an increase in apoptosis using HO-1 RNAi. Results from this 
laboratory have shown that the inhibition of HO-1 enzymatic activity using a 
competitive substrate analogue increases apoptosis 2 -fold in human skin fibroblasts 
(unpublished observations). Moreover, inhibition of HO-1 using a competitive 
substrate analogue has been shown to increase caspase-3 activity (Tanaka et al.,
2003). Findings have also been published indicating that in vitro application of a 
pegylated HO-1 competitive substrate analogue can decrease tumour diameter 
through promoting apoptosis, and furthermore solid tumour apoptosis can be 
enhanced through HO-1 RNAi (Fang et al., 2003; Sahoo et al., 2002). The literature 
clearly indicates that inhibition of HO-1 enzymatic activity or gene suppression may 
have therapeutic value since apoptotic resistance in tumours strongly influences the 
efficacy of cytotoxic cancer therapies.
Malignant melanoma is the most life-threatening cutaneous malignancy. 
Clinical oncology studies have indicated that the high probability of mortality 
associated with this type of cancer can be attributed to the high tendency to aggressive
33
growth and resistance to apoptosis; yet the cellular mechanisms responsible for 
melanoma resistance to cytotoxic cancer therapeutics remain to be elucidated. Drug 
resistance in melanoma is most likely caused by a deregulation of apoptotic pathways 
(for review see: Rockmann and Schadendorf, 2003; Soengas and Lowe, 2003). 
Therefore HO-1 may hold significant therapeutic value in the treatment of this cancer. 
Using a murine model, a single study has evaluated the effect of HO-1 over- 
expression in melanoma (Was et al., 2006). This study concluded that HO-1 over­
expression increased viability, proliferation, and angiogenic potential of melanoma 
cells, augmented metastasis, and decreased survival of tumour-bearing mice. 
However, very few studies have evaluated the influence of HO-1 in human 
melanoma. A recent study has however evaluated the relationship between a 
microsatellite polymorphism in the HMOXl promoter and risk of melanoma 
(Okamoto et al., 2006). It is known that a (GT)n dinucleotide repeat polymorphism in 
the HMOXl promoter can modulate HMOXl gene expression (Yamada et al., 2000). 
In vitro work has revealed that so called ‘short HMOXl alleles’ (fewer than 25 GT 
repeats), result in increased promoter activation in response to oxidative stimuli when 
compared to longer alleles (Hirai et al., 2003). Okamoto and co-workers were the 
first to investigate the role of this polymorphism in relation to melanoma. This study 
offers findings consistent with the interpretation that individuals with short (GT)n 
repeats have a greater probability of developing malignant melanoma. The results of 
this study indicate that individuals homozygous for the short allele have a risk of 
developing melanoma that is double that of heterozygous individuals. Taken 
together, all of these data indicate that HO-1, and the proteins involved in HMOXl 
regulation, may hold significant potential in augmentation of current modalities of 
cancer therapy. An objective of this study is to evaluate the role of HO-1 in human 
melanoma.
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1.6 Aims and Objectives
This study will determine the effect of UVA radiation on the transcription 
factor Nrf2 in primary human skin fibroblasts. Nrf2 is known to be principally 
regulated by two post-translational mechanisms: cytoplasmic retention (anchoring), 
and modulation of protein half-life. In this study the effect of UVA on the sub- 
cellular localisation of Nr£2 will be assessed; and, it will be determined whether 
UVA-generated reactive oxygen species influence Nrf2 nuclear localisation. In 
addition to this, this study will establish whether UVA results in Nrf2 protein 
accumulation. It is known that UVA releases the HO-1 substrate heme from heme- 
containing proteins, and that heme stabilises Nrf2 in murine cells. This study will 
address whether exogenous heme treatment results in Nrf2 accumulation in human 
cells, and whether heme is involved in UVA mediated accumulation of Nrf2. To do 
this intracellular heme will be depleted prior to UVA treatment. An assay will 
therefore be developed to allow the amount of intracellular heme to be monitored. 
Further to this, the effect of UVA on NRF2 gene activation will also be assessed. 
Nrf2 is known to activate phase II genes by binding to MARE sites in the 5’-flanking 
region of these genes. A principal concern of this study is to provide insight into the 
UVA activation of the anti-apoptotic phase II gene HMOXl.
In this study, the hypothesis that HO-1 modulates apoptosis in human 
melanoma cells will also be investigated. Human melanoma cells often lack apoptotic 
potential, and therefore prove highly resistant to cytotoxic cancer therapeutics. 
Studies using human and rodent models have indicated that HO-1 possesses potent 
anti-apoptotic activity. Employing the oxidising UVA component of solar radiation 
to induce apoptosis, this study will investigate whether HO-1 over-expression 
prevents UVA-apoptosis in human melanoma cells. This study aims to provide 
evidence that HO-1 may prove a suitable therapeutic target for intervention in order to 
increase the efficacy for cytotoxic cancer therapeutics in human melanoma cells.
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2. Materials and Methods
U N I V E R S I T Y  OF
BATH
2. Materials and Methods
2.1 Chemicals and Reagents
Unless otherwise stated all biochemicals were of analytical grade and were 
obtained from Sigma Aldrich (UK). All cell culture constituents were obtained from 
GIBCO (Invitrogen Life Technologies, UK).
2.2 Cell Culture
2.2.1 Cell storage and recovery
Cells were stored in liquid nitrogen within ampoules in medium supplemented 
with 10 % v/v dimethyl sulphoxide (DMSO). For cell recovery, each ampoule was 
rapidly thawed at 37°C and the contents transferred to a conical centrifuge tube 
containing 9 ml of warm culture medium. The cell suspension was then centrifuged 
(1,000 rpm for 5 minutes) and the supernatant discarded. The cell pellet was then re- 
suspended in an appropriate volume of culture medium and incubated using the cell 
culture conditions described in section 2 .2 .2 .
2.2.2 Cell maintenance
FEK4 /  JUSO /  IGR1
The primary human skin fibroblast cell line FEK4, and the human melanoma 
cell lines JUSO and IGR1 (refer to table 2.1), were cultured in Earle’s modified 
minimal essential medium (EMEM) supplemented with 10 % v/v heat-inactivated 
fetal bovine serum (FBS) (15 % FBS was used for FEK4), 2 mM glutamine, 0.2 % 
sodium hydroxide, 50 U/ml penicillin, and 50 pg/ml streptomycin. Cells were 
maintained at 37°C in a 5 % CO2 / 95 % air humidified incubator (LEEC Ltd, 
Nottingham, UK) and were passaged weekly using 0.25 % trypsin (5 minutes, 37°C). 




The human lymphoblastoid cell line TK6  (refer to table 2.1) was routinely 
cultured in RPMI 1640, supplemented with 10 % v/v heat-inactivated horse serum 
(HS), 2 mM glutamine, 0.2 % sodium hydroxide, 50 U/ml penicillin, and 50 (ig/ml 
streptomycin. The pH of the culture medium was adjusted to 7.0 by addition of 1.0 
ml of 5 M NaOH. Cells were maintained at 37°C in a 5 % CO2 / 95 % air humidified 
incubator. Using these conditions the cell doubling time was approximately 18 hours. 
Cells were maintained in exponential growth by splitting 1 in 10 v/v every 3 days.
NIR (041 and 999)
The primary human melanocyte cell line NIR (refer to table 2.1), was 
routinely cultured in Ham’s F-10 (PAA Laboratories, UK), supplemented with 5 % 
v/v heat-inactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 100 jig/ml 
streptomycin, 200 nM phorbol 12-myristate 13-acetate (PMA), 200 pM cholera toxin 
(type inaba 569B, azide free) (Merck Biosciences), and 10 ng recombinant human 
stem cell factor (Fahrenheit Laboratory Supplies, UK). Cells were maintained at 37°C 
in a 5 % CO2 / 95 % air humidified incubator and were passaged monthly using 0.25 
% trypsin (5 minutes, 37°C). NIR cells were only employed for experimental 
procedures between passages 3 and 5.
G361
The human melanoma cell line G361 (refer to table 2.1), was routinely 
cultured in McCoy’s 5A supplemented with 5 % v/v heat-inactivated FBS, 2 mM 
glutamine, 50 U/ml penicillin, and 50 pg/ml streptomycin. Cells were maintained at 
37°C in a 5 % CO2 / 95 % air humidified incubator and were passaged weekly using 
0.25 % trypsin (5 minutes, 37°C).
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Cell Line Description Reference / Source
FEK4 Primary human fore-skin 
fibroblast cell line
Tyrrell and Pidoux, 1986
IGR1 Pigmented human 
melanoma cell line
Dr S. Carrel 
Ludwig Institute, 
Lausanne, Switzerland
JUSO Lightly pigmented human 
melanoma cell line
Dr S. Carrel 
Ludwig Institute, 
Lausanne, Switzerland
G361 Lightly pigmented human 
melanoma cell line
National Radiological 
Protection Board, Didcot, 
UK
NIR Primary human 
melanocyte cell line
National Radiological 
Protection Board, Didcot, 
UK
TK6 Human lymphoblastoid 
cell line
Thilly, 1979
Table 2.1: Summary of cell lines




2.3.1 UVA irradiation source and conditions
Cells were irradiated using a broad-spectrum 4 kW UVA lamp (340 -  400 nm) 
(Sellas, Munich, Germany). The lamp exposure time was calculated using an IL1700 
radiometer (International Light, Newbury, USA) with an SEE400 probe. Prior to 
UVA irradiation, the growth medium was removed from the cells and retained; each 
dish was then washed twice with phosphate buffered saline (PBS) (Oxoid Ltd, UK). 
Cells were then covered with PBS supplemented with 0.01 % Ca2+ and 0.01 % Mg2+ 
prior to irradiation. In order to maintain a consistent temperature of 25°C throughout 
the irradiation procedure, irradiation was conducted in an air-conditioned room. Post 
irradiation the Ca2+ / Mg2+ supplemented PBS was removed and the dishes were 
washed twice with PBS. The retained media (referred to as conditioned media) was 
then added back. Control cells underwent identical treatment, except that they were 
not irradiated. A dose rate (fluence) of approximately 300 J m '2 sec"1 was used 
throughout this study. Therefore, the irradiation time for a dose of 250 kJ/m2 was 
between 20 and 30 minutes.
2.3.2 Actinomycin-D
A stock solution of 5 mg/ml actinomycin-D was prepared in DMSO. This 
stock solution was diluted by a factor of 1 , 0 0 0  into serum free medium to give a 
working concentration of 5 pg/ml actinomycin-D (0.1 % DMSO). Before this 
chemical was added to the cells, the culture medium was removed and the cells were 
washed twice with PBS. 5 pg/ml actinomycin-D (0.1 % DMSO) was added to the 
cells one hour post irradiation. The cells were cultured in the presence of this 
chemical for the time periods indicated at 37°C in a 5 % CO2 / 95 % air humidified 
incubator.
2.3.3 Cadmium chloride
A 100 pM stock solution of cadmium chloride (CdCb) was prepared in water. 
This stock solution was diluted by a factor of 10 into serum free medium to give a
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final working concentration of 10 pM CdC^. Cells were exposed to 10 pM CdCl2 or 
the vehicle control (serum free medium) for the time periods indicated at 37°C in a 5 
% CO2 / 95 % air humidified incubator.
2.3.4 Deuterium oxide
PBS was prepared by dissolving one PBS tablet in 100 ml of 99.9 % 
deuterium oxide (D2O). The D2O-PBS solution was then supplemented with 0.01 % 
Ca2+ and 0.01 % Mg2+ and filter sterilised. D20-PBS was used to cover cells during 
irradiation in place of H2O-PBS. Control cells were covered with H2O-PBS during 
irradiation. Cells were covered with the H2O- or D2O-PBS 15 minutes prior to 
irradiation.
2.3.5 Hemin
A stock solution of 10 mM bovine hemin was prepared in DMSO. This stock 
solution was diluted by a factor of 1 0 , 0 0 0  into serum free medium to give a working 
concentration of 1 pM hemin (0.01 % DMSO). Prior to addition of the chemical to 
the cells, the culture medium was removed and the cells were washed twice with PBS. 
Cells were exposed to 1 pM hemin, or the vehicle control (0.01 % DMSO), for the 
time periods indicated at 37°C in a 5% CO2 / 95% air humidified incubator and under 
darkened conditions to prevent photodegradation by hemin. Untreated cells remained 
within the incubator throughout the course of the experiment.
2.3.6 Succinyl acetone
A 1 mM working solution of 4, 6 -dioxoheptanoic acid [Succinyl Acetone 
(SA)] was prepared in serum free medium. The solution was subsequently filter 
sterilised. Prior to the addition of the chemical to the cells, the culture medium was 
removed and retained. Cells were then washed twice with PBS. Cells were exposed 
to 1 mM SA or the vehicle control (serum free medium) for 24 hours at 37°C in a 5 % 
CO2 / 95 % air humidified incubator. After 24 hours the serum free medium was 
removed and the conditioned medium returned. Untreated cells remained within the 
incubator throughout the course of the experiment.
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2.4 Protein extraction and quantification
2.4.1 Whole cell extracts
Following treatment cells were maintained at 37°C in a 5 % CO2 / 95 % air 
humidified incubator. At the time points stated, the cell culture medium was removed 
and each dish was washed twice with PBS. Cells were then collected by addition of 
an appropriate volume of 0.25 % trypsin (37°C for 5 minutes) and / or scraping with a 
rubber policeman. The detached cells were then pelleted by centrifugation (13,000 
rpm for 30 seconds) and the supernatant discarded. The cell pellet was then lysed into 
an appropriate volume of stabilisation buffer [50 mM tris-HCl pH 7.5, 150 mM NaCl, 
10 % Glycerol, 5 mM ethylene-diaminetetraacetic acid (EDTA), 1 % NP40, and 1 
mM phenylmethylsulfonyl fluoride (PMSF)]. The cell lysate was then centrifuged at 
4°C for 2 minutes at 13,000 rpm. The resultant supernatant containing total cellular 
free protein was retained and flash-frozen using 1 0 0  % ethanol containing dry-ice. 
Cell extracts were stored at -80°C until required.
2.4.2 Nuclear and cytoplasmic cell extracts
Following treatment cells were maintained at 37°C in a 5 % CO2 / 95 % air 
humidified incubator. At the time points stated, the cell culture medium was removed 
and each dish was washed twice with PBS. Cells were then collected by addition of 
an appropriate volume of 0.25 % trypsin (37°C for 5 minutes) and / or scraping with a 
rubber policeman. The detached cells were then pelleted by centrifugation (13,000 
rpm for 30 seconds) and the supernatant was discarded. The cell pellet was then lysed 
into an appropriate volume of cytosolic extraction buffer [10 mM Hepes pH 7.9, 10 
mM KC1, 0.1 M ethylene-glycoltetraacetic acid (EGTA), 0.1 M EDTA, 1.5 mM 
MgCl2 , 1 mM 1,4-dithio-DL-threitol (DTT), and 0.1 x protease inhibitor cocktail 
(Roche)], and incubated on ice for 15 minutes. NP40 was then added to a final 
concentration of 0.5 % and the lysate was vigorously vortexed for 10 seconds. The 
cell lysate was then centrifuged at 13,000 rpm for 30 seconds. The supernatant 
containing the cytoplasm and RNA was collected and flash-frozen using 100 % 
ethanol containing dry-ice. The nuclear pellet was then washed in the cytoplasmic 
extraction buffer before lysis into an appropriate volume of the nuclear extraction
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buffer [20 mM Hepes pH 7.9, 400 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM 
DTT, and 0.1 x protease inhibitor cocktail]. The nuclear lysate was then placed on a 
rocking platform for 15 minutes at 4°C. The nuclear lysate was the centrifuged at 
13,000 rpm for 5 minutes. The supernatant containing the nuclear fraction of the cell 
was collected and flash-frozen using 100 % ethanol containing dry-ice. Both 
cytoplasmic and nuclear extracts were stored at -80°C until required.
2.4.3 Microsome isolation
Following treatment the cell culture medium was removed and each cell 
population was washed twice with an appropriate volume of PBS. The cells were 
then collected by scraping in 1 ml of PBS using a rubber policeman. The cell 
suspension was then pelleted by centrifugation (1,000 rpm for 5 minutes at 4°C); the 
supernatant was discarded. The cell pellet was re-suspended into 3 ml of ice cold 0.1 
M potassium phosphate buffer (pH 7.0). The cells were then disrupted by 3 cycles of 
rapid freezing and thawing, and sonication ( 2  x 1 0  seconds at the lowest strength). 
The cell debris and mitochondria were removed by centrifugation at 15,000 g (5 
minutes at 4°C). The supernatant was then ultra-centrifuged at 100,000 g (1 hour at 
4°C) in order to sediment the microsomal fraction. The resultant firmly packed pellet 
of microsomes was re-suspended in 100 pi of ice cold 0.1 M potassium phosphate 
buffer (pH 7.0) and stored at -20°C until required for analysis.
2.4.4 Quantification of protein concentration
Protein concentration was calculated using the Bio-Rad protein assay based on 
the Bradford dye binding procedure (Bradford, 1976). A calibration curve was 
generated using six concentrations of bovine serum albumin (BSA) ( 0 - 1 7  pg/ml) in 
the same solvent as the cell extract. Each calibration standard was produced in 
duplicate. For each cell extract the protein concentration was determined in duplicate 
using 5 pi of extract using a 96-well spectrophotometric microplate reader 
(VERSAmax, Molecular Devices) and the software package SoftMax Pro.
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2.5 mRNA extraction and quantification
2.5.1 mRNA extraction
Following treatment the cell culture medium was removed and each dish was 
washed twice with an appropriate volume of PBS. Cells were then collected by 
scraping with a rubber policeman. The detached cells were then pelleted by 
centrifugation (13,000 rpm for 30 seconds) and the supernatant was discarded. The 
cell pellet was then flash-frozen in 100 % ethanol containing dry-ice. Cell extracts 
were stored at -80°C until RNA extraction. Total RNA isolation was accomplished 
using Sigma’s GenElute™ Mammalian Total RNA Kit according to the 
manufacturer’s instructions. RNA was eluted from the binding column using 50 pi of 
elution buffer and stored at -80°C until required for experiments.
2.5.2 Quantification of mRNA concentration
RNA concentration was determined by spectrophotometric absorbance at 260 
nm (GeneQuant II, Pharmacia Biotech). The ratio of absorbance at 260 nm to 280 nm 
(A260/A280) was also determined as a measure of extract purity.
2.6 Gel electrophoresis
2.6.1 Acrylamide gel electrophoresis
Denaturing gels comprising of either 7.5 % or 10 % acrylamide were used 
throughout this study. 7.5 % acrylamide gels were prepared as follows: 2.8 ml of 40 
% acrylamide (40 %, 29:1, acrylamide: bis-acrylamide) (Fluka, Biochemika), 5.6 ml 1 
M Tris pH 8.8, 75 pi of 20 % sodium dodecyl sulphate (SDS), 6.6 ml MilliQ water; 
total volume approximately 15 ml (enough for two gels). 10 % acrylamide gels were 
prepared in the same manner but contained 3.8 ml of 40 % acrylamide and 5.6 ml 
MilliQ water. Both 7.5 % and 10 % acrylamide gels were set by the addition of 100 
pi of 10 % ammonium persulphate (APS) and 40 pi of N,N,N',N!- 
tetramethylethylenediamine (TEMED). The gels were cast between two BioRad glass 
plates. During setting 20 pi of butanol was poured onto the top of the gel solution in
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order to prevent evaporation and to ensure an even surface for a stacking (loading) 
gel. Stacking gels were prepared as follows: 0.51 ml of 40 % acrylamide (40 %, 29:1, 
acrylamide: bis-acrylamide), 0.5 ml 1 M Tris pH 6.8, 20 pi of 20 % SDS, 2.86 ml 
MilliQ water; total volume approximately 4 ml (enough for two gels). Stacking gels 
were set by the addition of 50 pi of 10 % APS and 20 pi of TEMED. The gels were 
allowed to set for one hour prior to use.
2.6.2 Agarose gel electrophoresis
Agarose gels composed of between 2 and 5 % agarose were used throughout 
this study. The density of the gel used for each experiment was selected based on the 
fragment size of the smallest oligonucleotide that was expected to be visualised. 100 
ml of agarose gel was prepared as follows: 2 - 5  grams of electrophoresis grade 
agarose (Invitrogen Life Technologies, UK) was added to 100 ml of either tris-acetate 
buffer (TAE) (20 mM tris acetate, 1 mM EDTA pH 8.0) or tris-borate buffer (TBE) 
(45 mM tris base, 45 mM boric acid, 1 mM EDTA pH 8.0) and dissolved using a 
microwave oven on low power for 2 - 3 minutes. The solution was allowed to cool to 
approximately 60°C before it was poured into a horizontal casting tray (Danaphor, 
Grandvaux, Switzerland). The gel was allowed to cool to room temperature for 
approximately one hour prior to use.
The gel was covered with sufficient TAE or TBE in order to cover the wells. 
Electrophoresis was performed at 55 volts for an appropriate length of time (usually 
60 -  90 minutes) until full band separation had taken place. In order to visualise the 
bands the gel was bathed in a solution containing 0.7 pg/pl ethidium bromide at room 
temperature for 20 minutes. Based were visualised under UV light (SynGene, 




The expression vector pcDNA3.1(+) (Invitrogen Life Technologies, UK) was 
employed in this study to independently over-express both green fluorescent protein 
(GFP) and HO-1. pcDNA3.1 is a non-replicative 5.4 kb vector that has been designed 
for high-level transient expression in mammalian cells. The vector contains a human 
cytomegalovirus immediate-early (CMV) promoter for high-level gene expression, 
and ampicillin resistance gene to allow for selection of transformed E.coli (refer to 
figure 2.1). All transient transfection experiments employed the empty pcDNA3.1 
vector as a control. The two over-expression vectors used in this study were 
propagated as described in section 2.8 and were transfected into cultured mammalian 
cells as described in section 2.9.
2.7.2 HO-1 over-expressing construct
pcDNA3.1-HO-l (a kind gift from Professor Roland Stocker, Medical 
Foundation Building, The University of Sydney, Australia) was employed throughout 
this investigation to over-express HO-1. pcDNA3.1-HO-l contains a lkb insert of the 
human HMOX1 open reading frame. The presence o f the lkb insert was confirmed 
by restriction digest by this study.
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2.7.3 Green fluorescent protein over-expressing construct
pcDNA3.1-EGFP was employed throughout this investigation to over-express 
green fluorescent protein. pcDNA3.1-EGFP was constructed prior to the start of this 
investigation by Dr Stephen Mitchell, University of Bath.
Green fluorescent protein (GFP) is coded for by the gfp gene derived from the 
jellyfish Aequorea Victoria. The gene encodes a protein of 238 residues which 
produces stable fluorescence with no requirement for exogeneous substrates and that 
is not destructive to living tissues (Chalfie et al., 1994). The protein absorbs blue 
light (maximally 395 nm) and emits green light (peak emission at 509 nm). The wild 
type gene has been engineered to produce mutated forms which have both increased 
protein stability and enhanced absorption / emission. pcDNA3.1-EGFP contains the 
GFP mutant F64L / S65T, enhanced (EGFP) (for review see Tsien, 1998). This 
mutant has an altered emission spectrum allowing visualisation of the protein with a 
fluorescence microscope using standard FITC filter settings, and also has emission 






The figure above summarises the features of pcDNA3.1(+ / -)
Full information relating to this expression vector can be found at: 
www. invitrogen. com 
(Invitrogen Life Technologies)
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2.8 Construct propagation and purification
Transformed Escherichia coli (E. coli) containing either pcDNA3.1-HO-l or 
pcDNA3.1-EGFP (or the empty control vector) were cultured overnight at 37°C in a 
shaking incubator (New Brunswick Scientific Shaker, UK) in 250 ml of Luria-Betani 
(LB) broth supplemented with 125 pg/pl ampicillin. The cell suspension was then 
centrifuged (5000 rpm for 10 minutes at 4°C) and the supernatant discarded. The 
bacterial pellet was loosened by vortexing and re-suspended into 5 ml of ice cold re­
suspension solution (1 % glucose, 25 mM tris-HCl pH 8.0, and 1 mM EDTA pH 8.0). 
The suspension was then placed on ice and 10 ml of cell lysis solution was added (0.2 
M NaOH, 2 % SDS). The solution was then mixed by inversion and placed onto ice 
for 15 minutes. 7.5 ml of neutralisation solution (0.8 M acetic acid, 0.8 M potassium 
acetate) was then added. The solution was again mixed by inversion and placed onto 
ice for 15 minutes. The solution was then centrifuged (10,000 rpm for 15 minutes at 
4°C) and the clear DNA containing supernatant retained. 100 pi of RNase A (10 
mg/ml) was added and the solution was incubated at 37°C for 30 -  60 minutes. After 
this incubation period, 10 ml of phenol chloroform was added and the solution 
vigorously vortexed. The solution was then centrifuged (10,000 rpm for 15 minutes 
at 4°C). The lower phase containing protein contaminants was discarded, the clear 
supernatant was retained. Approximately 20 ml of 100 % ethanol was added, and the 
solution was vortexed vigorously for 1 minute. The solution was then centrifuged 
(10,000 rpm for 15 minutes at 4°C) and the supernatant again discarded. The pellet 
was then washed in 70 % ethanol and air-dried for 2 0 - 3 0  minutes. Once dried, the 
pellet was re-suspended into 555 pi of sterile MilliQ water. 106 pi of 5 M NaOH 
followed by 172 pi of 50 % PEG4000 was then added. The solution was vortexed and 
incubated on ice for 30 minutes. After this incubation period the solution was 
centrifuged (13,000 rpm for 15 minutes at room temperature) and the supernatant was 
discarded. The resulting DNA pellet was washed in 70 % ethanol and air dried until 
clear. The pellet was then re-suspended into 300 pi of TE buffer (10 mM Tris, 1 mM 




Cells were seeded into 6-well plates (Nunc, Wiesbaden, Germany) 48 - 72 
hours prior to transfection. Cells were maintained according to the conditions 
described in section 2.2.2. Cells were transfected with either pcDNA3.1-HO-l or 
pcDNA3.1-EGFP (refer section 2.7.2 and 2.7.3 respectively), or the empty control 
vector using the commercially available transfection reagents Lipofectamine™ 2000 
(Invitrogen Life Technologies, UK) or Gene Juice® (Novagen, UK) according to the 
manufacturer’s instructions. Cell monolayers were transfected whilst in exponential 
growth (50 -  80 % confluent). Cells were transfected with the amount of plasmid 
DNA, and using the ratio of plasmid DNA to transfection reagent indicated. Prior to 
transfection the cell culture medium was removed and each dish was washed twice 
with an appropriate volume of PBS. Cells were then bathed in the serum free 
medium Opti-MEM containing the transfection reagent / DNA complex and incubated 
for 4 - 5 hours at 37°C in a 5 % CO2 / 95 % air humidified incubator. After this 
period, the transfection medium was replaced with fresh complete medium and the 
cells were cultured for the time periods indicated before treatment or harvesting. 
Cells were collected by addition of 500 pi of 0.25 % trypsin (37°C for 5 minutes).
2.10 Spectrophotometric detection of intracellular heme
Spectrophotometry was used to determine the intracellular heme 
concentration. The assay is based on the work of Kvam et al., (1999). In this assay 
the nitrogen ligands from the protein-bound heme are replaced by pyridine in alkali. 
The resultant hemochrome is quantified by the difference spectrum of the reduced 
versus oxidised compound. Whole cell extracts were harvested and prepared as 
described in section 2.4.1. The protein concentration of each extract was determined 
as described in section 2.4.4.
For each sample a 0.84 ml aqueous cell extract of known protein content was 
produced. 200 pi of reagent grade pyridine was added, and the solution vortexed. 
100 pi of 1 M NaOH was then added, and the solution again vortexed. The sample 
was then split in equal volumes into two disposable cuvettes and a baseline
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absorbance spectrum taken from 500 to 600 nm (UVIKON 922 Spectrophotometer). 
A few crystals of sodium dithionite and 10 pi of water was added to one of the 
cuvettes in order to reduce the hemochrome. 10 pi of 3 M potassium ferricyanide was 
added to the other cuvette to oxidise the hemochrome. An absorbance spectrum of 
the reduced versus oxidised heme was then obtained between 500 and 600 nm. The 
heme concentration was calculated based on the difference in absorption between the 
peak at 557 nm and the trough at 575 nm of the reduced sample, and using a 
millimolar extinction coefficient of 20.7.
2.11 Fluorometric detection of intracellular heme
An assay for the fluorometric determination of intracellular heme was 
developed based on the work of Morrison, (1965) and Sassa, (1976). The assay is 
based on the conversion of heme to its fluorescent porphyrin derivative by the 
removal of heme iron under acidic conditions. Either whole cell tissue homogenate or 
a solution containing total cellular microsomes was used for this assay. Whole cell 
extracts were harvested and prepared as described in section 2.4.1. Protein 
concentration was determined as detailed in section 2.4.4. Microsomes were isolated 
as described in section 2.4.3.
For each sample the amount of protein stated in the figure legend was added to 
1 ml of 2 M oxalic acid (the volume of oxalic acid was always at least 20 times 
greater than the volume of homogenate used). In addition to this, a series of 8 hemin 
standards were prepared in 0.1 M phosphate buffer pH 7.4 containing 0.05 % BSA, 
and diluted 1:1 v/v with 2 M oxalic acid. The final concentration of the hemin 
standards ranged from 100 -  800 nM. Each cell extract sample and standard was 
produced in duplicate, one of which was boiled at 100°C for 30 minutes (in order to 
remove the heme iron), the other control sample was incubated at room temperature 
for the same time period. All samples were covered during this incubation period in 
order to prevent evaporation. Each cell extract and standard, both boiled and control, 
was produced in duplicate.
The fluorescence of each sample was read at 600 nm emission using a 
spectrofluorometer (SFM 25, Kontron Instruments) set at 405 nm excitation. The 
value of the un-boiled control sample (representing background fluorescence) was 
subtracted from the boiled sample fluorescence where the heme iron had been
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removed. The relative fluorescence of the 8 hemin standards was plotted against 
concentration on a linear scale in order to produce a standard curve. If the standards 
were not linear when plotted, the experiment was considered void. The standard 
curve was used to estimate the heme concentration of the cell extracts.
2.12 Western blotting
Total cellular protein or nuclear and cytoplasmic fractions were prepared as 
described in section 2.4.1 and 2.4.2 respectively. Protein concentration was 
determined as described in section 2.4.4. Cell extracts were diluted with 3 x Laemmli 
(loading) buffer [180 mM tris pH 6.8, 3 % SDS, 150 mM DTT, 30 % glycerol, 0.0015 
% bromophenol blue] and heated to 95°C for 5 minutes. Protein bands were then 
separated on 7.5 -  10 % denaturing acrylamide gels at 150 volts for 60 -  90 minutes 
whist bathed in running buffer (1.5 % w/v tris, 7.2 % w/v glycine, 0.5 % SDS). 
Acrylamide gels were prepared as described in section 2.6.1. The separated protein 
bands were then transferred onto nitrocellulose membrane (Amersham Biosciences, 
UK) using a BioRad eletro-transfer unit at 100 volts for 90 minutes. The cassette 
holding the acrylamide gel and nitrocellulose membrane was bathed in transblot 
buffer (3 % w/v tris, 14.4 % w/v glycine, 20 % methanol) and placed on ice during 
protein electro-transfer.
Following electro-transfer the nitrocellulose membranes were stained with red 
ponceau in order to visualise successful protein transfer. Membranes were then 
thoroughly washed with PBS supplemented with 0.5 % tween (Acros Organics, Geel, 
Belgium). The nitrocellulose membranes were then blocked at 4°C over-night in 5 % 
w/v milk powder in PBS. After blocking, nitrocellulose membranes were incubated 
for 60 -  90 minutes at room temperature bathed in a 5 % w/v milk powder-PBS 
solution containing one of the following primary antibodies: 1:200 anti-Nr£2 rabbit 
polyclonal antibody (H-300, Santa Cruz Biotechnology); 1:200 anti-HO-1 mouse 
monoclonal antibody (OSA-110, Stressgen Bioreagents); 1:500 anti-actin mouse 
monoclonal antibody (A4700, Sigma-Aldrich). After exposure of the primary 
antibody, nitrocellulose membranes were washed thoroughly in 0.5 % tween-PBS. 
Membranes were then covered in a 5 % w/v milk powder-PBS solution containing 
either 1:5000 anti-mouse- or anti-rabbit-HRP conjugated secondary antibody and 
rocked gently on a 3D rocking platform (Stuart Scientific) for 60 minutes at room
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temperature. Immunoreactive bands were visualised using enhanced 
chemiluminescent plus detection (Amersham Biosciences, UK).
In order to re-probe for other immunoreactive bands, membranes were bathed 
in stripping solution [62.5 mM tris-HCl pH 6.8, 1 % SDS, 0.1 M b-mercaptoethanol 
(Acros Organics, Geel, Belgium)] and incubated at 55°C for 20 minutes. Prior to re­
probing membranes were thoroughly washed in both 0.5 % tween-PBS and 5 % w/v 
milk powder in PBS.
2.13 Flow cytometry
2.13.1 General comments
Flow cytometry was performed using a FACScan (Becton Dickinson, 
Erembodegon, Belgium). All flow cytometric data was analysed using the software 
package CellQuest (Becton Dickinson, Erembodegon, Belgium). Unless otherwise 
stated cells were suspended in PBS during FACScan acquisition; for each sample 
10,000 events were recorded. For experiments involving dual colour acquisition, 
sufficient compensation was employed to resolve any emission spectra overlap.
2.13.2 Quantification of apoptosis
Quantification of apoptosis and necrosis was accomplished using the annexin- 
V-fluos (AV) (Roche, UK) and propidium iodide (PI) staining method. Fine changes 
in the cell surface, but not loss of membrane integrity, is a morphological feature 
associated with apoptosis (Andree et al., 1990; Creutz, 1992; Fadok et al., 1992). 
Phosphatidylserine (PS) is a plasma membrane component that is known to 
translocate from the inner part of the membrane to the outer surface during apoptosis 
(Vermes et al., 1995). AV is a Ca2+-dependent phospholipid-binding protein with a 
high affinity for PS (Vermes et al., 1995). Thus, AV can be used as a sensitive probe 
for apoptotic cells (Homburg et al., 1995; Koopman, et al., 1994; Verhoven et al., 
1995). Necrotic cells also exhibit PS on the outer surface of the membrane, however 
this can be related to a loss of membrane integrity. Thus, the application of a dye 
exclusion test in the form of PI in combination with AV allows apoptotic cells to be 
differentiated from necrotic cells.
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Following treatment cells were maintained at 37°C in a 5 % CO2 I 95 % air 
humidified incubator. At the time points stated in the figure legend the cell culture 
medium was removed and retained, and each dish was washed twice with an 
appropriate volume of PBS. Cells were then collected by addition of 500 pi of 0.125 
% trypsin (37°C for 5 minutes). The retained conditioned medium was then added to 
the detached cell suspension in order to inactivate the trypsin, and the cells were 
pelleted by centrifugation (1,000 rpm for 5 minutes). The supernatant was discarded 
and the cell pellet re-suspended into 1 ml of PBS to wash the cells. The cell 
suspension was then centrifuged (1,000 rpm for 5 minutes) and the supernatant 
discarded. The cell pellet was then re-suspended into 100 pi of AV / PI labelling 
solution. The labelling solution comprised of 98 pi of incubation buffer [19 parts 
annexin V w/o Ca2+ buffer (0.15 M NaCl, 10 mM hepes), 1 part 100 mM CaCh], 1 pi 
AV, and 1 pi PI (1 in 20 dilution in PBS). The cells were then incubated in the 
labelling solution at room temperature for 15 minutes under darkened conditions. A 
further 400 pi of incubation buffer was then added to each sample prior to FACScan 
acquisition. All samples were stored on ice under darkened conditions whilst 
acquisition was taking place. During acquisition and analysis, data was viewed using 
a two-dimensional log dot plot defined by the FL1 and FL3 fluorescent profiles. 
Double stained cells were considered necrotic, whereas AV positive PI negative 
stained cells were deemed to be apoptotic (refer to figure 2.2).
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Figure 2.2: Two dimensional flow cytogram: determination of apoptosis
(next page)
In order to determine the percentage of cells undergoing apoptosis in any given 
population, cells were treated as described in section 2.13.2 and analysed by flow 
cytometry. During acquisition and analysis, data was viewed using a two- 
dimensional log dot plot defined by the FL1 and FL3 fluorescent profiles. The 
percentage of living, apoptotic, and necrotic cells was determined by 
superimposing four quadrants over the flow cytogram. The position of these four 
quadrants remained constant for each experiment. Double stained cells, those that 
increased in fluorescence on both the FL1 and FL3 axis, were considered necrotic 
(upper right). Annexin positive / propidium iodide negative stained cells, those 
that increased in fluorescence on the FL1 axis but not on the FL3 axis, were 
deemed to be apoptotic (lower right). Figure 2.2(a) shows a typical cytogram of 
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2.13.3 Quantification of transient transfection efficiency
In order to quantify transfection efficiency, cells were transfected with the 
GFP over-expressing construct pcDNA3.1-EGFP as described in section 2.9. At the 
time points indicated, the cell culture medium was removed and each cell population 
was washed twice with an appropriate volume of PBS. Cells were then collected by 
addition of 1 ml of 0.25 % trypsin (37°C for 5 minutes) and / or scraping with a 
rubber policeman. The detached cells were then pelleted by centrifugation (1,000 rpm 
for 5 minutes) and the supernatant was discarded. During acquisition and analysis 
data was viewed using a one-dimensional log histogram plot defined by the FL1 
fluorescent profile. The percentage of cells transfected was deemed to be the 
percentage of cells exhibiting a higher fluorescence than 98 % of the lowest 
fluorescing cells in the control sample population (refer to figure 2.3).
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Figure 2.3: One dimensional flow cytogram: determination of transfection
efficiency
(next page)
In order to determine the percentage of transfected cells in any given population, 
cells were treated as described in sections 2.9 and 2.13.3 and analysed by flow 
cytometry. During acquisition and analysis data was viewed using a one­
dimensional log histogram plot defined by the FL1 fluorescent profile. The 
percentage of cells transfected was deemed to be the percentage of cells exhibiting 
a higher fluorescence than 98 % of the lowest fluorescing cells in the control 
sample population. Figure 2.3(a) shows a typical histogram of un-transfected 
control cells (Ml < 2 %). Figure 2.3(b) shows a typical cytogram of cells 
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2.14 Immunocytochemistry
Cells were grown to 80 % confluency on sterilised glass coverslips (thickness 
1, 22 x 22 mm, VWR International) using the cell culture conditions described in 
section 2.2.2. Following treatment, and at the time points indicated in the figure 
legend, the cell culture medium was removed and each coverslip was gently washed 
twice with PBS. Each coverslip was then bathed in 2 ml of a 4 % solution of PFA and 
incubated at room temperature for 15 minutes on a 3D rocking platform (lowest speed 
setting). Warmed PBS and PFA were used for these steps to prevent possible 
temperature shock to the cells and subsequent alteration in protein localisation. The 
PFA was removed, and the coverlsips were washed twice with PBS. The cells were 
then permeabilised by bathing the coverslips with -20°C 100 % methanol for 5 
minutes. The methanol was removed, and again the coverlsips were washed twice 
with PBS. Blocking of non-specific sites was accomplished by application of 1 - 2 
drops of Image-iT™ Fx signal enhancer according to the manufacturer’s instructions 
(Alexa-Fluor system, Invitrogen Life Technologies). The coverslips were then 
washed twice in PBS and incubated at room temperature for one hour with the 
primary antibody [anti-Nrf2 rabbit IgG polyclonal antibody (H-300, Santa Cruz 
Biotechnology)]. The primary antibody was diluted 1:100 in PBS; a final 
concentration of approximately 2 pg/pl. The coverslips were then washed twice in 
PBS for 5 minutes on a 3D rocking platform (intermediate speed setting) and then 
incubated in the dark for 2 hours with the secondary antibody according to the 
manufacturer’s instructions [Alexa-Fluor goat anti-rabbit (Invitrogen Life 
Technologies)]. The coverslips were then washed twice in PBS for 5 minutes on a 3D 
rocking platform (intermediate speed setting). Cells were then incubated in Hoechst 
stain (1:1000 dilution in PBS) for 5 minutes at room temperature to allow 
visualisation of nuclei. Coverslips were then washed twice in PBS for 5 minutes and 
were mounted onto glass microscope slides (1.0 mm thick, BDH) using 
Dakocytomation fluorescent mounting medium (DakoCytomation, UK). The cells 
were analysed by oil immersion epifluorescence (Zeiss Immersol, 518N) at 63x 
magnification on a Nikon Eclipse TE2000-U microscope equipped with a Lambda 10- 
2 filter unit (Shutter Instrument Co, UK). Alexa-Fluor goat anti-rabbit was excited at 
650 nm and emission was collected at 668 nm. Hoechst stain was excited by 
ultraviolet light at 350 nm and emission collected at 461 nm. Images were recorded
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using the software program UltraVIEW. The mean fluorescence of each image was 
determined using the software package ImageJ. For each cell the fluorescence 
intensity was determined in both the cytoplasm and the nucleus. A predefined area 
was chosen and superimposed over the cytoplasm and then the nucleus of each cell. 
The mean fluorescence of each cell was determined by dividing the fluorescence 
intensity by the area. The mean fluorescence for each entire image is the mean 
fluorescence of all of the cells contained in that image. For each experiment the mean 
fluorescence intensity of each image has been normalised against the mean 
fluorescence of the untreated control.
2.15 Reverse transcription
RNA was extracted and quantified as described in sections 2.5.1 and 2.5.2 
respectively. For each sample, reverse transcription was performed using 1 pg of 
total RNA using the Superscript™ III system (Invitrogen Life Sciences) for first 
strand cDNA synthesis according to the manufacturer’s instructions. For each sample 
1 pi of 50 pM oligo(dT)2o was used as primer. Oligo(dT) primers were chosen as this 
priming method is known to produce a product suitable for real-time polymerase 
chain reaction (PCR) more consistently than random hexamers or gene-specific 
primers. Reverse transcription was performed using a FlexiGene (Techne) heating 
block. Following reverse transcription the remaining RNA template was destroyed by 
the addition of 1 pi of RNase H to all of the samples in order to increase the 
sensitivity of subsequent PCR reactions. Samples were stored at -20°C until required 
for PCR.
2.16 Real-time polymerase chain reaction (PCR)
2.16.1 General remarks
Real time PCR was performed using the LightCycler system (Roche Applied 
Science, Germany). The LightCycler instrument provides an extremely powerful tool 
for real time quantification of gene expression using a cDNA pool generated as 
described in section 2.15. The LightCycler system functions through the 
incorporation of the DNA binding dye SYBR Green I (Roche Molecular
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Biochemicals, Germany), which exhibits greatly enhanced fluorescence when bound 
to double stranded DNA. At the end of each elongation phase the SYBR Green I dye 
binds to the amplified PCR product and can be detected by fluorescence at 530 nm 
excitation; thus, the level of fluorescence recorded after each elongation phase is 
proportional to the amount amplicon contained within each sample.
2.16.2 Real time PCR -  Roche LightCycler system
Throughout this study, gene expression was measured by relative 
quantification using the software programme LightCycler 4.0 (Roche Applied 
Science, Germany). For quantification of HMOX1, NRF2, and GAPDH gene 
expression, calibrator normalised relative quantification monocolour with efficiency 
correction of 2 was employed throughout this study. Relative quantification allows 
the comparison of two ratios: the ratio of a target cDNA sequence (NRF2 /  HMOX1) 
to a housekeeping reference cDNA sequence (GAPDH) in an unknown sample, to the 
ratio of the same two sequences in a standard sample called a ‘calibrator’. The 
calibrator represents typical proportions of the target and reference sequences against 
which the unknown sample can be compared. The same calibrator was included in all 
of the LightCycler experiments throughout this study allowing for inter-experimental 
comparison. The melting temperature (Tm) of all PCR products was also determined 
at the end of each PCR reaction in order to confirm the product identity and 
differentiate from non-specific products such as primer-dimers.
For all LightCycler experiments the LightCycler -  DNA Master SYBR Green 
I ready to use PCR reaction mix was used (Roche Applied Science, Germany). This 
reaction mix contained Taq DNA polymerase, dNTPs, SYBR Green I dye, and 10 
mM MgCk; only the addition of the specified gene-specific primers, and an 
adjustment in the Mg2+ concentration, was required for optimal PCR. For analysis of 
NRF2, HMOX1, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene 
expression, a reaction mix was prepared containing a final concentration of 0.5 pM of 
both the forward and reverse primer. The primer sequences used are represented in 
table 2.2.
For real time PCR a total volume of 20 pi of reaction mixture was prepared for 
each sample. The reaction mixture was contained within a 20 pi LightCycler 
capillary (Roche Applied Science, Germany) during analysis. Samples were analysed
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using the LightCycler 1.5 instrument (Roche Molecular Biochemicals, Germany). 
For analysis of HMOX1 and GAPDH gene expression, PCR conditions determined by 
this laboratory prior to the start of this study were used (as detailed in table 2.3 and 
2.4). A final Mg2+ concentration of 3.0 mM was used in all experiments for analysis 
of both HMOX1 and GAPDH gene expression. For analysis of NRF2 expression, the 
conditions required for optimal real time PCR were determined (as discussed in 






NRF2 GCG ACGG AAAG AGT AT G AGC GTT GGC AG ATCC ACT GGTTT
HMOX1 AAGAGGCCAAGACTGCGTTC GGTGTCATGGGTCAGCAGC
GAPDH GACATCAAGAAGGTGGTGAA T GT CAT ACC AGG AAAT G AGC
Table 2.2: The primer sequences used for NRF2, HMOX1, and GAPDH RT-PCR 
The primers were designed by Dr Stephen Mitchell (NRF2) and Dr Sharmila Basu- 








Table 2.4: The settings used for real time PCR monitoring o f the GAPDH 
gene using the LightCycler system. These conditions were determined by Dr 








Denaturation 95 30 20 None
Amplification 95 0 20 None
60 5 20 None
72 8 20 Single
Melting Curve 95 0 20 None
65 15 20 None
95 0 0.1 Continuous








Denaturation 95 30 20 None
Amplification 95 0 20 None
55 5 20 None
72 4 20 Single
Melting Curve 95 0 20 None
65 15 20 None
95 0 0.1 Continuous
Cooling 40 30 20 None
Table 2.3: The settings used for real time PCR monitoring o f the HMOX1 
gene using the LightCycler system. These conditions were determined by Dr 
Sharmila Basu-Modak prior to the start o f this study.
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2.16.3 Optimisation of magnesium concentration for NRF2 PCR
In order for optimal NRF2 real time PCR to take place, the Mg2+ concentration 
of the reaction mixture was first optimised. The optimum Mg2+ concentration was 
determined using a calibrator cDNA pool and the NRF2 primers shown in table 2.2. 
Nine reaction mixtures were prepared using the LightCycler -  DNA Master SYBR 
Green I PCR reaction mix according to the manufacturer’s instructions containing
9 4 - 9 +final Mg concentrations ranging from 1.0 -  5.0 mM. For each Mg concentration 
duplicate samples were produced. Samples that contained no cDNA were produced at 
the lowest and highest Mg2+ concentrations. Real time PCR was performed on the 
samples using pre-optimised LightCycler settings including an assumed primer 
annealing temperature of 55°C.
2.16.4 Optimisation of NRF2 primer annealing temperature
The optimum primer annealing temperature for NRF2 real-time PCR was 
determined using non-quantitative gel PCR. A reaction mixture was prepared 
containing the NRF2 primers shown in table 2.2 using Sigma’s ReadyMix™ Taq 
without MgCh according to the manufacturer’s instructions. All of the samples
9  i
contained a final Mg concentration of 2.0 mM and a final primer concentration of 
0.5 pM. PCR was performed on a FlexiGene (Techne) heating block with variable 
temperature gradient using the following programme: Denaturation [95°C, 180 
seconds]; Amplification [(94°C, 20 seconds) {50 -  70°C, 10 seconds) (72°C, 20 
seconds)]; Termination [(72°C, 300 seconds) (4°C, oo)]. The samples were subjected 
to 30 cycles of amplification. During the primer annealing phase, the temperature of 
the heating block was set at a gradient ranging from 50 -  70°C at increments of 
approximately 2°C. For each sample, 10 pi of the reaction product was subjected to 
agarose gel electrophoresis using a 3 % gel as described in section 2.6.2.
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2.17 Statistical Analysis
Unless otherwise stated, results are expressed as a mean and error bars 
represent one standard deviation above and below the mean. A one-way analysis of 
variance (ANOVA) was used as appropriate to test the significance of data. A p  value 








3.1 The sub-cellular distribution of Nrf2 following UVA irradiation
FEK4 cells are primary fibroblasts derived from a human foreskin explant 
(Tyrrell and Pidoux, 1986). Researchers from this laboratory have extensively 
investigated the response of this cell line to UVA radiation, and it is known that UVA 
up-regulates the defence enzyme HO-1 in these cells (Keyse and Tyrrell, 1987; Keyse 
and Tyrrell, 1989). In this study FEK4 primary human fibroblasts have been 
employed as a model to investigate the effect of UVA on the transcription factor Nrf2. 
The sub-cellular distribution of Nrf2 was monitored in FEK4 cells following a 
physiologically relevant dose of UVA radiation (250 kJ/m2). Following treatment, 
FEK4 cells were incubated in conditioned media for the indicated time periods before 
fixing. Nrf2 was then visualised by means of immunocytochemistry.
As shown in figure 3.1, the staining system used to monitor Nrf2 resulted in 
virtually no non-specific binding of the fluorophor conjugated secondary antibody 
allowing for precise monitoring of Nrf2. Further to this, a low level of fluorescence 
was observed in unirradiated control cells allowing Nrf2 accumulation to be 
visualised. As shown in figure 3.1, UVA irradiation resulted in immediate 
accumulation of Nrf2 in both the cytoplasm and the nucleus of FEK4 primary human 
fibroblasts. The images show accumulated Nrf2 in the peri-nuclear region of FEK4 
cells 1 and 2 hours post UVA treatment. UVA irradiation resulted in Nrf2 protein 
accumulation in the nucleus of FEK4 cells from 1 to 4 hours post treatment. The 
mean fluorescence of each image has been determined as described in section 2.14. 
The fluorescence of each image has been normalised against the fluorescence of the 
unirradiated controls and is shown as a relative fold change. These data are consistent 
with the interpretation that UVA enhances Nrf2 accumulation in human skin cells.
To further investigate this effect, Nrf2 was monitored in both the cytoplasmic 
and nuclear fraction of FEK4 fibroblasts using SDS-PAGE and western blotting. 
Cells were UVA treated (250 kJ/m2) and subsequently incubated in conditioned media 
for the indicated time period before cytoplasmic and nuclear extracts were prepared. 
As shown in figure 3.2 and 3.3, UVA treatment did not enhance the level of Nrf2 
residing in the cytoplasm, but did enhance the level of Nrf2 in nucleus when 
compared to an unirradiated control sample. As determined by western blotting, the
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level of Nrf2 residing in the nucleus was substantially enhanced within 1 hour of 
irradiation. Nrf2 nuclear accumulation continued until 3 or 4 hours after UVA 
treatment. Both of these experiments were independently repeated with nearly 
identical results (data not shown). With respect to figure 3.2 and 3.3, cadmium was 
employed as a positive control. In Hepa cells work has shown that Nrf2 continues to 
accumulate up to 4 hours following treatment with cadmium (Stewart et al., 2003). 
As shown in figure 3.3, the physiologically relevant dose of UVA radiation used here 
resulted in stronger nuclear accumulation of Nr£2 than in response to treatment with 
10 pM CdCl2.
Taken together these data show that UVA causes whole cell accumulation of 
Nrf2 in primary human skin cells; an effect that can possibly be attributed to the 
release of Nrf2 from the proteasome degradation pathway.
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Figure 3.1: UVA causes NrO protein accumulation in human skin cells:
Immunocytochemistry
(next page)
FEK4 primary human fibroblasts were treated with UVA (250 kJ/m2) and incubated 
in conditioned media at 37°C for the indicated time period. The control samples were 
treated exactly the same as the UVA irradiated samples, but were not irradiated. Cells 
were fixed and immunostained with anti-Nrf2 rabbit polyclonal primary antibody 
followed by Invitrogen’s Alexa-Fluor goat anti-rabbit antibody as described in the 
section 2.14. Blocking of non-specific sites was accomplished by application of 
Invitrogen’s Image-iT™ Fx signal enhancer. Cells were incubated in Hoechst stain to 
allow visualisation of nuclei. The cells were analysed by oil immersion 
epifluorescence microscopy at 63x magnification on a Nikon Eclipse TE2000-U 
microscope and using the software programme UltraVIEW. The images were 
produced by superimposing the nuclei (BLUE) onto Nrf2 protein (PINK). The mean 
fluorescence of each image was determined using the software package ImageJ as 
described in section 2.14.
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Figure 3.2: Cytoplasmic Nrf2 is unaffected by UVA radiation
Freshly confluent FEK4 primary human fibroblasts were treated with either 
UVA (250 kJ/m2) or a CdCh (10 pM) and incubated in conditioned media at 
37°C for the indicated time period. Cytoplasmic extracts were prepared as 
described in section 2.4.2, and protein concentration was determined using the 
method o f Bradford. Equal amounts o f  cytoplasmic protein (10 pg/lane) were 
analysed by SDS-PAGE and western blotting as described in section 2.12. 
After visualisation o f Nrf2 protein, the membrane was re-probed for actin to 
evaluate equal loading. The control sample was treated exactly the same as 
the UVA irradiated samples, but was not irradiated. This experiment was 
independently repeated with nearly identical results (data not shown).
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Figure 3.3: UVA radiation causes nuclear accumulation of Nrf2
Freshly confluent FEK4 primary human fibroblasts were treated with either 
UVA (250 kJ/m2) or a CdCh (10 pM ) and incubated in conditioned media at 
37°C for the indicated time period. Nuclear extracts were prepared as 
described in section 2.4.2, and protein concentration was determined using the 
method o f Bradford. Equal amounts o f nuclear protein (10 pg/lane) were 
analysed by SDS-PAGE and western blotting as described in section 2.12. 
After visualisation o f Nrf2 protein, the membrane was re-probed for actin to 
evaluate equal loading. The control sample was treated exactly the same as 
the UVA irradiated samples, but was not irradiated. This experiment was 
independently repeated with nearly identical results (data not shown).
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3.2 The effect of UVA irradiation and hemin on Nrf2 accumulation
Following UVA treatment, Nrf2 was monitored in FEK4 primary human 
fibroblast whole cell extracts using SDS-PAGE and western blotting. FEK4 cells 
were irradiated with a physiologically relevant dose of UVA (250 kJ/m2) and 
subsequently incubated in conditioned media. The cells were incubated for the 
indicated time periods before whole cell extracts were prepared. As shown in figure
3.4 and 3.5, UVA treatment substantially increased the total cellular level of Nrf2 
protein when compared to unirradiated control cells. These data show that UVA 
treatment resulted in immediate accumulation of Nrf2 protein (1 hour post 
irradiation), and that Nrf2 accumulation continued for up to 12 hours following 
treatment. These findings are consistent with the idea that UVA stabilises Nrf2.
Previous work from this laboratory has shown that UVA treatment of FEK4 
fibroblasts leads to an immediate release of the HO-1 substrate, heme, from heme- 
containing proteins (Kvam et al., 1999). Furthermore, recent data derived from a 
murine model has indicated that heme promotes stabilisation of Nrf2 through 
prevention of ubiquitination (Alam et al., 2003). It was therefore hypothesised that 
heme may stabilise Nrf2 in human cells, and that the Nrf2 protein accumulation 
observed in response to UVA treatment may be dependent on the release of heme 
from heme-containing proteins. The effect of heme on Nrf2 was investigated in 
primary human fibroblasts using SDS-PAGE and western blotting. FEK4 cells were 
treated with 1 pM hemin and incubated in conditioned media for the indicated time 
periods before whole cell extracts were prepared. As shown in figure 3.6, hemin 
treatment resulted in accumulation of Nrf2. Using 30 pg pf total cellular protein 
extract for SDS-PAGE and western blotting, the data indicate that Nrf2 accumulation 
can be detected in FEK4 cells from 1 hour following treatment with 1 pM hemin.
Nrf2 was also monitored following treatment with hemin by means of 
imaging. FEK4 cells were treated with 1 pM hemin and incubated in conditioned 
media for the indicated time periods. Nrf2 was visualised by means of 
immunocytochemistry and epifluorescence microscopy. As shown in figure 3.7, the 
staining system employed to monitor Nr£2 resulted in virtually no non-specific 
binding of the fluorophor conjugated secondary antibody allowing for precise 
monitoring of Nrf2. In agreement with the data depicted in figure 3.6, the imaging 
data shown in figure 3.7 confirms the accumulation o f Nrf2 in response to hemin
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treatment. The mean fluorescence of each image has been determined as described in 
section 2.14. For each image the mean fluorescence has been normalised against the 
mean fluorescence of the untreated control. The data indicate a moderate fold 
increase inNrf2 of between 1.17 and 1.35.
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Figure 3.4: UVA radiation causes immediate whole cell accumulation of 
Nrf2 protein in human skin fibroblasts
Freshly confluent FEK4 primary human fibroblasts were treated with UVA 
(250 kJ/m2) and incubated in conditioned media at 37°C for the indicated time 
period. The control samples were treated exactly the same as the UVA 
irradiated samples, but were not irradiated. Whole cell extracts were prepared 
as described in section 2.4.1. Protein concentration was determined using the 
method o f Bradford. Equal amounts o f protein (30 pg/lane) were analysed by 
SDS-PAGE and western blotting as described in section 2.12. After 
visualisation o f Nrf2 protein, the membrane was re-probed for actin in order to 
evaluate equal loading.
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Figure 3.5: UVA radiation causes whole cell accumulation of Nrf2 protein 
in human skin fibroblasts up to 12 hours post irradiation
Freshly confluent FEK4 primary human fibroblasts were treated with UVA 
(250 kJ/m2) and incubated in conditioned media at 37°C for the indicated time 
period. The control sample was treated exactly the same as the UVA 
irradiated sample, but was not irradiated. Whole cell extracts were prepared as 
described in section 2.4.1. Protein concentration was determined using the 
method o f Bradford. Equal amounts o f protein (30 pg/lane) were analysed by 
SDS-PAGE and western blotting as described in 2.12. After visualisation of 
Nrf2 protein, the membrane was striped and re-probed for actin in order to 
evaluate equal loading.
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Figure 3.6: Hemin treatment causes Nrf2 protein accumulation in human 
skin fibroblasts as determined by western blotting
Freshly confluent FEK4 primary human fibroblasts were treated with either 1 
pM hemin (H) or the vehicle [0.01 % DMSO (D)] and incubated in serum free 
medium at 37°C for the time period indicated. The control sample (—) was 
untreated and remained in the incubator for the duration o f the experiment. 
Whole cell extracts were prepared as described in section 2.4.1, and protein 
concentration was determined using the method of Bradford. Equal amounts 
o f protein (30 pg/lane) were analysed by SDS-PAGE and western blotting as 
described in section 2.12. After visualisation o f Nrf2 protein, the membrane 
was striped and re-probed for actin in order to evaluate equal loading.
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Figure 3.7: Hemin causes Nrf2 protein accumulation in human skin fibroblasts 
as determined by epifluorescence microscopy
(next page)
FEK4 primary human fibroblasts were treated with either 1 pM hemin or the vehicle 
(0.01 % DMSO) and incubated in conditioned media at 37°C for the indicated time 
period. The untreated sample remained in the incubator for the duration of the 
experiment. Cells were fixed and immunostained with anti-Nrf2 rabbit polyclonal 
primary antibody followed by Invitrogen’s Alexa-Fluor goat anti-rabbit as described 
in the Materials and Methods (section 2.14). Blocking of non-specific sites was 
accomplished by application of Invitrogen’s Image-iT™ Fx signal enhancer. Cells 
were incubated in Hoechst stain to allow visualisation of nuclei. The cells were 
analysed by oil immersion epifluorescence at 63x magnification on a Nikon Eclipse 
TE2000-U microscope and using the software programme UltraVIEW. The images 
were produced by superimposing the visualised nuclei (BLUE) onto Nrf2 protein 
(PINK). The mean fluorescence of each image was determined using the software 
package ImageJ as described in section 2.14.
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3.3 Monitoring of intracellular heme
3.3.1 Spectrophotometric monitoring of intracellular heme
As shown in section 3.2, both UVA and heme treatment resulted in whole cell 
accumulation of Nrf2 in FEK4 primary human fibroblasts. UVA is known to release 
heme from heme-containing proteins (Kvam et al., 1999). It was therefore 
hypothesised that UVA-mediated whole cell accumulation of Nrf2 may be dependent 
on heme. To fully explore this hypothesis, the effect of depleting intracellular heme 
prior to UVA treatment was examined.
A spectrophotometric assay was developed to allow the amount of 
intracellular heme to be monitored. In this assay the nitrogen ligands from protein- 
bound heme are replaced by pyridine in alkali. The resultant hemochrome is 
quantified by the difference in absorption between a baseline and reduced sample. As 
discussed in section 2.10, the baseline absorbance of each sample was obtained from 
500 to 600 nm. Each sample was then split into two, one of which was oxidised, the 
other reduced. An absorbance reading of the reduced and oxidised samples was then 
obtained between 500 and 600 nm. Using Beer’s law and a millimolar extinction 
coefficient of 20.7, the heme concentration was calculated based on the difference in 
absorption between the peak at 557 nm and the trough at 575 nm of the reduced 
sample.
Hemin standards were initially used to assess the sensitivity of this assay. As 
shown in figure 3.8, oxidation of the hemin standards resulted in virtually no change 
in absorption when compared to the baseline absorbance. This result was expected, 
and indicated that complete sample oxidation was occurring without the requirement 
for the oxidising agent potassium ferricyanide. The accuracy of this assay was 
assessed using the reduced samples. The actual concentration of the hemin standards 
was compared to the theoretical concentration calculated using the absorption profile 
shown in figure 3.8. A discrepancy was observed. The possibility that the 
hemochrome was incompletely reduced was explored through addition of further 
reducing agent. No change in absorption was observed. The discrepancy between the 
actual hemin concentration of the hemin standards, and the value calculated from the 
spectrophotometric absorption of the hemin standards, suggested that the 
concentration of heme calculated for tissue extracts would not be accurate. This
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discrepancy suggested that a standard curve would be required if this assay was to be 
employed through-out this investigation. Prior to the generation of a standard curve, 
it was determined whether or not the assay was sufficiently sensitive to detect 
endogenous heme in cell extracts.
The sensitivity of this assay, as determined using hemin spiked standards, 
suggested the need for a large quantity of tissue extract. In order to generate 
sufficient cell extract the human lymphoblastoid cell line TK6 was employed (Thilly, 
1979). As shown in figure 3.9, the sensitivity of this assay was barely sufficient to 
detect intracellular heme in 1.2 mg total protein of TK6 whole cell tissue extract. 
What’s more, large disparities in absorption were observed between identical tissue 
extracts (data not shown). The low sensitivity and poor reproducibility of this assay 
clearly defined the need for the development of a more accurate methodology. 
Experimental investigations by means of spectrophotometry were terminated.
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Figure 3.8: Spectrophotometric quantification of heme concentration:
hemin standards
Hemin standards o f 800 nM and 1.6 pM were produced as described in section 2.11. 
Samples were prepared as detailed in section 2.10 through the addition o f pyridine. 
A baseline absorbance spectrum was taken from 500 to 600 nm. Each sample was 
then split into two, one o f which was oxidised, the other reduced. An absorbance 
spectrum of the reduced and oxidised sample was then obtained between 500 and 
600 nm. Based on the difference in absorption o f the reduced sample between the 
peak at 557 nm and the trough at 575, the actual concentration o f the heme standards 
was compared to the theoretical concentration calculated using Beer’s law and a 








Figure 3.9: Spectrophotometric quantification of intracellular heme 
concentration in TK6 cells
The human lymphoblastoid cell line TK6 was employed to generate a large pool of 
cell extract. A whole cell tissue extract containing 1.2 mg o f total protein was 
prepared as described in section 2.10. A baseline absorbance spectrum was recorded 
from 500 to 600 nm. The sample was then split into two, one o f which was 
oxidised, the other reduced. An absorbance spectrum o f the reduced and oxidised 
extract was then obtained between 500 and 600 nm.
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3.3.2 Spectrofluorometric monitoring of intracellular heme
A spectrofluorometric assay was developed to allow accurate monitoring of 
intracellular heme. This methodology is based on the work of Morrison, (1965) and 
Sassa, (1976). The assay involves the conversion of heme to it’s fluorescent 
porphyrin derivative by the removal of heme iron under acidic reducing conditions (as 
described in section 2.11).
This assay has a linear range that must be established before the concentration 
of heme in cell extracts can be determined. The linear range of this assay varies 
between spectrofluorometers and is a function of the sensitivity of each instrument. 
Using hemin standards, preliminary experiments revealed the non-linear range of this 
assay to be below 80 nM (data not shown). As shown in figure 3.10, hemin standards 
ranging from 100 nM to 800 nM produced a linear standard curve. The capacity of 
this assay to detect heme in whole cell tissue extracts was next examined. FEK4 
primary human fibroblasts were treated with 1 mM hemin or the vehicle (0.1 % 
DMSO) for one hour. Duplicate samples containing 100 pg of total protein were 
prepared for each treatment. As discussed in section 2.11, one sample from each pair 
was boiled with 2 M oxalic acid at 100°C for 30 minutes (in order to remove the heme 
iron); the other sample was incubated at room temperature. The fluorescence of each 
sample was read at 600 nm emission using a spectrofluorometer set at 405 nm 
excitation. As shown in figure 3.11, with respect to FEK4 cells treated with DMSO, 
the fluorescence of the un-boiled samples (representing background fluorescence) was 
virtually identical to that of the fluorescence of the equivalent boiled sample. The 
fluorescence of the boiled samples was only greater than the control samples when 
cells had been pre-treated with 1 mM heme. These results indicated that non-specific 
fluorescence was preventing detection of endogenous heme in FEK4 cells.
Work from this laboratory has shown that it is microsome localised heme- 
containing proteins that are destroyed in response to UVA. In an attempt to reduce 
the level of non-specific background fluorescence observed in the FEK4 whole cell 
extracts, total cellular microsomes were isolated (as described in section 2.4.3). As 
shown in figure 3.11, marginally greater fluorescence was observed in some boiled 
samples when compared to the equivalent control sample. It was hypothesised that a 
sample containing a greater amount of total cellular protein may allow visualisation of 
endogenous heme fluorescence above the background fluorescence. The human
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lymphoblastoid cell line TK6 (Thilly, 1979) was again used to generate sufficient cell 
extract. As shown in figure 3.12, the assay of 1 mg of total protein from TK6 cells 
produced marginally higher fluorescence in the boiled samples when compared to the 
control samples. However, when this experiment was independently repeated using 2 
mg of total protein, heme fluorescence could not be detected (data not shown). Taken 
altogether, these data indicate that non-specific fluorescence negates the possibility of 
visualisation of endogenous heme using this methodology. Experimental 
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3.10: Spectrofluorometric determination of heme concentration:
standard curve
A series o f 8 heme standards were prepared in a 0.1 M phosphate buffer pH 7.4 
containing 0.05 % BSA. Each standard was then diluted 1:1 v/v with 2 M oxalic 
acid (as described in section 2.10). Each standard was produced in duplicate, one 
o f which was boiled at 100°C for 30 minutes (in order to remove the heme iron), 
the other control sample was incubated at room temperature for the same period. 
All samples were covered during this incubation period to prevent evaporation. 
Each standard, both boiled and control, was produced in duplicate. The 
fluorescence o f each sample was read at 600 nm emission using a 
spectrofluorometer set at 405 nm excitation. The value o f the un-boiled control 
sample (representing background fluorescence) was subtracted from the boiled 
sample fluorescence where the heme iron had been removed. The relative 
fluorescence o f the 8 hemin standards has been plotted against concentration on a 
linear scale in order to produce a standard curve. Each point represents the mean 
fluorescence o f two independent samples. Error bars represent one standard 




Vehicle (2)1 mM Hemin (1) 1 mM Hemin (2) Vehicle (1)
3.11: Spectrofluorometric determination of intracellular heme concentration:
FEK4
FEK4 primary human fibroblasts were treated with 1 mM hemin or the vehicle 
(0.1 % DMSO) for one hour. Whole cell extracts were prepared as described in 
section 2.4.1 and the protein concentration o f each extract was determined as 
described in section 2.4.4. Microsomal cell extracts were untreated, and were 
prepared as described in section 2.4.3. For each sample (microsomal and whole 
cell), 100 pg o f protein was added to 1 ml o f 2 M oxalic acid. Each sample was 
produced in duplicate, one o f which was boiled at 100°C for 30 minutes (in order 
to remove the heme iron) (BLACK), the other control sample was incubated at 
room temperature for the same period (GREY). All samples were covered during 
this incubation period to prevent evaporation. The fluorescence o f each sample 













3.12: Spectrofluorometric determination of intracellular heme concentration:
TK6
The human lymphoblastoid cell line TK6 was used to generate a large pool o f cell 
extract. Whole cell extracts were prepared as described in section 2.4.1 and the 
protein concentration o f each cell extract was determined as described in section 
2.4.4. For each sample, 1 mg o f protein was added to 1 ml o f 2 M oxalic acid. 
Each sample was produced in duplicate, one o f  which was boiled at 100°C for 30 
minutes (in order to remove the heme iron) (BLACK), the other control sample 
was incubated at room temperature for the same period (GREY). All samples 
were covered during this incubation period to prevent evaporation. The 
fluorescence o f each sample was read at 600 nm emission using a 
spectrofluorometer at 405 nm excitation.
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3.4 The effect of intracellular heme depletion on UVA-mediated Nrf2 
accumulation
Work from this laboratory has shown that UVA treatment of FEK4 primary 
human fibroblasts results in degradation of microsomal heme-containing proteins in a 
dose dependant manner (Kvam et al., 1999). Moreover, Kvam et al., (1999) observed 
no change in the total amount of microsomal heme, or in the total amount of cellular 
heme. Taken together, these data are consistent with the interpretation that UVA 
releases heme from microsomal heme-containing proteins. Interestingly, Kvam et al., 
(1999) demonstrated a clear correlation between the level of heme released and the 
subsequent accumulation of HO-1 mRNA, therefore indicating that UVA-induced 
heme release plays a role in up-regulation of HMOX1 by UVA. In relation to this, 
recent data derived from a murine model has shown that heme promotes stabilisation 
of Nrf2 (Alam et al., 2003).
As shown in section 3.2, Nrf2 whole cell accumulation was observed in 
response to UVA or heme treatment in human skin fibroblasts. The hypothesis that 
UVA-mediated Nrf2 accumulation is dependent on the UVA-induced release of heme 
from heme-containing proteins was examined by means of depletion of intracellular 
heme prior to UVA irradiation. Succinylacetone [(SA) 4,6-dioxoheptanoic acid] was 
used to deplete intracellular heme. SA is a metabolite of tyrosine, and is a potent 
irreversible inhibitor of delta-aminolevulinic acid dehydrase, the rate limiting enzyme 
in heme synthesis (Tschudy et al., 1981). As shown in section 3.3, endogenous heme 
was below the level of detection by both spectrophotometry and spectrofluorometry in 
the cell types employed in this study. This prevented monitoring of heme depletion 
by SA. Previously published data were therefore used to calculate the required SA 
concentration and treatment time. An SA concentration of 1 mM and treatment time 
of 24 hours was judged to be sufficient to more than halve the concentration of 
intracellular heme-containing proteins (Giger and Meyer, 1983).
FEK4 primary human fibroblasts were treated with 1 mM SA or the vehicle 
(serum free medium) for 24 hours. The cells were then UVA treated (250 kJ/m2) and 
incubated for the time period indicated before fixing. Immunocytochemistry and 
epifluorescence microscopy was used to visualise Nrf2. As shown in figure 3.13, the 
staining methodology employed to visualise Nrf2 resulted in no non-specific binding 
of the fluorophor conjugated secondary antibody allowing for the precise monitoring
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of Nrf2. In agreement with the data shown in section 3.1, the imaging data presented 
in figure 3.13 shows an immediate accumulation of Nrf2 in response to UVA 
irradiation of vehicle-treated FEK4 cells; however, this effect was virtually abolished 
by pre-treatment with the heme synthesis inhibitor SA. The mean fluorescence of 
each image has been determined and normalised against the fluorescence of the 
untreated control (as described in section 2.14). The results show between a 1.31 to 
1.46 fold increase in fluorescence in irradiated cells pre-treated with the vehicle. 
Cells treated with the heme synthesis inhibitor prior to irradiation, showed only a 1.10 
to 1.13 fold increase in fluorescence. These data therefore validate the hypothesis 
that, in human skin cells, UVA leads to Nrf2 stabilisation by means of heme.
In this study the effect of intracellular heme depletion on UVA up-regulation 
of HO-1 was also examined. As determined by western blotting, SA treatment of 
FEK4 cells prior to UVA treatment was observed to marginally reduce HO-1 
accumulation (data not shown). This observation supports the idea that UVA- 
mediated Nrf2 accumulation by means of heme release, may influence the 
transcriptional up-regulation of the phase-II gene HMOX1.
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Figure 3.13: Heme synthesis inhibition reduces UVA-mediated Nrf2 whole cell 
protein accumulation in primary human skin cells
(next page)
FEK4 primary human fibroblasts were treated with either 1 mM succinyl acetone or 
the vehicle (semm free medium) for 24 hours at 37°C. After this time period cells 
were irradiated at 250 kJ/m2 and incubated in conditioned media for the time periods 
indicated. The control samples were treated exactly the same as the irradiated 
samples, but were not irradiated. The untreated sample remained in the incubator for 
the duration of the experiment. Cells were fixed and immunostained with anti-Nrf2 
rabbit polyclonal primary antibody followed by Invitrogen’s Alexa-Fluor goat anti­
rabbit as described in the Materials and Methods (section 2.14). Blocking of non­
specific sites was accomplished by application of Invitrogen’s Image-iT™ Fx signal 
enhancer. Cells were incubated in Hoechst stain to allow visualisation of nuclei. The 
cells were analysed by oil immersion epifluorescence at 63x magnification on a Nikon 
Eclipse TE2000-U microscope and using the software programme UltraVIEW. The 
images were produced by superimposing the visualised nuclei (BLUE) onto Nrf2 
protein (PINK). The mean fluorescence of each image was determined using the 
software package ImageJ as described in section 2.14.
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3.5 The role of UVA generated *02 in Nrf2 activation
Regulation of Nrf2 is partly achieved through prevention of nuclear 
availability (Dhakshinamoorthy and Jaiswal, 2001; Itoh et al., 1999). Under reducing 
conditions Nrf2 is sequestered by Keapl anchoring the transcription factor within the 
cytoplasm (Kang et al., 2004), and therefore preventing transcriptional activation of 
phase II genes. Evidence has been provided to suggest that Keapl acts as a sensor of 
oxidative stress; here the influence of UVA-generated ROS on this regulatory system 
has been investigated in FEK4 primary human fibroblasts.
Singlet oxygen (’0 2 ) is widely regarded to be the primary effector in UVA 
gene regulation. In this study the effect of this ROS on Nrf2 sub-cellular localisation 
has been examined using deuterium oxide (D2O), a strong and reasonably specific ]02 
lifetime enhancer (Lindig et al., 1980). FEK4 primary human fibroblasts were treated 
with 250 kJ/m UVA whilst bathed in PBS prepared using either H2O or D2O as a 
solvent. Following treatment the cells were incubated in conditioned media for the 
indicated time periods before cytoplasmic and nuclear extracts were prepared. The 
cytoplasmic and nuclear cell extracts were analysed using SDS-PAGE and western 
blotting.
As shown in figure 3.14, a moderate increase in the amount of Nrf2 residing in 
the cytoplasm was observed in FEK4 cells treated with UVA (250 kJ/m2) whilst 
bathed in H2O-PBS. However no such accumulation was observed in the cytoplasm 
of cells treated with the same dose of UVA whilst bathed in D2O-PBS. The reduced 
level of Nrf2 observed in the D2O treated tissue extracts indicates that UVA-generated 
ROS communicate some authority over Nrf2 residing in the cytoplasm. As shown in 
figure 3.15, accumulation of Nrf2 was detected in the nucleus of FEK4 cells treated 
with UVA whilst bathed in H2O-PBS or D2O-PBS. However, the amount of Nrf2 
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Figure 3.14: The effect of D20 on cytoplasmic Nrf2
Freshly confluent FEK4 primary human fibroblasts were UVA treated (250 
kJ/m2) as described in section 2.3.1. During irradiation cells were covered 
with PBS supplemented with 0.01 % Ca2+ and 0.01 % Mg2+ prepared using 
either H20 or 99.9 % deuterium oxide (D20 ), as detailed in section 2.3.4. The 
control cells were treated exactly the same as the UVA treated cells, but were 
not irradiated. Cytoplasmic extracts were prepared as described in the 
Materials and Methods (section 2.4.2), and protein concentration was 
determined using the method o f Bradford. Equal amounts o f cytoplasmic 
protein (5 pg/lane) were analysed by SDS-PAGE and western blotting as 
described in the Material and Methods (section 2.12). After visualisation of 
Nrf2 protein, the membrane was re-probed for actin to evaluate loading. This 
experiment was repeated with similar results.
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Figure 3.15: The effect of D20 on nuclear levels of Nrf2
Freshly confluent FEK4 primary human fibroblasts were UVA treated (250 
kJ/m2) as described in section 2.3.1. During irradiation cells were covered 
with PBS supplemented with 0.01 % Ca2+ and 0.01 % Mg2+ prepared using 
either H20 or 99.9 % deuterium oxide (D20 ), as detailed in section 2.3.4. The 
control cells were treated exactly the same as the UVA treated cells, but were 
not irradiated. Nuclear extracts were prepared as described in the Materials 
and Methods (section 2.4.2), and protein concentration was determined using 
the method o f Bradford. Equal amounts o f nuclear protein (5 pg/lane) were 
analysed by SDS-PAGE and western blotting as described in Material and 
Methods (section 2.12). After visualisation o f Nrf2 protein, the membrane 
was re-probed for actin in order to evaluate loading.
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3.6 The effect of UVA radiation on NRF2 transcriptional activity
3.6.1 General remarks
The LightCycler instrument (Roche Applied Science) provides an extremely 
powerful tool for real time quantification of gene expression by accurately measuring 
mRNA levels (refer to section 2.16). In this study, the LightCycler system was used 
to determine the effect o f UVA radiation on the level of NRF2 gene activation by 
means of real time RT-PCR. Throughout this study gene expression was measured by 
calibrator normalised relative quantification. Relative quantification is based upon 
the comparison of two ratios: the ratio o f a target cDNA sequence (NRF2) to a 
housekeeping reference cDNA sequence (GAPDH) in an unknown sample, to the 
ratio of the same two sequences in a standard sample called a ‘calibrator’. The 
calibrator represents typical proportions o f the target and reference sequences against 
which the unknown sample can be compared. Throughout this study the same 
calibrator was included in all of the LightCycler experiments to allow for inter- 
experimental comparison. The results of this investigation (figure 3.26 and 3.27) are 
expressed as the target / reference ratio o f each sample normalised by the target / 
reference ratio of the calibrator (set as 1).
3.6.2 Data presentation
LightCycler data has been presented in the form of amplification curves, and 
as melting curves / peaks. Amplification curves are used to assess the relative cDNA 
starting concentration of the target (NRF2) and reference (GAPDH) sequences. The 
number of PCR amplification cycles is plotted against relative fluorescence at 530 nm 
after each amplification cycle. The relative cDNA starting concentration is based 
upon the crossing point (Cp) of each sample; that is the number of PCR cycles that are 
required for the fluorescence of each sample to be detected above background 
fluorescence (expressed as a cycle number). Relative quantitative analysis is 
therefore based on the assumption that the concentration of cDNA at a sample’s 
crossing point is the same for every sample containing the same target cDNA.
The melting temperature (Tm) of all PCR products was determined at the end 
of each PCR reaction to confirm the product identity, and to differentiate the specific
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PCR product from non-specific double stranded oligonucleotides such as primer- 
dimers. The temperature required to separate complementary DNA strands can vary 
enormously. This melting temperature (Tm) is dependent upon the length of the 
strand, the sequence of the strand, and the GC content of the strand. The unique 
melting temperature of a PCR product therefore allows identification of non-specific 
PCR products which may influence the outcome of a PCR reaction. Using the DNA 
binding dye SYBR Green I (refer to section 2.16), the LightCycler System defines the 
melting temperature of a PCR product as the point at which half of the SYBR Green I 
dye has separated from the double strand PCR product. In this study, the melting data 
has been presented in two forms: a melting curve (fluorescence versus time) and a 
melting peak (-dF/dT versus temperature). The melting peak is derived from the 
melting curve and shows the negative derivative of fluorescence with respect to 
temperature. Integration of the area under a melting peak can be used for quantitative 
comparisons between samples. Displaying the melting profile of a PCR product as a 
peak allows for straightforward identification of non-specific PCR products.
3.6.3 Optimisation of the conditions required for NRF2 real time RT-PCR
For accurate real time PCR quantification of gene expression, the conditions 
of the reaction must first be optimised. The conditions used for HMOX1 and GAPDH 
real time PCR were determined in this laboratory by Dr. Sharmila Basu-Modak prior 
to the start of this study. A Mg2+ concentration of 3.0 mM and the LightCycler 
settings displayed in tables 2.3 and 2.4 were used through-out this study for these two 
genes. The conditions required for NRF2 real time PCR were determined.
The concentration of Mg2+ required for effective primer / template association
9+is unique for each PCR reaction. Therefore, optimisation of the Mg concentration is 
a pre-requisite for effective PCR. The optimal magnesium concentration required for 
NRF2 real time RT-PCR was determined as described in section 2.16.3. Identical 
samples with Mg2+ concentrations of between 1.0 -  5.0 mM were analysed using the 
LightCycler settings shown in table 3.1 and an arbitrary primer annealing temperature 
of 55°C. For each Mg2+ concentration duplicate samples were analysed. No- 
template-control (NTC) samples were also included. The results are shown in figure 
3.16.
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94- 94-The optimal Mg concentration for any PCR reaction is defined as the Mg 
concentration that correlates with the greatest amount of PCR product generated per 
amplification cycle. Using the DNA binding dye SYBR Green I with the LightCycler 
system, the optimal Mg2+ concentration is defined as the sample(s) with the steepest 
amplification gradient during log-linear PCR amplification; and as the Mg2+ 
concentration that generates the greatest amount of specific PCR product at the end of 
the reaction. As shown in figure 3.16, both of the samples supplemented with 1 mM 
Mg2+ to the 1 mM of Mg2+ already contained in the ready to use PCR reaction mix 
produced the steepest amplification gradient during log-linear PCR. As determined
94-by the area underneath the PCR melting peak, this concentration of Mg also 
generated the greatest amount of PCR product. Further confirmation that optimal 
PCR resulted from sample supplementation with 1 mM Mg2+ can be found in the 
samples supplemented with 0.5 mM and 1.5 mM Mg2+; all of which showed reduced 
reaction efficiency, and less PCR product.
The optimum primer annealing temperature for NRF2 real-time RT-PCR was 
determined using non-quantitative gel PCR (as described in section 2.16.4). PCR was 
performed on a heating block with a variable temperature gradient. During the primer 
annealing phase the temperature of the heating block was set at a gradient ranging 
from 50 -  70°C using the temperature increments indicated in figure 3.17. As shown 
in figure 3.17, primer annealing temperatures of 52.4 and 54.1°C produced the 
greatest amount of PCR product after 30 cycles of amplification. A second 
experiment was conducted in which a temperature gradient of approximately 40 -  
60°C was used during primer annealing (data not shown). The results of this 
experiment confirmed the data shown in figure 3.17. Based on these data, a primer 
annealing temperature of 53°C was used for NRF2 real time PCR.
Serial dilution of cDNA was used to determine the relative cDNA starting 
dilution required for effective NRF2 real time PCR. A cDNA pool was generated by 
a large-scale reverse transcription reaction (as descried in section 2.15) using total 
RNA extracted from FEK4 cells 3 hours after a dose of 250 kJ/m2 UVA. A serial 
cDNA dilution ranging from undiluted to a 1 in 100 dilution was analysed using the
94-optimised Mg concentration and primer annealing temperature (refer figure 3.16 and 
3.17). As shown in figure 3.18, a low NRF2 cDNA copy number was observed. The 
data show that only the use of undiluted FEK4 cDNA is sufficient for relative 
quantification of NRF2 gene expression using the LightCycler system. The data
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shown in figure 3.18 were also used to assess the potential for the generation of a 
standard efficiency value.
Calibrator normalised relative quantification can be used to determine relative 
gene expression with or without PCR efficiency correction. In theory, a perfect PCR 
reaction would generate two daughter strands of DNA per parental strand of DNA per 
amplification cycle; an efficiency of two. However, no PCR reaction is perfect. 
Efficiency correction adjusts for this. A standard efficiency value is generated by 
serial dilution of cDNA. The concentration of the dilution series is plotted against the 
Cp values of the samples. The slope of this standard curve is equal to the efficiency 
of the PCR reaction. Efficiency correction influences the relative fold change in gene 
expression of any reaction, and is generally employed in experiments where a large 
gene induction is expected. However, the use of a single efficiency value for all PCR 
reactions can incur inaccuracies if inter-experimental differences in amplification 
efficiency are observed. In this study, inter-experimental differences in NRF2 
amplification efficiency, and a low NRF2 copy number, were observed. The 
determination of a reaction efficiency value therefore proved unfeasible and would 
only serve to incorporate error. An efficiency value of 2 was therefore employed 
throughout this study. Using this efficiency value, the LightCycler system 
automatically generates the ratio of the target cDNA sequence (NRF2) to a 
housekeeping reference cDNA sequence (GAPDH) in an unknown sample based on a 
mathematical model were no calibration curve is needed (Phaffl, 2001).
PCR product size should not exceed 700 base pairs for real time PCR using 
the LightCycler system. The NRF2 primers employed throughout this study (shown 
in table 2.1) correspond to an amplicon size of 142 base pairs. The Taq DNA 
polymerase used throughout this study can incorporate 25 base pairs per second. An 
elongation time of 7 seconds (n + 1 seconds) was therefore used throughout. The 
optimised conditions for NRF2 real time PCR are shown in table 3.1.
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Figure 3.16: Optimisation of the magnesium concentration required for
NRF2PCR
(next page)
The optimal magnesium concentration required for NRF2 real time RT-PCR 
[LightCycler System (Roche Applied Science, Germany)] was determined using 
a cDNA pool generated by a large-scale reverse transcription reaction (as 
descried in section 2.15) using total RNA extracted from FEK4 primary human 
fibroblasts (as described in section 2.5.1). 2 pi of this cDNA pool was added to 
a PCR master-mix (as described in section 2.16.2) containing 0.5 pM of both the 
forward and reverse NRF2 primers (as shown in table 2.1). Mg2+ concentrations 
of between 1.0 and 5.0 mM were analysed. A total reaction mixture volume of 
20 pi was prepared for each sample. All of the samples were assayed in 
duplicate and no-template-control (NTC) samples were included. All of the 
samples were analysed simultaneous using the settings shown in table 3.1, and 
using an arbitrary primer annealing temperature of 55°C. Samples were 
analysed using the LightCycler 1.5 instrument. Gene expression was measured 
by relative qualification using the software programme LightCycler 4.0. The 
data is presented in the form of fluorescence history and as a melting peak.
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Figure 3.17: Optimisation of the primer annealing temperature required for
N R F 2PCR
The optimum primer annealing temperature for NRF2 real-time RT-PCR was 
determined using non-quantitative gel PCR. A reaction mixture was prepared 
using Sigma’s Readymix™ Taq without MgCl2 according to the manufacturer’s 
instructions. All o f the samples contained 0.5 pM of both the forward and reverse 
NRF2 primer (shown in table 2.1), and a final Mg2+ concentration o f 2.0 mM. 
The calibrator pool was used as a source o f cDNA. PCR was performed on a 
FlexiGene (Techne) heating block with a variable temperature gradient using the 
following programme: Denaturation [95°C, 180 seconds]; Amplification [(94°C, 
20 seconds) (50 -  7(fC, 10 seconds) (72°C, 20 seconds)]; Termination [(72°C, 
300 seconds) (4°C, oo)]. 30 cycles o f PCR amplification were used. During the 
primer annealing phase, the temperature o f the heating block was set at a gradient 
ranging from 50 -  70°C at the temperature increments indicated above. For each 
sample, 10 pi o f the reaction product was used for agarose gel electrophoresis 
using a 3 % gel as described in section 2.6.2.
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Figure 3.18: cDNA dilution series
(next page)
A serial dilution of cDNA was analysed to determine an appropriate starting 
dilution for NRF2 real time PCR using the LightCycler system; and to assess the 
potential for the generation of a standard efficiency file. A cDNA pool was used 
that had been generated by a large-scale reverse transcription reaction using total 
RNA extracted from FEK4 cells 3 hours after a dose of 250 kJ/m2 UVA. 2 pi of 
this cDNA pool, ranging from undiluted to a 1 in 100 dilution, was added to a 
PCR master-mix (as described in section 2.16.2) containing 0.5 pM of both the 
forward and reverse NRF2 primers (as described in table 2.1), and a final Mg2+ 
concentration of 2.0 mM. A total reaction mixture volume of 20 pi was prepared 
for each sample. Each cDNA dilution was analysed four times. A no-template- 
control (NTC) sample was also included. All of the samples were analysed 
simultaneous using the settings shown in Table 3.1. Samples were analysed using 
the LightCycler 1.5 instrument. Gene expression was measured by relative 
qualification using the software programme LightCycler 4.0. The data is 
presented in both the form of an amplification curve and as a melting peak / curve.
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Cycles
■  1 1 ■  14 1/10
■  2 1 ■  15 1/10
■  3 1 ■  16 1/10
■  4 1 ■  17 1/50
■  5 1/2 ■  18 1/50
■  6 1/2 ■  19 1/50
■  7 1/2 ■  20 1/50
■  8 1/2 ■  21 1/100
9 1/5 ■  22 1/100
■  10 1/5 ■  23 1/100
■  11 1/5 ■  24 1/100
■  12 1/5 ■  25 NTC
■  13 1/10 B  26 Ca.
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Denaturation 95 30 20 None
Amplification 95 0 20 None
53 5 20 None
72 7 20 Single
Melting Curve 95 0 20 None
65 15 20 None
95 0 0.1 Continuous
Cooling 40 30 20 None
}40 Cycles1 . 
Cycle
Table 3.1: The optimised settings used for real time PCR monitoring o f the 
NRF2 gene using the LightCycler system. A Mg2+ concentration o f 2 mM 
was used throughout this study for NRF2 real time PCR.
107
3.6.4 Determination of NRF2 mRNA half-life
To determine the time period required to assess the effect of UVA on NRF2 
gene activation, an attempt was made to determine the half-life of NRF2 mRNA. The 
half-life of NRF2 mRNA was measured in FEK4 primary human fibroblasts which 
were either untreated, control treated, or UVA treated (250 kJ/m2). Cells were 
incubated for one hour following UVA treatment to allow accumulation of NRF2 
mRNA. The cells were then treated with 5 pg/ml of the transcriptional inhibitor 
actinomycin-D (as described in section 2.3.2), and cultured for the indicated time 
periods before harvesting (shown in hours). Total RNA extraction and reverse 
transcription was performed as described in section 2.5.1 and 2.15 respectively. 
Previous work this laboratory has shown that GAPDH mRNA is not significantly 
degraded following actinomycin D treatment (Keyse et al., 1990). GAPDH was 
therefore employed as a reference to normalise inter-sample variation in cDNA 
starting concentration.
As shown in figure 3.20, a single melting temperature was observed at the end 
of this PCR reaction. This illustrates that only specific PCR product was generated. 
The amplification curves for this experiment are shown in figure 3.19. The data 
indicated that treatment with actinomycin-D did not influence the relative amount of 
NRF2 mRNA in the untreated, control treated, or UVA treated FEK4 cells treated up 
to 4 hours. These data therefore indicate that the half-life of NRF2 mRNA may be in 
excess of 4 hours. Further experimental investigations are required to determine this.
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Figure 3.19: Determination of NRF2 mRNA half-life: amplification curves
(next page)
FEK4 primary human fibroblasts were either untreated (Un), control treated 
(Sm), or UVA treated [(Uv) 250 kJ/m2]. All of the cells were exposed to 5 
pg/ml actinomycin-D (as described in section 2.3.2) one hour after the start of 
the experiment (determined to be the completion of irradiation of the irradiated 
samples). Cells were then cultured for the indicated time period before 
harvesting (indicated in hours). Total RNA was extracted as described in 
section 2.5.1, and reverse transcription was performed as described in section
2.15. 2 pi of this cDNA, either undiluted for NRF2, or a 1 in 5 dilution for 
GAPDH, was added to a PCR master-mix (as described in section 2.16.2) 
containing 0.5 pM of both the forward and reverse primer (shown in table 2.1). 
A Mg2+ concentration of 2.0 mM was used for NRF2 and 3.0 mM for GAPDH. 
A total reaction mixture volume of 20 pi was prepared for each sample. A no- 
template-control (NTC) and calibrator (Cal) sample was also included. The 
samples were analysed independently for either NRF2 or GAPDH using the 
settings shown in Table 3.1 or Table 2.4 respectively. Samples were analysed 
using the LightCycler 1.5 instrument. Gene expression was measured by 
relative qualification using the software programme LightCycler 4.0. The NRF2 
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Figure 3.20: Determination of AJRF2 mRNA half-life: NRF2 PCR product
melting peak / curve
The melting curve and melting peak relates to the NRF2 data in figure 3.19. The 
data is shown as both a melting curve (fluorescence versus time) and meting peak 
(-dF/dT versus temperature).
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3.6.5 Real time PCR monitoring of NRF2 gene expression following UVA treatment
In order to determine the influence of UVA radiation on NRF2 transcriptional 
activity, FEK4 primary human fibroblasts were either control treated (Sham), or UVA 
treated (250 kJ/m2). The time frame required to assess the influence of UVA on 
NRF2 gene activity was selected based on previously published data (Kwak et al., 
2002). Following treatment, total RNA was extracted at the time points indicated (as 
described in section 2.5.1). Reverse transcription was performed as described in 
section 2.15. Two independent time courses (series A and series B) both consisting of 
irradiated and control samples were produced. The optimised conditions for NRF2 
PCR (shown in table 3.1) were used throughout this study for real time RT-PCR using 
the LightCycler 1.5 instrument.
UVA is known to transcriptionally up-regulate the HO-1 gene (Keyse et al., 
1990). The relative levels of HO-1 mRNA were therefore determined in both series A 
and B. Virtually no HO-1 gene up-regulation was observed in the unirradiated 
samples with respect to both of these independent series. With respect to series A, 
approximately a 40-fold up-regulation of the HMOX1 locus was observed in the UVA 
irradiated samples (refer figure 3.21). This experiment was independently repeated 
using series B with nearly identical results. These data reflect observations 
previously made by this laboratory and serve as a positive control.
The NRF2 and GAPDH amplification curves relating to series A and series B 
are shown in figures 3.22 and 3.24 respectively. The data from these amplification 
curves has been graphed and is presented in figures 3.26 (series A) and 3.27 (series 
B). These graphs represent the target (NRF2) / reference (GAPDH) ratio of each 
sample divided by the target / reference ratio of the calibrator. For ease of 
understanding the calibrator target concentration divided by the calibrator reference 
concentration has been set as 1 for both series. This allows these two sets of data to 
be unequivocally compared. The melting data relating to the NRF2 PCR products for 
both series A and B are shown in figure 3.23 and 3.25 respectively. The melting data 
for both series A and B suggests impeccable PCR priming and reaction parameters 
resulting in the generation of only specific PCR product.
As shown in figure 3.26 and 3.27, both of the independent sample series 
analysed for NRF2 transcriptional activity display low frequency oscillations in the 
level of NRF2 mRNA in both the control and UVA treated samples. The UVA
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irradiated samples show disruption to these oscillations, and exhibit a lower level of 
NRF2 transcriptional activity immediately following UVA treatment when compared 
to the unirradiated control samples. The data shown in figures 3.26 and 3.27 has been 
combined in figure 3.28. Here the data have been combined to show the intra- 
experimental calibrator normalised mean of the irradiated samples divided by the 
mean of the control (unirradiated) samples for both series. This graph allows 
visualisation of the relative transcriptional activity of the irradiated samples over the 
unirradiated samples.
This graph exemplifies a period of reduced NRF2 transcriptional activity in 
the irradiated samples when compared to the unirradiated samples for between 2 - 4  
hours post-irradiation. This period of reduced transcriptional activity is succeeded by 
a period of enhanced transcriptional activity lasting in excess of 12 hours. Both series 
A and series B indicate a transcriptional time peak of 8 hours post treatment in the 
irradiated samples. A 1.67-fold and 2.02-fold relative fold increase in transcriptional 
activity in the irradiated samples over the un-irradiated control samples is observed in 
series A and series B respectively. These data show that UVA radiation exercises an 
influence over NRF2 transcriptional activity in these primary human skin cells.
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Figure 3.21: The relative fold change of HMOX1 transcriptional activity in 
both control and UVA irradiated FEK4 cells (series A)
The graph shows HO-1 mRNA levels in both UVA (250 kJ/m2) and control 
treated FEK4 cells. The samples have been normalised against the same 
calibrator. The graph shows the target (HMOX1) / reference (GAPDH) ratio of 
each sample divided by the target / reference ratio o f the calibrator. Here the 
calibrator target concentration divided by the calibrator reference concentration 
has been set as 1. Each point represents the mean o f two identical intra- 
experimental samples ran simultaneously. The error bars represent one standard 
deviation above and below the mean. This experiment was repeated with time 
course B with similar results.
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Figure 3.22: Determination of the effect of UVA radiation on NRF2 
transcriptional activity: amplification curves (series A)
(next page)
FEK4 primary human fibroblasts were either untreated, control treated (Sham), 
or UVA treated (250 kJ/m ). Control cells were treated exactly the same as 
UVA irradiated samples, but were not irradiated. Cells were then cultured for 
the indicated time period before harvesting. The untreated cells remained in the 
incubator for the duration of the experiment. Total RNA was extracted as 
described in section 2.5.1, and reverse transcription was performed as described 
in section 2.15. 2 pi of this cDNA, either undiluted for NRF2, or a 1 in 5 
dilution for GAPDH, was added to a PCR master-mix (as described in section 
2.16.2) containing 0.5 pM of both the forward and reverse primer (shown in 
table 2.1). A final Mg2+ concentration of 2.0 mM was used for NRF2 and 3.0 
mM for GAPDH. A total reaction mixture volume of 20 pi was prepared for 
each sample. A no-template-control (NTC) and calibrator (Cal) sample was also 
included. The samples were analysed independently for either NRF2 or GAPDH 
using the settings shown in table 3.1 and table 2.4 respectively. Samples were 
analysed using the LightCycler 1.5 instrument. Gene expression was measured 
by relative qualification using the software programme LightCycler 4.0. The 
NRF2 (Target) and GAPDH (Reference) data is presented in the form of 
amplification curves. The melting curve analysis relating to the NRF2 PCR 
product is presented in figure 3.23, and the relative fold change in NRF2 
transcriptional activation for both the irradiated and control samples is shown in 
figure 3.26.
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Figure 3.23: Series A: NRF2 PCR product melting curve and melting peak
The melting curve and melting peak relates to the NRF2 data in figure 3.22. The 





Figure 3.24: Determination of the effect of UVA radiation on NRF2 
transcriptional activity: amplification curves (series B)
(next page)
FEK4 primary human fibroblasts were either control treated (Sham), or UVA 
treated (250 kJ/m2). Control cells were treated exactly the same as UVA 
irradiated samples, but were not irradiated. Cells were then cultured for the 
indicated time period before harvesting. Total RNA was extracted as described 
in section 2.5.1, and reverse transcription was performed as described in section
2.15. 2 pi of this cDNA, either undiluted for NRF2, or a 1 in 5 dilution for 
GAPDH, was added to a PCR master-mix (as described in section 2.16.2) 
containing 0.5 pM of both the forward and reverse primer (shown in table 2.1). 
A final Mg2+ concentration of 2.0 mM was used for NRF2 real time PCR and 
3.0 mM for GAPDH real time PCR. A total reaction mixture volume of 20 pi 
was prepared for each sample. Several no-template-control (NTC) samples and 
calibrator (Cal) sample were included. The samples were analysed 
independently for either NRF2 or GAPDH using the settings shown in table 3.1 
and table 2.4 respectively. Samples were analysed using the LightCycler 1.5 
instrument. Gene expression was measured by relative qualification using the 
software programme LightCycler 4.0. The NRF2 (target) and GAPDH 
(reference) data is presented in the form of amplification curves. The melting 
curve analysis relating to the NRF2 PCR product is presented in figure 3.25, and 
the relative fold change in NRF2 transcriptional activation for both the irradiated 
and control samples is shown in figure 3.27.
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Figure 3.25: Series A: NRF2 PCR product melting curve and melting peak
The melting curve and melting peak relates to the NRF2 data in figure 3.24. The 
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Figure 3.26: The relative fold change of NRF2 transcriptional activity in both 
control and UVA irradiated cells (series A)
The graphs represent the data shown in figure 3.22. For clarity the control and 
UVA irradiated samples have been plotted separately. To allow for inter- 
experimental comparison, all o f the LightCycler data has been normalised against 
the same calibrator. The graph shows the target (NRF2) / reference {GAPDH) 
ratio o f each sample divided by the target / reference ratio o f the calibrator. Here 
the calibrator target concentration divided by the calibrator reference 
concentration has been set as 1. Each point represents the mean o f two identical 
intra-experimental samples ran simultaneously. The error bars represent one 
standard deviation above and below the mean.
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Figure 3.27: The relative fold change of NRF2 transcriptional activity in both 
control and UVA irradiated cells (series B)
The graphs represent the data shown in figure 3.24. For clarity the control and 
UVA irradiated samples have been plotted separately. To allow for inter- 
experimental comparison, all o f the LightCycler data has been normalised against 
the same calibrator. The graph shows the target (NRF2) / reference {GAPDH) 
ratio o f each sample divided by the target / reference ratio o f the calibrator. Here 
the calibrator target concentration divided by the calibrator reference 
concentration has been set as 1. Each point represents the mean o f two identical 
intra-experimental samples ran simultaneously. The error bars represent one 
standard deviation above and below the mean.
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Figure 3.28: The relative fold change in AJRF2 transcriptional activity in 
response to UVA irradiation
The graph represents the data shown in figures 3.26 and 3.27. The graph shows 
the intra-experimental calibrator normalised mean of the irradiated samples 
divided by the control (un-irradiated) samples for both independent time courses.
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3.7 The anti-apoptotic role of HO-1 in human melanoma cells
3.7.1 General remarks
Using both murine and human models, studies have shown the transcription 
factor Nrf2 to be involved in the activation of the phase II enzyme HO-1 (refer to 
sections 1.3.6 and 1.4.4). HO-1 has been shown to possess potent anti-apoptotic 
activity and has been implicated in the pathogenesis and proliferation of various 
neoplastic pathologies (refer to section 1.5.4). This study has examined the anti- 
apoptotic activity of HO-1 in human skin cells.
Prior to the start of this investigation, work from this laboratory had shown the 
primary human fibroblast cell line FEK4 to be highly resistant to UVA-induced 
apoptosis (Proteggente et al., 2003). Furthermore, this cell line is known to exhibit 
strong up-regulation of the HO-1 gene in response to UVA radiation (Keyse et al., 
1989). It was hypothesised that the lack of susceptibility of this cell line to UVA- 
apoptosis may be attributable to UVA up-regulation of HMOX1, and furthermore, that 
this resistance to apoptosis may ultimately be dependent on UVA-activation of the 
transcription factor Nrf2. To investigate this hypothesis, it was determined whether or 
not HO-1 enzymatic activity could modulate apoptosis in FEK4 cells (data not 
shown).
FEK4 fibroblasts were treated with various doses of UVA. Immediately 
following irradiation the cells were treated with varying concentrations ( 0 - 1  mM) of 
the HO-1 competitive substrate analogue tin-protoporphyrin IX dichloride. To assess 
whether reduced HO-1 enzymatic activity resulted in increased apoptosis, the cells 
were assayed for characteristics inherent to apoptosis at various time points. These 
experiments produced data indicating that treatment with 1 mM of this competitive 
substrate analogue could mediate a two-fold increase in the percentage of cells 
undergoing UVA-apoptosis when compared to irradiated vehicle treated cells. 
However, the HO-1 competitive substrate analogue tin-protoporphyrin IX dichloride 
is known to be highly photo-reactive and generate ROS in response to exposure to 
sunlight. Data was obtained that indicated that the increased percentage of FEK4 
cells undergoing UVA-apoptosis when treated with tin-protoporphyrin IX dichloride 
was not entirely specific to reduced HO-1 enzymatic activity. Owing to the
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experimental complications associated with this compound, investigations by this 
methodology were discontinued.
In order to investigate the anti-apoptotic role of HO-1 in human skin cells 
further, a HO-1 over-expressing construct suitable for eukaryotic transient 
transfection was employed (refer section 2.7.2). In order, to explore the effect of HO- 
1 over-expression there was a prerequisite to establish a cell line that satisfied two 
criteria: firstly, the cell line needed to exhibit sufficient UVA-induced apoptosis to 
observe resistance to apoptosis conferred by HO-1 over expression; and secondly, the 
cell line needed to be amenable to transient transfection with this construct. The lack 
of UVA-apoptosis observed in FEK4 cells prevented the use of this cell line for this 
investigation.
As discussed in section 1.5.3, malignant melanoma is the most life-threatening 
cutaneous malignancy. Clinical oncology studies have shown that the high 
probability of mortality associated with this type of cancer can be attributed to 
resistance to apoptosis; yet the cellular mechanisms underlying this resistance remain 
to be elucidated. As such, investigations were conducted into the anti-apoptotic 
activity of HO-1 in human skin using human melanoma cells. Melanoma cells are 
phenotypically diverse. A number of human melanoma cell lines were therefore 
assessed for fulfilment of the afore mentioned criteria.
3.7.2 Quantification of UVA-apoptosis and transient transfection efficiency in human 
melanocytes and melanoma cells
To investigate the potential anti-apoptotic role of HO-1 in human skin there 
was a requirement to identify a human melanoma cell line that was both amenable to 
transient transfection with the HO-1 over-expressing construct pcDNA-3.1-H01, and 
that exhibited apoptotic potential. The human melanoma cells lines G361, JUSO, and 
IGR1 (refer to section 2.2.2) were selected for this investigation. Investigations prior 
to the start of this study had shown these cells lines to be sensitive to UVA induced 
cell death (unpublished observations). The human melanocyte cell line NIR (refer 
section 2.2.2) was also employed during this investigation to allow for a degree of 
comparison between human melanoma cells and melanocytes. As discussed in 
section 1.5.3, UVA has been shown to induce both immediate ( 0 - 4  Hrs) and delayed 
(20 Hrs) apoptosis. Up-regulation of HMOX1 is likely to pre-dominantly influence
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late UVA-apoptosis. UVA-induced late apoptosis and necrosis was therefore 
quantified in the cell lines G361, JUSO, IGR1, and NIR.
Cells in exponential growth were treated with varying doses of UVA. After 
20 hours the cells were collected and incubated in a labelling solution containing 
annexin V and prodidium iodide (as described in section 2.13.2). The percentage of 
cells exhibiting characteristics inherent to apoptosis and necrosis was determined by 
flow cytometry (as described in section 2.13). Figures 3.29 and 3.30 show the 
percentage of cells undergoing UVA-apoptosis and -necrosis respectively. As 
expected, necrosis was the predominant form of cell death observed in FEK4 cells. 
For this reason, FEK4 cells were not employed to investigate the effect of HO-1 over­
expression on UVA-apoptosis. Similarly, G361 human melanoma cells proved highly 
resistant to UVA-apoptosis, and sensitive to UVA-induced necrosis. IGR1 human 
melanoma cells proved sensitive to both forms of UVA induced cell death, and 
exhibited virtually identical necrotic and apoptotic profiles. The exceptionally long 
growth period associated with NIR049 human melanocytes (doubling time > 7 days) 
dictated a limited investigation into the form of cell death induced by UVA in this cell 
line. These data identified necrosis to be the sole form of cell death undertaken by 
this cell line. The necrotic and apoptotic profiles relating to JUSO human melanoma 
cells proved more favourable to the needs of this study. As shown in figure 3.29 and 
3.30, JUSO cells proved sensitive to UVA-induced apoptosis, but not necrosis. The 
cell survival data relating to JUSO is in agreement with data published previously 
(Applegate et a l, 1996).
The potential for high level transient transfection was determined. G361, 
JUSO, IGR1, and NIR cells were seeded at various densities 48 - 72 hours prior to 
transfection. The cells were transfected with 1.5 pg of the green fluorescent protein 
over-expressing construct pcDNA3.1-EGFP (refer section 2.7.3). Transfection of this 
construct allowed for rapid determination of transfection efficiency by flow 
cytometry. Transfection was accomplished using 3 pi of Lipofectamine™ 2000 
according to the manufacturer’s instructions (as described in section 2.9). 
Untransfected cells were treated exactly the same as the transfected cells, but were not 
transfected. The cells were cultured for 40 - 48 hours prior to determination of 
transfection efficiency (as described in section 2.13.3). The percentage of cells 
transfected was deemed to be the percentage of cells exhibiting a higher fluorescence 
than 98 % of the lowest fluorescing cells in the untransfected cell population (refer to
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figure 2.3). As shown in figure 3.31, with the exception of G361 cells, all of the cell 
lines analysed exhibited a transfection efficiency in excess of 40 %. Further to this, 
separate investigations indicated that a transfection efficiency of approximately 70 % 
could be expected with respect to JUSO cells. The high transfection efficiency and 
pro-apoptotic nature of both JUSO and IGR1 human melanoma cells underlined the 
suitability of these two cells lines for this investigation. HO-1 over-expression by 
pcDNA3.1-HO-l transient transfection was next evaluated in JUSO, IGR1, and NIR 
cells.
pcDNA3.1-H01 (a kind gift from Professor Roland Stocker, The University of 
Sydney) was subjected to restriction enzyme digestion. This confirmed the presence 
of the 1 kb HO-1 insert (data not shown). IGR1 cells were subsequently transfected 
with 1.5 pg of either pcDNA3.1 or pcDNA3.1-H01 using the commercially available 
transfection reagents GeneJuice® and Lipofectamine™ 2000 (as described in section 
2.9). As shown in figure 3.32, strong HO-1 over-expression was observed in IGR1 
cells transfected using the cationic transfection reagent Lipofectamine™ 2000, but not 
in cells transfected using GeneJuice®. All subsequent transfections were therefore 
performed using Lipofectamine™ 2000. As shown in figure 3.33, strong pcDNA3.1- 
HOl mediated HO-1 over-expression was observed in the cell lines JUSO and FEK4 
using Lipofectamine™ 2000. However, HO-1 over-expression was not observed in 
NIR049 human melanocytes, a result possibly attributable to the protracted doubling 
time associated with this cell line.
After consideration, based upon pro-apoptotic and anti-necrotic 
characteristics, and the strong potential for HO-1 over-expression, the cell line JUSO 
was selected for further investigations into the potential anti-apoptotic activity of HO- 
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Figure 3.29: Determination of late UVA-induced apoptosis
Cells in exponential growth were irradiated with UVA at the stated dose and then 
incubated in conditioned media at 37°C for 20 hours. The cells were then 
collected and incubated in a labelling solution containing annexin V and 
prodidium iodide for 15 minutes (as described in section 2.13.2). The percentage 
o f cells undergoing apoptosis was determined using flow cytometry (as described 
in section 2.13). During acquisition and analysis, data was viewed using a two- 
dimensional log dot plot defined by the FL1 and FL3 fluorescent profiles. 
Annexin V positive propidium iodide negative stained cells were deemed to be 
apoptotic (refer to figure 2.2). 10000 events were recorded for each sample. The 
percentage of NIR049 cells undergoing both early and late apoptosis was 
quantified. For NIR049 the percentages indicated represent one sample. For all of 
the other cells lines, each point represents the mean o f three independent samples. 
The error bars represent one standard deviation above and below the mean.
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Figure 3.30: Determination of UVA-induced necrosis
Cells in exponential growth were irradiated with UVA at the stated dose and then 
incubated in conditioned media at 37°C for 20 hours. The cells were then 
collected and incubated in a labelling solution containing annexin V and 
prodidium iodide for 15 minutes (as described in section 2.13.2). The percentage 
o f cells undergoing necrosis was determined using flow cytometry (as described in 
section 2.13). During acquisition and analysis, data was viewed using a two- 
dimensional log dot plot defined by the FL1 and FL3 fluorescent profiles. Double 
stained cells were considered to be necrotic (refer to figure 2.2). 10000 events 
were recorded for each sample. The percentage o f NIR049 cells undergoing 
necrosis at both 4 and 20 hours after treatment was quantified. For NIR049 the 
percentages indicated represent one sample. For all o f the other cells lines, each 
point represents the mean o f three independent samples. For clarity only the upper 
error bars are shown. The error bar represents one standard deviation above mean.
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Figure 3.31: Determination of the transfection efficiency of pcDNA3.1-EGFP
using Lipofectamine™ 2000
(Next page)
Cells were seeded at the stated density into 6-well plates 48 - 72 hours prior to 
transfection. Cells were transfected with 1.5 pg of pcDNA3.1-EGFP (refer to 
section 2.7.3) using 3 pi of Lipofectamine™ 2000 according to the manufacturer’s 
instructions (as described in section 2.9). The untransfected cells were treated 
exactly the same as the transfected cells, but were not transfected. Cells were 
incubated at 37°C in serum free medium containing the transfection reagent / 
DNA complex for 4 -  5, after which the transfection medium was replaced with 
fresh complete medium. The cells were then cultured for 40 - 48 hours prior to 
the determination of transfection efficiency. Transfection efficiency was 
determined by flow cytometry (as described in section 2.13.3). 10000 events were 
recorded for each sample. During acquisition and analysis, data was viewed using 
a one-dimensional log histogram plot defined by the FL1 fluorescent profile. The 
percentage of cells transfected was deemed to be the percentage of cells exhibiting 
a higher fluorescence than 98 % of the lowest fluorescing cells in the 
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Figure 3.32: pcDNA3.1-HO-l mediated HO-1 over-expression in IGR1
human melanoma cells
IGR1 human melanoma cells were transfected with either 1.5 pg o f the HO-1 
over-expressing construct pcDNA3.1-H01, or the empty control vector 
(pcDNA3.1), using the commercially available transfection reagent GeneJuice® or 
Lipofectamine™ 2000 according to the manufacturer’s instructions (as described 
in section 2.9). Cells were harvested 48 hours after transfection and whole cell 
extracts were prepared as described in section 2.4.1. Protein content was 
determined using the method of Bradford (refer to section 2.4.4). Equal amounts 
o f protein (40 pg/lane) were analysed by SDS-PAGE and western blotting as 
described in Material and Methods (refer to section 2.12). After visualisation of 




Figure 3.33: pcDNA3.1-H01 mediated HO-1 over-expression in NIR049, 
JUSO, and FEK4 human skin cells
Cells were transfected with either 1.0 |xg o f the HO-1 over-expressing construct 
pcDNA3.1-H01, or the empty control vector (pcDNA3.1), using the commercially 
available transfection reagent Lipofectamine™ 2000 according to the 
manufacturer’s instructions (as described in section 2.9). Cells were harvested 44 
- 48 hours after transfection and whole cell extracts were prepared as described in 
section 2.4.1. Protein content was determined using the method o f Bradford 
(section 2.4.4). Equal amounts of protein (10 jig/lane) were analysed by SDS- 
PAGE and western blotting as described in Material and Methods (refer section 
2.12). After visualisation o f HO-1 protein, the membrane was stripped and re­
probed for actin to evaluate loading.
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3.7.3 Determination of UVA up-regulation of HO-1 in human melanocytes and 
melanoma cells
As shown in section 3.7.2, JUSO human melanoma cells proved sensitive to 
UVA-induced apoptosis and amenable to transfection with the HO-1 over-expressing 
construct pcDNA3.1-H01. This cell line was therefore selected for further 
investigation into the anti-apoptotic activity of HO-1 in human skin. It was 
hypothesised that a lack of up-regulation of the anti-apoptotic protein HO-1 may 
underlie the sensitivity of JUSO cells to UVA-apoptosis. The effect of UVA 
irradiation on HO-1 protein levels was therefore determined in this cell line. In 
addition to this, the effect of UVA radiation on HO-1 was also evaluated in NIR049, a 
cell line shown to be resistant to UVA-apoptosis.
JUSO human melanoma cells and NIR049 human melanocytes were treated 
with UVA (250 kJ/m2) whilst in exponential growth. Following treatment, the cells 
were covered with conditioned media and returned to the incubator. At the stated 
time point, cells were harvested and whole cell extracts were prepared as described in 
section 2.4.1. Equal amounts of protein were analysed by SDS-PAGE and western 
blotting as described in section 2.12. As shown in figure 3.34, UVA irradiation (250 
kJ/m2) of JUSO cells resulted in a moderate increase in HO-1 protein at 24, 36, and 48 
hours following treatment when compared to an unirradiated control sample. As 
shown in figure 3.35, strong HO-1 up-regulation was observed in human melanocytes. 
HO-1 protein accumulation was visualised from 4 hours following UVA treatment 
(250 kJ/m2) of NIR049 cells. Peak HO-1 protein accumulation was observed 12 
hours after UVA treatment. This experiment was independently repeated with nearly 
identical results. The repeat of this experiment included control and irradiated 
samples for two hours following treatment, both of which did not show HO-1 
accumulation (data not shown).
As shown in figure 3.29, JUSO human melanoma were shown to be sensitive 
to late UVA-apoptosis, NIR049 human melanocytes were not. Only moderate HO-1 
protein accumulation was observed in UVA treated JUSO cells, whereas strong HO-1 
protein accumulation observed in NIR049 human melanocytes. Taken together, these 
data support the notion that HO-1 may exert some influence over apoptosis in these 
human skin cells.
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Figure 3.34: UVA treatment causes whole cell accumulation of HO-1 
protein in JUSO human melanoma cells
JUSO human melanoma cells were treated with UVA (250 kJ/m2). The cells 
were then incubated in conditioned media at 37°C for the indicated time 
period. The control sample was treated exactly the same as the UVA 
irradiated sample, but was not irradiated. Whole cell extracts were prepared as 
described in the Materials and Methods (refer to section 2.4.1). Protein 
concentration was determined using the method o f Bradford. Equal amounts 
o f protein (30 pg/lane) were analysed by SDS-PAGE and western blotting as 
described in Material and Methods (refer to section 2.12). After visualisation 
o f HO-1 protein, the membrane was re-probed for actin to evaluate loading.
135
Untreated Control UVA (250 kJ/m2)
Time (Hr): 48 4 8 12 24 48
HO-1
Actin
Figure 3.35: UVA radiation causes whole cell accumulation of HO-1 
protein in primary human skin melanocytes
N1R049 human melanocytes in exponential growth were treated with UVA 
(250 kJ/m2). The cells were then incubated in conditioned media at 37°C for 
the indicated time period. The control sample was treated exactly the same as 
the UVA irradiated sample, but was not irradiated. Whole cell extracts were 
prepared as described in the Materials and Methods (refer to section 2.4.1). 
Protein concentration was determined using the method o f Bradford. Equal 
amounts o f protein (15 pg/lane) were analysed by SDS-PAGE and western 
blotting as described in Material and Methods (refer section 2.12). After 
visualisation o f HO-1 protein, the membrane was re-probed for actin to 
evaluate loading. This experiment was repeated with nearly identical results.
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3.7.4 The role of HO-1 in UVA-apoptosis in JUSO human melanoma cells
Prior to the optimisation of transfection conditions, preliminary experiments 
were conducted using JUSO human melanoma cells to assess the involvement of HO- 
1 in both early and late UVA-apoptosis. JUSO cells were seeded at 1 x 105 into 6- 
well plates 48 hours prior to transfection. Cells were then transfected with 1.5 pg of 
either pcDNA3.1-H01, or the empty control vector pcDNA3.1, using 3 pi of 
Lipofectamine™ 2000 according to the manufacturer’s instructions (as described in 
section 2.9). Cells were then cultured for the stated time period before UVA 
treatment. Following UVA treatment the cells were cultured for either 4 or 20 hours. 
The percentage of cells exhibiting characteristics inherent to necrosis or apoptosis was 
then determined by flow cytometry (as described in section 2.13). The transfection 
efficiency of each experiment was estimated by transfection of pcDNA3.1-EGFP into 
a separate cell population using the transfection conditions described above.
As shown in figure 3.36, with respect to cells transfected with the control 
vector pcDNA3.1, a marginal increase in early UVA-apoptosis (1.1 % to 1.5 %) was 
observed between unirradiated cells and UVA treated cells (400 kJ/m2). Crucially, 
HO-1 over-expression prevented this increase in apoptosis. Virtually no change in the 
percentage of cells undergoing necrosis was observed in this experiment. These data 
indicate that HO-1 may mediate protection against early UVA-apoptosis in melanoma 
cells. The transfection efficiency of this experiment was approximately 36 %.
As shown in figure 3.37, JUSO cells displayed a dose-dependent increase in 
late UVA-apoptosis (20 hours post treatment). A moderate dose-dependent increase 
in UVA-necrosis was observed. Transfection of JUSO cells with the HO-1 over­
expressing construct pcDNA3.1-H01 reduced the level of apoptosis in unirradiated 
and irradiated cells. However, this effect was dose independent. HO-1 over­
expression did not influence necrosis in this experiment. These preliminary data 
indicate that HO-1 may mediate protection against background apoptosis, but it is not 
clear whether HO-1 influences late UVA-apoptosis. The transfection efficiency of 
this experiment was approximately 69 %.
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Figure 3.36: Quantification of UVA induced early cell death in JUSO human 
melanoma cells transfected with pcDNA3.1 or pcDNA3.1-H01
(Next page)
Cells were seeded at 1 x 105 into 6-well plates 48 hours prior to transfection. 
Cells were transfected with 1.5 pg of either pcDNA3.1-H01 or the control vector 
pcDNA3.1 (refer to section 2.7). Cells were transfected using 3 pi of 
Lipofectamine™ 2000 according to the manufacturer’s instructions (as described 
in section 2.9). The cells were incubated at 37°C in serum free medium 
containing the transfection reagent / DNA complex for 4 hours, after which the 
transfection medium was replaced with fresh complete medium. The cells were 
then cultured for 38 hours prior to UVA treatment. Following UVA treatment the 
cells were cultured for 4 hours. The cells were then collected and incubated in a 
labelling solution containing annexin V and prodidium iodide for 15 minutes (as 
described in section 2.13.2). The percentage of cells undergoing apoptosis and 
necrosis was determined using flow cytometry (as described in section 2.13). 
During acquisition and analysis data was viewed using a two-dimensional log dot 
plot defined by the FL1 and FL3 fluorescent profiles. Annexin V positive, 
propidium iodide negative stained cells were considered to be apoptotic, double 
stained cells were considered to be necrotic (refer to figure 2.2). 10000 events 
were recorded for each sample. The percentages represent the mean of three 
independent samples. The error bars represent one standard deviation above and 
below the mean. The transfection efficiency of this experiment was 
approximately 36 % as determined by transfection of pcDNA3.1-EGFP (refer to 
section 2.13.3). pcDNA3.1-EGFP was transfected using the same conditions used 
for cells transfected with pcDNA3.1 or pcDNA3.1-H01. This experimental data 
can be viewed in appendix A.
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Figure 3.37: Quantification of UVA induced late cell death in JUSO human 
melanoma cells transfected with pcDNA3.1 or pcDNA3.1-H01
(Next page)
Cells were seeded at 1 x 105 into 6-well plates 48 hours prior to transfection. 
Cells were transfected with 1.5 pg of either pcDNA3.1-H01 or the control vector 
pcDNA3.1 (refer to section 2.7). Cells were transfected using 3 pi of 
Lipofectamine™ 2000 according to the manufacturer’s instructions (as described 
in section 2.9). The cells were incubated at 37°C in serum free medium 
containing the transfection reagent / DNA complex for 6 hours, after which the 
transfection medium was replaced with fresh complete medium. The cells were 
then cultured for 20 hours prior to UVA treatment. Following UVA treatment the 
cells were cultured for 20 hours. The cells were then collected and incubated in a 
labelling solution containing annexin V and prodidium iodide for 15 minutes (as 
described in section 2.13.2). The percentage of cells undergoing apoptosis was 
determined using flow cytometry (as described in section 2.13). During 
acquisition and analysis data was viewed using a two-dimensional log dot plot 
defined by the FL1 and FL3 fluorescent profiles. Annexin V positive, propidium 
iodide negative stained cells were considered to be apoptotic, double stained cells 
were considered to be necrotic (refer to figure 2.2). 10000 events were recorded 
for each sample. The percentages represent the mean of three independent 
samples. The error bars represent one standard deviation above and below the 
mean. The transfection efficiency of this experiment was approximately 69 % as 
determined by transfection of pcDNA3.1-EGFP (refer to section 2.13.3). 
pcDNA3.1-EGFP was transfected using the same conditions used for cells 
transfected with pcDNA3.1 or pcDNA3.1-H01. This experimental data can be 
viewed in appendix B.
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3.7.5 Transfection condition optimisation
The conditions for JUSO transient transfection were optimised. JUSO cells 
were seeded at 1 x 105 into 6-well plates. Cells in exponential growth were 
transfected with the stated amount of pcDNA3.1-EGFP using the commercially 
available transfection reagent Lipofectamine™ 2000 (as described in section 2.9). In 
order, to determine the optimal conditions for transfection, both the quantity of DNA, 
and the ratio of DNA to transfected reagent was varied. For all conditions the 
transfection efficiency was determined by flow cytometry after 20 hours, and after 44 
hours. The percentage of cells transfected was considered to be the percentage of 
cells exhibiting greater fluorescence than 98 % of the lowest fluorescing cells 
transfected with 0 pg of DNA (refer to figure 2.3). Prior to analysis by flow 
cytometry, the percentage of cells attached to the dish was used to estimate the 
percentage of surviving cells for each transfection condition. The percentage of cells 
transfected was consistently observed to be greater at 20 hours opposed to 44 hours 
after transfection. As shown in figure 3.38, 2 pg of DNA transfected using 4 pi of 
Lipofectamine™ 2000 resulted in the greatest percentage of transfected cells. These 
conditions resulted in a transfection efficiency of approximately 70 %. 
Approximately 75 % of cells survived to the point of analysis using these conditions.
The size of a construct is known to influence transfection efficiency, and an 
increase in transfection efficiency is known to correlate with increased cytotoxicity. 
Therefore, the possibility of a difference between the transfection efficiency of the 
control vector pcDNA3.1, and the HO-1 over-expressing vector pcDNA3.1-H01 was 
investigated. It was determined whether such a discrepancy could underlie the 
reduced apoptosis observed in cells transfected with the larger HO-1 over-expressing 
construct. Cells were co-transfected with the smaller control construct (pcDNA3.1), 
or with the larger HO-1 over-expressing construct (pcDNA3.1-H01), in combination 
with the green fluorescent protein over-expressing construct pcDNA3.1-EGFP.
JUSO cells were seeded at 1 x 105 into 6-well plates 48 hours prior to 
transfection. Cells in exponential growth were transfected with either pcDNA3.1- 
EGFP only, or, with 1 pg of pcDNA3.1-EGFP combined with 1 pg of pcDNA3.1 or 
pcDNA3.1-H01. Cells were transfected using the commercially available 
transfection reagent Lipofectamine™ 2000 according to the manufacturer’s 
instructions (as described in section 2.9). The cells were cultured for 20 hours prior to
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determination of transfection efficiency. Transfection efficiency was determined by 
flow cytometry as described previously (refer to figure 2.3). As shown in figure 3.39, 
the percentage of JUSO cells transfected with the green fluorescent protein over­
expressing construct pcDNA3.1-EGFP was not influenced by the presence of either 
pcDNA3.1 or pcDNA3.1-H01. These data show that a difference in transfection 
efficiency resulting from a difference in construct size does not underlie the protection 
against apoptosis mediated by the HO-1 over-expressing construct pcDNA3.1-H01.
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Figure 3.38: Optimisation of the conditions required for transient transfection
of JUSO human melanoma cells
(next page)
Cells were seeded at 1 x 105 into 6-well plates. Cells in exponential growth were 
transfected with the stated amount of pcDNA3.1-EGFP ( 0 - 3  pg) using the 
commercially available transfection reagent Lipofectamine™ 2000 according to the 
manufacturer’s instructions (as described in section 2.9). To determine the optimal 
conditions for transfection, both the quantity of DNA, and the ratio of DNA to 
transfection reagent was varied. The cells were incubated at 37°C in serum free 
medium containing the transfection reagent / DNA complex for 5 hours, after which 
the transfection medium was replaced with fresh complete medium. The cells were 
then cultured for either 20 or 44 hours. Transfection efficiency was determined by 
flow cytometry (as described in section 2.13.3). 10000 events were recorded for 
each sample. During acquisition and analysis data was viewed using a one­
dimensional log histogram plot defined by the FL1 fluorescent profile. The 
percentage of cells transfected was considered to be the percentage of cells 
exhibiting a higher fluorescence than 98 % of the lowest fluorescing cells in the 
cells transfected with 0 pg of DNA (refer to figure 2.3). The percentage of cells 
surviving at the point of analysis (20 hours only) was determined by visualisation of 
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Figure 3.39: Co-transfection of pcDNA3.1 or pcDNA3.1-H01 with pcDNA3.1-
EGFP
Cells were seeded at 1 x 105 into 6-well plates 48 hours prior to transfection. Cells 
in exponential growth were transfected with either 1 pg o f pcDNA3.1-EGFP only, 
or, with 1 pg o f pcDNA3.1-EGFP combined with 1 pg o f pcDNA3.1 or pcDNA3.1- 
H O l. Cells were transfected using the commercially available transfection reagent 
Lipofectamine™ 2000 according to the manufacturer’s instructions (as described in 
section 2.9). The cells were incubated at 37°C in serum free medium containing the 
transfection reagent / DNA complex for 4 hours, after which the transfection 
medium was replaced with fresh complete medium. The cells were then cultured for 
20 hours prior to determination o f transfection efficiency. Transfection efficiency 
was determined by flow cytometry (as described in section 2.13.3). 10000 events 
were recorded for each sample. During acquisition and analysis data was viewed 
using a one-dimensional log histogram plot defined by the FL1 fluorescent profile. 
The percentage o f cells transfected was considered to be the percentage o f cells 
exhibiting a higher fluorescence than 98 % o f the lowest fluorescing cells in cells 
transfected with 0 pg o f DNA (refer to figure 2.3). The percentages represent the 
mean o f three independent samples. The error bars represent one standard deviation 
above and below the mean.
146
3.7.6 The role of HO-1 in late UVA-apoptosis in JUSO melanoma cells
Determination of the time point at which peak UVA-induced apoptosis occurs 
in JUSO human melanoma cells was attempted by means of nuclear blebbing. 
However, experimental complications were encountered. Therefore, using optimised 
transfection conditions (refer figure 3.38), the effect of HO-1 over-expression on late 
UVA-apoptosis was determined at the time point at which considerable UVA- 
apoptosis was observed previously (approximately 20 hours). Cells were seeded at 1 
x 105 into 6-well plates 48 hours prior to transfection. Cells were transfected with 2.0 
pg of either pcDNA3.1-H01 or the control vector pcDNA3.1. Cells were transfected 
using 4 pi of Lipofectamine™ 2000 according to the manufacturer’s instructions (as 
described in section 2.9). The cells were then cultured for 20 hours prior to 
irradiation. Following UVA treatment the cells were cultured for 22 hours. The cells 
were then collected and incubated in a labelling solution containing annexin V and 
prodidium iodide for 15 minutes (as described in section 2.13.2). The percentage of 
cells exhibiting characteristics inherent to apoptosis and necrosis was determined by 
flow cytometry (as described in section 2.13). Annexin V positive, propidium iodide 
negative stained cells were considered to be apoptotic, double stained cells were 
considered to be necrotic (refer to figure 2.2). The transfection efficiency of this 
experiment was shown to be approximately 69 %.
As shown in figure 3.40, a dose dependent increase in late UVA-apoptosis was 
not observed in untransfected cells in this experiment. Only transfected cells proved 
sensitive to UVA irradiation. With respect to cells transfected with the control 
construct pcDNA3.1, a dose-dependent increase in UVA-apoptosis was observed. 
Crucially, transfection with the HO-1 over-expressing construct pcDNA3.1-H01 
abolished this dose dependent increase in late UVA-apoptosis. HO-1 over-expression 
did not influence necrosis. These data indicate that HO-1 over-expression confers 
protection against apoptosis in JUSO human melanoma cells. However, it is unclear 
whether HO-1 confers resistance to late UVA-apoptosis, or whether HO-1 confers 
resistance to the cytotoxicity associated with cationic transfection reagents.
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Figure 3.40: Quantification of late UVA-induced cell death in JUSO human 
melanoma cells transfected with pcDNA3.1 or pcDNA3.1-H01 (optimised
conditions)
(Next page)
Cells were seeded at 1 x 105 into 6-well plates 48 hours prior to transfection. 
Cells were transfected with 2.0 pg of pcDNA3.1-H01 or the empty control vector 
pcDNA3.1. Cells were transfected using 4 pi of Lipofectamine™ 2000 according 
to the manufacturer’s instructions (as described in section 2.9). The cells were 
incubated at 37°C in serum free medium containing the transfection reagent / 
DNA complex for 4 hours, after which the transfection medium was replaced with 
fresh complete medium. The cells were then cultured for 20 hours prior to 
irradiation. Following UVA treatment cells were cultured for 22 hours. After 22 
horns the cells were collected and incubated in a labelling solution containing 
annexin V and prodidium iodide for 15 minutes (as described in section 2.13.2). 
The percentage of cells undergoing apoptosis was determined by flow cytometry 
(as described in section 2.13). During acquisition and analysis data was viewed 
using a two-dimensional log dot plot defined by the FL1 and FL3 fluorescent 
profiles. Annexin V positive, propidium iodide negative stained cells were 
considered to be apoptotic, double stained cells were considered to be necrotic 
(refer to figure 2.2). 10000 events were recorded for each sample. The
percentages represent the mean of two independent samples. The error bars 
represent one standard deviation above and below the mean. The transfection 
efficiency of this experiment was approximately 69 % as determined by 
transfection of pcDNA3.1-EGFP and quantification by flow cytometry, (refer to 
section 2.13.3). pcDNA3.1-EGFP was transfected using the conditions used for 
cells transfected with pcDNA3.1 or pcDNA3.1-H01. A one-way analysis of 
variance (ANOVA) was used to test the significance between control transfected 
(pcDNA3.1) and HO-1 transfected cells (pcDNA3.1-HO-l). A p  value of less 
than 0.05 was considered to be significant \p < 0.05 (*), p  < 0.01 (**), p  = 0.001 
(***)]. This experimental data can be viewed in appendix C.
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4. Discussion




This study has examined the effect of UVA radiation on the transcription 
factor Nrf2 in human skin fibroblasts. UVA activation of Nrf2 has been shown by 
this study; this has been attributed to three regulatory mechanisms: enhanced nuclear 
localisation of Nrf2, accumulation of Nrf2 as a result of UVA-induced heme release, 
and NRF2 gene activation. Moreover, in this study the implications of UVA 
activation of Nrf2 have been investigated. Nrf2 is known to bind to cis-acting 
elements termed MARE (Maf associated recognition elements) within the promoter 
region of phase II detoxification enzymes and antioxidant proteins. One example is 
the UVA up-regulated enzyme HO-1. In this study data have been provided 
indicating that HO-1 modulates apoptosis in human melanoma cells. It is proposed 
that the anti-apoptotic influence of HO-1 may be dependent on Nrf2 in human skin.
The UVA component of sunlight is considered to be the primary source of 
oxidative stress to human skin and has been implicated in the pathogenesis of skin 
aging and cancer. In relation to this, the transcription factor Nrf2 has been shown to 
be central to the cellular response to oxidative stress. Studies have shown that the 
cytoplasmic actin-binding protein Keapl acts as a sensor of oxidative and 
electrophilic stress, and plays the co-ordinating role in the Nrf2 stress response 
mechanism. In this study the hypothesis that UVA modulates Nrf2 nuclear 
availability through the generation of reactive oxygen species (ROS) has been 
explored.
The ROS singlet oxygen ( ^ 2) is widely regarded as the primary effector in 
UVA-regulated gene expression. Here, the effect of UVA-generated ]02 on the sub- 
cellular localisation of Nrf2 has been investigated. Results were obtained showing 
that UVA treatment of primary human skin fibroblasts bathed in H2O resulted in 
cytoplasmic accumulation of Nrf2. However, when cells were irradiated whilst 
bathed in the *02 lifetime enhancer D2O, Nrf2 did not accumulate in the cytoplasm. 
Singlet oxygen is known to activate various protein kinases (for review see: Ryter and 
Tyrrell, 1998). Moreover, Nrf2 is known to be released from its cytoplasmic anchor 
protein Keapl and translocate into the nucleus in response to phosphorylation at Ser40 
(Bloom and Jaiswal, 2003). Thus, it is conceivable that irradiation of primary human 
skin fibroblasts whilst bathed in the ]C>2 lifetime enhancer D2O may result in
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phosphorylation and nuclear localisation of Nrf2. A study published after the start of 
this investigation has provided support to the notion that UVA-generated ]C>2 
augments Nrf2 nuclear localisation. Hirota et al., (2005) documented that UVA, but 
not UVB, increased nuclear accumulation of Nrf2 in mouse dermal fibroblasts. 
Hirota and co-workers also demonstrated that UVA-induced nuclear accumulation of 
Nrf2 was enhanced in a concentration-dependent manner in mouse dermal fibroblasts 
treated with the ]02 generating compound hematoporphyrin. In contrast to this, the 
results of the present study have shown that D20  treatment does not affect the amount 
of nuclear Nrf2. Keapl is known to have 27 reactive cysteine residues. Several 
studies have shown that oxidation of cysteine residues 151, 273, and 288 prevents 
Keapl acting as a substrate adaptor for Cullin3 containing ubiquitin ligases which 
mark Nrf2 for proteasome attention (for review see: Zhang, 2006). The reduced 
accumulation of cytoplasmic Nrf2 observed during this investigation contradicts the 
notion of ROS-mediated enhanced nuclear translocation of Nrf2, and indicates that 
!02 may in fact promote degradation of cytoplasmic Nrf2. However, further work is 
required to fully elucidate the effect of UVA-generated ROS on Nrf2.
The effect of UVA on Nrf2 accumulation has also been investigated by this 
study. Recent data from a murine model has shown that heme stabilises Nrf2 (Alam 
et al., 2003). In relation to this, a study has shown that UVA releases heme from 
microsomal heme-proteins (Kvam et al., 1999). It has been investigated by the 
present study whether UVA treatment of FEK4 fibroblasts results in accumulation of 
Nrf2, and if so, whether this effect is dependent on heme. Here, it has been shown 
that treatment of primary human fibroblasts with a physiologically relevant dose of 
UVA (250 kJ/m2) results in whole cell accumulation of Nrf2. It is shown that this 
effect is immediate (1 hour post irradiation), that the level of total Nrf2 continues to 
accumulate for at least 4 hours following UVA treatment, and that the level of Nrf2 
remains elevated for up to 12 hours following UVA treatment. Treatment of primary 
human fibroblasts with heme also resulted in Nrf2 whole cell accumulation. 
Furthermore, treatment with a heme synthesis inhibitor prior to irradiation resulted in 
decreased UVA-mediated Nrf2 accumulation. These data indicate that UVA 
stabilises the transcription factor Nrf2, and are consistent with the interpretation that 
this effect is dependent on the pro-oxidant HO-1 substrate, heme. A concern of this 
study has been to elucidate the mechanism underlying UVA regulation of HMOX1. 
Kvam et al., (1999) observed a clear correlation between the amount of heme released
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in response to UVA treatment of FEK4 cells, and subsequent accumulation of HO-1 
mRNA. These data, taken together with the findings of the present study, advocate 
the hypothesis that UVA up-regulation of HMOX1 may be the result of UVA-released 
heme stabilising the transcription factor Nrf2.
Studies have shown that in un-stimulated cells Nrf2 is expressed at a 
constitutive level but is rapidly degraded by the ubiquitin-proteasome proteolysis 
system (Itoh et al., 2003; Kobayashi et al., 2006; Nguyen et al., 2003; McMahon et 
al., 2003; Sekhar et al., 2002; Stewart et al., 2003; Zhang and Hannink, 2003); a 
pathway that is known to regulate the activity of other transcription factors, such as, 
p53, c-Fos, c-Jun, NF-kB, and STAT1 (for review see: Hershko and Ciechanover,
1998). Previous studies have proved that it is interference with the Nrf2 degradation 
pathway that permits Nrf2 accumulation, and furthermore, that the stability of Nrf2 is 
dependent on its association with the cytoplasmic ‘anchor’ protein Keapl. It is 
possible that the stabilisation of Nrf2 by heme observed by this study is an effect that 
is dependent on ROS-mediated dissociation of Nrf2 from Keapl. The HMOX1 
inducers cadmium, arsenite, and heme have all been shown to promote Nrf2 stability 
(Alam et al., 2003; Stewart et al., 2003). Crucially, all of these structurally distinct 
agents have the ability to generate oxidative stress. It is therefore likely that it is ROS 
generated in the presence of these agents that confers increased stability of Nrf2 by 
promoting the dissociation of Nrf2 from Keapl or by preventing Keapl acting as a 
substrate adaptor for ubiquitin ligases.
In the present study, enhanced nuclear accumulation of Nrf2 was observed in 
response to UVA treatment. However, by means of western blotting, cytoplasmic 
Nrf2 was barely detectable. With respect to murine cells, this is an observation made 
by another research group (Alam et al., 2003). At present the mechanism by which 
Nrf2 is transported into the nucleus remains largely uncharacterised. The lack of 
accumulation of Nrf2 in the cytoplasm observed by the present study is evidence that 
Nrf2 is constitutively and rapidly transported into the nucleus in response to 
dissociation from Keapl. Based on the findings of the present study, it is 
hypothesised that, in response to UVA treatment of human skin fibroblasts, a 
molecular regulatory system exists where ROS generated by the UVA chromophore 
heme promote dissociation of Nrf2 from Keapl and / or prevent Keapl acting as a 
substrate adaptor for ubquitin ligases. Keapl homodimers will therefore become 
saturated with existing Nrf2 and allow newly synthesised Nrf2 to exist in a free state.
153
The net result of these processes will be accumulation of Nrf2 within the nucleus and 
activation phase II genes.
Using real time RT-PCR, the effect of UVA on NRF2 gene activation was 
investigated in human skin fibroblasts. Rhythmic low frequency oscillations were 
observed in the level of Nrf2 mRNA in both control and UVA treated cells. UVA 
treatment disrupted these oscillations. The amount of accumulated Nrf2 mRNA was 
lower in UVA treated cells than in control cells for between 1 and 4 hours 
immediately following irradiation. After 4 hours, the amount of Nrf2 mRNA was 
increased up to 2-fold in the UVA treated cells compared to the control treated cells. 
To the best of our knowledge this is the first study to document oscillations in NRF2 
expression and indicates that NRF2 may autoregulate expression. Evidence of nrf2 
autoregulation was recently published. Treatment of murine keratinocytes with the 
anti-carcinogen 3H-1,2-dithiole-3-thione (D3T) was shown to result in a 2-fold 
increase in Nrf2 mRNA levels (Kwak et al., 2002). Kwak and co-workers examined 
the transcriptional activation of nrf2 by D3T and located two ARE-like sequences in 
the murine nrf2 promoter. Using a full-length promoter reporter construct, Kwak and 
co-workers demonstrated that these ARE-like sequences were required for nrf2 gene 
activation by D3T. Moreover, by chromatin immunoprecipitation assay, this study 
showed direct binding of Nr£2 to its own promoter. A search of the human NRF2 
promoter by the present study has identified that the ARE-like sequences required for 
D3T activation of nrf2 are conserved between these two species. With respect to the 
NRF2 promoter, these sequences are situated approximately 3.8 and 4.0 kb upstream 
of the NRF2 start codon. The present study has also identified sequences in the NRF2 
promoter situated approximately 5.8 and 6.0 kb upstream of the NRF2 transcriptional 
start site that closely resemble the MARE consensus sequence. The mechanism of 
autoregulation of gene expression has been documented in the case of other 
transcription factors. NF-kB is known to positively regulate its transcription by 
means of binding to a regulatory element within its promoter (Liptay et al., 1994). 
Moreover, the transcription factors c-Jun and c-Fos autoregulate expression (Angel et 
al., 1998; Verma and Sassone-Corsi, 1987). It therefore seems likely that Nrf2 may 
regulate its expression through cw-acting elements in its promoter. Nrf2 
accumulation by UVA has been observed in this study. Therefore, the delayed Nrf2 
mRNA accumulation following UVA treatment may be symptomatic of UVA 
stabilisation of Nrf2 which subsequently serves to up-regulate NRF2 gene activation
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through binding to its own promoter. Nrf2 autoregulation may therefore be indicative 
of a biological mechanism to extend activation of phase II genes. The observation 
that the level of NRF2 gene activation is reduced immediately following UVA 
treatment may be indicative of a separate effect. Sunlight, particularly blue light 
(420-440 nm), is known to re-set circadian genes (Newman et al., 2003). UVA (320- 
400 nm) may exert a similar influence. Hence, reduced NRF2 gene activation 
immediately following UVA treatment denotes that NRF2 may exhibit a “circadian 
trait”.
A primary concern of this study has been to provide insight into UVA 
regulation of HMOX1. The observations made by this, and other studies, has now 
allowed a model for UVA activation of HMOX1 to be envisaged. As stated, it is 
known that UVA treatment of primary human skin fibroblasts leads to an immediate 
release of the HO-1 substrate heme from microsomal heme-proteins (Kvam et al.,
1999). Furthermore, Kvam et al., (1999) observed a high degree of correlation 
between the amount of heme released and the subsequent degree of activation of 
HMOX1. In addition, a study has shown that ]02 is a major effector in UVA up- 
regulation of HMOX1 (Basu-Modak and Tyrrell, 1993). The results of the present 
study have allowed a regulatory system to be envisaged in human skin where UVA 
generated ROS and UVA released heme up-regulate HMOX1 by means of Nrf2.
Searches of human chromosome 22 (Raval and Tyrrell, unpublished 
observations) have identified two MARE sites upstream of the HMOX1 
transcriptional start site. MARE sites are known to be recognised and bound by 
heterodimers comprising of a small Maf protein and a CNC-bZIP protein. 
Heterodimers comprising of a small Maf protein and Nrf2 have been shown to 
activate the HO-1 gene. Heterodimers comprising of a small Maf protein and Bachl 
have been shown to negatively regulate the HO-1 gene. In the present study, findings 
have been presented consistent with the idea that UVA stabilises Nr£2 through the 
release of heme. Interestingly, Bachl is a heme binding protein, and the DNA 
binding activity of Bachl has been shown to be negatively regulated by heme binding 
in vitro (Ogawa et al., 2001). Moreover, a more recent investigation has shown that 
Bach-1 is titrated away from the HO-1 promoter and undergoes nuclear export in the 
presence of the HO-1 substrate heme (Suzuki et al., 2004). Taken altogether, the 
findings of this and other studies indicate that heme may act as a signalling molecule 
for MARE-driven gene expression. Heme may act as a molecular switch for UVA-
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regulation of the HMOX1 locus, modulating activity of both the activator and 
repressor in an elegant eukaryote regulatory system analogous to the lac operon.
In cells that have not been irradiated, a model has been proposed where 
repressor protein complexes such as Bachl-Maf heterodimers occupy MARE sites in 
enhancer regions upstream of the HO-1 transcriptional start site in favour of activating 
protein complexes such as Nrf2-Maf heterodimers. In this model the repressor 
protein complex activity will be dominant over the activating protein complexes for 
two reasons. Firstly, a Bachl-Maf heterodimer is likely to be more stable and have a 
higher affinity for DNA than an Nrf2 containing heterodimer; and secondly, proteins 
with potent transcriptional activation domains are highly unstable and possess very 
short half-lives when compared to DNA-binding proteins that lack such domains 
(Alam et al., 2003; Hershko and Ciechanover, 1998; Stewart et al., 2003). Therefore, 
it is likely that under basal (reducing) physiological conditions, the HO-1 upstream 
MARE sites will be occupied by Bachl-Maf heterodimers that either through direct 
steric blocking, or through the enlistment of co-repressors, will prevent assembly of 
the pre-transcription complex. In this situation HO-1 transcription will cease 
completely, or only a very low level of gene expression will be observed. In a 
stimulated cell system, it is likely that Nrf2-Maf heterodimers will occupy the 
HMOX1 upstream MARE sites. In this situation Nrf2 will interact directly and 
indirectly to increase recruitment of transcription machinery such as co-activators 
which will ultimately sponsor the recruitment of RNA pol II. In this model for UVA 
activation of HMOX1, heme will play the co-ordinating role in the dynamic exchange 
between these activating and repressing protein complexes (refer to figure 4.1). Heme 
released from heme-containing proteins in response to UVA will titrate repressive 
Bachl-Maf complexes away from MARE within the HO-1 promoter region and 
promote the nuclear export of Bachl. Concurrently, UVA-released heme will 
promote stabilisation of Nrf2, therefore enhancing nuclear accumulation of activating 
Nrf2-Maf heterodimers.
In the present study data have been produced consistent with the interpretation 
that UVA generated *02 modulates the amount of cytoplasmic Nrf2. This effect may 
be indicative of *02 promoting nuclear translocation o f Nrf2 which may in itself 
promote stabilisation of Nrf2 by decreasing the proximity of the transcription factor to 
proteasome degradation machinery. Accordingly, it is important to state that the role 
of heme and ROS may not be mutually exclusive. In the same way as heme, ROS
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may stabilise Nrf2 through decreasing the probability of ubiquitination; and likewise, 
the stabilising effect of heme released by UVA may be attributable to heme generated 
ROS. In relation to this, cadmium and heme, both of which are pro-oxidant and 
strong inducers of HMOX1, have been shown to induce nuclear export of the 
repressor protein Bachl. Bachl is redox sensitive owing to the presence of cysteine 
thiol residues in its DNA binding domain. Hence, it is reasonable to hypothesise that 
nuclear export of Bachl is dependent on redox state, and that UVA generated ROS 
may induce export of this HMOX1 repressor. Therefore, UVA up-regulation of 
HMOX1 may involve a simple feedback loop dependant on intracellular levels of the 
HO-1 substrate heme; up-regulation that is further enhanced as a result of UVA 
generated ROS. The net effect of this dynamic protein exchange will be rapid 
transcriptional up-regulation of the HO-1 gene and accumulation of the enzyme which 
will then remove the pro-oxidant heme.
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Figure 4.1: Diagrammatic representation of the proposed molecular regulatory
system of HMOX1 by UVA
(next page)
The schematic depicts the regulation of HMOX1 by UVA. In this model the HO-1 
substrate heme plays the co-ordinating role. Under basal physiological conditions, 
Bachl-MafK heterodimers occupy upstream enhancer elements preventing 
assembly of the pre-transcription complex. UVA irradiation causes an immediate 
release of heme from heme containing proteins. In the presence of heme, the heme 
binding protein Bachl is titrated away from the HMOX1 promoter allowing pre­
transcription complex assembly. Heme stabilises the transcriptional activator 
protein Nrf2 simultaneously. This promotes nuclear accumulation of Maf-Nrf2 
heterodimers resulting in further up-regulation of HMOX1. It is likely that free 
heme accumulation following UVA treatment plays a crucial role in the dynamic 
exchange in the occupation of MARE enhancer sites by Bachl and Nrf2 proteins 
bound to Maf. Thus, regulation of HO-1 promoter availability involves a simple 
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Evidence to support this regulatory system can be found in a recent 
investigation into the regulation of the phase II gene, NAD(P)H:quinone 
oxidoreductase 1 (NQOl). Dhakshinamoorthy et al., (2005) investigated the 
involvement of both Nrf2 and Bachl in the regulation of this gene in human 
hepatoblastoma cells. Using chromatin immunoprecipitation assay (ChIP), 
Dhakshinamoorthy and co-workers observed competition between Bachl and Nrf2 
for binding to the NQOl gene MARE, and furthermore, that MARE-driven gene 
expression was dependent on a critical balance between Nrf2 and Bachl within the 
nucleus. Crucially, this study investigated the role of heme in this human model. The 
results of this study were consistent with the hypothesis that heme mediates a 
dynamic exchange between Nrf2 (activating) and Bachl (repressive) dimeric 
complexes in MARE-driven gene expression.
Further insight into this model for heme co-ordinated UVA up-regulation of 
HMOX1 can be found in three other observations. Firstly, re-irradiation of FEK4 
primary human fibroblasts after an initial dose of UVA leads to a much smaller HO-1 
mRNA induction response than in a control experiment in which no pre-irradiation is 
given (Noel et al., 1997). Secondly, as previously stated, micro-molar concentrations 
of heme are released from microsomal heme-proteins immediately after UVA 
treatment, and this heme release precedes the induction of HO-1 transcription and 
enzymatic activity (Kvam et al., 1999). Kvam and co-workers noted however that 
HO-1 transcriptional up-regulation was not observed for UVA treatments that 
released an amount of heme below a threshold level of 2 pM. Thirdly, UVA radiation 
enhances expression of the Bachl gene several-fold (Raval and Tyrrell, unpublished 
observations). These three observations indicate a heme-dependent biological 
mechanism to shut off unwanted and potentially deleterious HO-1 gene activation. It 
seems likely that the refractoriness to re-induction of the HO-1 gene by UVA is 
dependent on the total cellular amount of heme-protein, and that a release of heme 
below a threshold level is not capable of titrating the heme binding repressive protein 
Bachl away from the HO-1 promoter, therefore permitting Nrf2-MARE binding. Up- 
regulation of the Bachl gene in response to UVA will further augment UVA 
refractoriness to re-induction of the HMOX1 locus, and may represent a novel feed­
back mechanism resulting from UVA photochemical destruction of existing Bachl 
protein bound to heme. These observations indicate that refractoriness to re-induction 
exists in a situation where the amount of heme-containing proteins has been
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substantially reduced, and where free heme has been destroyed by newly synthesised 
HO-1. In this situation the presence of newly synthesised Bach-1 will prevent Nrf2- 
MARE binding, and furthermore, a lack of heme-containing proteins will prevent 
UVA stabilisation of Nrf2. Extremely strong HMOX1 down-regulation will therefore 
develop. It has been shown that the development of a complete refractory period to 
re-induction of the HO-1 gene is limited to UVA and heme, and is not observed in 
response to other known inducers of the gene (unpublished observations, this 
laboratory). This refractoriness event therefore emphasises the unique biological 
mechanism associated with UVA up-regulation of HMOX1, further underlining the 
importance of elucidation of this regulatory mechanism.
In the present study a complete model for UVA activation of Nrf2 has been 
proposed. This has provided further insights into UVA up-regulation of HMOX1. 
The functional significance of HO-1 protein accumulation in response to UVA has 
also been investigated by this study. HO-1 accumulation has been documented in a 
variety of tumours. This accumulation has been linked with cellular proliferation and 
loss of apoptotic potential, factors that are necessary for in vivo tumour growth. This 
study has therefore investigated the ability of HO-1 to modulate apoptosis. Malignant 
melanoma is the most life-threatening cutaneous malignancy; this has largely been 
attributed to the resistance of this form of cancer to apoptosis. However, no studies 
have addressed the relationship between HO-1 and apoptosis in human melanoma 
cells. Employing the oxidising UVA component of solar radiation to induce 
apoptosis, this study has investigated the effect of HO-1 over-expression on apoptosis 
in human melanoma cells. The results of this investigation have shown that HO-1 
prevents UVA-apoptosis in a dose-dependant manner. What's more, the model for 
UVA activation of HMOX1 proposed by this study indicates that the anti-apoptotic 
influence of HO-1 may be dependant on UVA-activation of the transcription factor 
Nr£2.
In order to investigate the effect of HO-1 over-expression on apoptosis in 
human melanoma cells, there was a prerequisite to establish a melanoma cell line that 
was both sensitive to UVA-apoptosis, and that was amenable to transient transfection 
with the HO-1 over-expressing construct pcDNA3.1-H01. The human melanoma cell 
line JUSO satisfied these prerequisites and was selected in this investigation. In 
preliminary experiments it was observed that HO-1 over-expression protected against 
‘background’ apoptosis. However, negligible protection against UVA-apoptosis was
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observed. The conditions for transient transfection were then optimised. Using 
optimised conditions, it was later observed that transfection with the HO-1 over­
expressing construct conferred some protection against UVA-induced late apoptosis 
when compared to cells transfected with the parental vector. These results were 
statistically significant with respect to cells treated with 100 and 200 kJ/m2 UVA. In 
this experiment only a moderate increase in UVA-apoptosis was observed in 
untransfected cells. This indicates that transfection sensitises JUSO cells to UVA- 
apoptosis. HO-1 over-expression had no influence on UVA-induced necrosis in 
JUSO cells. Taken together, these data show that HO-1 over-expression confers 
protection against apoptosis in JUSO human melanoma cells. However, it remains 
unclear whether HO-1 confers resistance to UVA-apoptosis, or whether HO-1 confers 
resistance to the cytotoxicity associated with cationic transfection reagents.
In this study, data consistent with the interpretation that HO-1 possesses anti- 
apoptotic activity have been provided. These findings are in agreement with studies 
that have shown that HO-1 down-regulation may have therapeutic value with regards 
to its ability to augment the efficacy of cytotoxic cancer therapeutics (for review see: 
Fang et al., 2004; Prawan et al., 2005). To the best of our knowledge, this is the first 
study to evaluate this therapeutic potential in human melanoma cells. A previous 
study has however investigated the influence of HO-1 in murine melanoma cells (Was 
et al., 2006). This study published findings indicating that excess HO-1 protein 
increased viability, proliferation, and angiogenic potential of melanoma cells, 
augmented metastasis, and decreased survival of tumour-bearing mice. Recently the 
relationship between microsatellite polymorphism in the HMOX1 promoter and risk 
of melanoma was evaluated (Okamoto et al., 2006). It is known that a (GT)n 
dinucleotide repeat polymorphism in the HMOX1 promoter can modulate gene 
expression through promoting the formation of Z-DNA which suppresses HMOX1 
activation (Yamada et al., 2000). Okamoto et al., (2006) offers findings consistent 
with the interpretation that individuals homozygous for short (GT)n alleles (fewer 
than 25 repeats) have a risk of developing melanoma that is double that of 
heterozygous individuals. Taken together, the findings of the present study, and 
others, indicate that HO-1 may be a key gene in the pathogenesis of malignant 
melanoma.
As stated, the transcription factor Nrf2 is known to activate HMOX1. The 
anti-apoptotic activity of HO-1 may therefore be dependent on this activating
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transcription factor. Hirota et al., (2005) evaluated the role of Nrf2, and its 
cytoplasmic anchor protein Keapl, in UVA-apoptosis in murine skin fibroblasts. 
Using cells derived from knock-out mice, Hirota and co-workers show that disruption 
of nrf2 correlates with up to a 1.7-fold increase in UVA-apoptosis, and that a similar 
effect is observed in response to disrupted Keapl. The anti-apoptotic influence o f the 
Nrf2 / Keapl regulatory system has been investigated in a variety of other cell types 
(Kweon et al., 2006; Liu et al., 2007; So et al., 2006; Vargas et al., 2005). These 
studies produced data consistent with the interpretation that Nrf2 possesses anti- 
apoptotic activity, and indicated that this anti-apoptotic activity results from HO-1 up- 
regulation. Similarly to HO-1, excess Nr£2 accumulation has been documented in 
human tumours (Stacy et al., 2006). It is therefore reasonable to conjecture that Nrf2 
may modulate apoptosis by means of HO-1 in human melanoma cells.
Recent scientific literature has advocated Nrf2 inducing agents as potential 
targets for cancer chemoprevention (for review see: Giudice and Montella, 2006; 
Jeong et al., 2006; Shen et al., 2005). Up-regulation of Nrf2 resulting in the 
subsequent induction of phase II detoxifying enzymes presents obvious benefits in the 
prevention of neoplastic pathologies. However, as indicated by this and other studies, 
up-regulation of Nr£2 is likely to up-regulate the anti-apoptotic protein HO-1, and this 
may only serve to exacerbate existing cancerous pathologies. Up-regulation of Nr£2 
may therefore offer both beneficial and detrimental effects to patient health, and this 
indiscriminate approach to phase II gene activation must be viewed with caution.
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Marker % Total 
All 100.00 
M1 69.50
238
